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PREFACE: 
A BRIEF STATEMENT ON BIOPHYSICS AND BIOPHYSICAL TECHNIQUES 
AND THEIR RELATIONSHIP TO PURE CHEMISTRY 
 
Biophysics is, at its roots, the application of physical principles to biological systems at 
both a gross biological and a chemical level, creating a truly interdisciplinary field at the 
interface of the three major natural sciences. Biophysics is not limited to pure biology and 
chemistry, however, as it has influences biochemistry, bioengineering, computational biology, 
nanotechnology, and even a development of basic physical principles from quantum dynamics 
and quantum and statistical mechanics. Essentially, biophysics focuses on a quantitative analysis 
of biological systems, rather than the more qualitative forms seen in direct biological analysis. 
Examples of biophysical techniques include fluorescent imaging, microscopy, nuclear magnetic 
resonance, mass spectrometry, circular dichromism, atomic force microscopy, and many others. 
Theoretical techniques, such as computational analysis via statistical mechanics, are also used. 
Many of these methods fall under the scope of physical chemistry as well, and it is in that 
context that the investigations presented herein are discussed. Biophysical analyses were done in 
this investigation to study two terminal illnesses: cancer and Alzheimer’s disease. Though on the 
surface these two diseases may seem unconnected, they are linked through the physical 
technique applied to study them. Through the biophysical analysis of urine and lipid membranes, 
investigations into the early detection of cancer and the mechanism of Alzheimer’s disease were 
carried out. These analyses may be biophysical in nature, but they remain a physical procedure in 
principle. No science is truly one discipline anymore, and it is in that spirit that we proceed.
  
 
 
 
 
 
 
SECTION 1:  
METABOLOMICS AND CANCER 
M1 
Chapter 1: 
Introduction 
 
1.1. An Introduction to Metabolomics 
 Metabolomics is a form of scientific analysis that exploits the biochemical processes in 
the cell to make statements on the health or illness of that cell.
1
 In doing so, it looks at the levels 
and characterization of the metabolic side products from biochemical processes, giving a picture 
of the state of the global metabolism of the cell or organism.
2-5
 Essentially, metabolomics 
focused on the metabolome, which is the full profile of the small molecules present in cells, 
tissues, and organisms, and change as a result of processes ranging from gene expression, the 
Krebs cycle, glycolysis, and cell division, to even system perturbations caused by the 
consumption of food, pharmaceuticals, and illicit drugs, giving direct measurements of 
biochemical activity.
6-7
 This is in contrast to other “omics” sciences, such as proteomics, which 
focuses solely on protein expression and levels, and genomics, which concentrates on the DNA 
and various RNA samples found in a cell.
 8-10
 In studying these small molecules, metabolomics 
actually gives a snapshot or chemical fingerprint of the cell and its processes. As they are 
chemically changed during metabolism, their relative concentrations give insight into the 
physiological state of a biological system at the moment of sampling, giving a holistic analysis, 
and improving on genomics and proteomics.
1-5, 8-10
 Genes and proteins are limited to epigenetic 
and posttranslational modification, being less direct in identifying specific biochemistry, 
affording less specific information as small molecule analyses, nor is their information as good 
of a representation of the specific, current state of a cell.
11-12
 This process is also known as 
M2 
metabonomics, metabolic profiling, metanomics, and metabolic fingerprinting, depending on the 
quantitative level of analysis and the application.
1-5
  
In studying the metabolome and metabolomics, the exact range of metabolites to be 
investigated remains under debate, as do the various components and samples to be analyzed, 
and the exact mode by which this analysis is done. Though the number of individual metabolites 
numbers in the tens of thousands, no analytical technique can accurately characterize the full 
range of metabolites.
13-14
 Therefore, many techniques focus on those that are able to be easily 
characterized. Some important metabolites, with all the processes they are involved in, appear in 
Figure 1.1.
6-7
 In the full analysis of these metabolites, comparisons can be made between a 
healthy, unperturbed system, and those subject to some kind of stress, whether 
pathophysiological, pharmaceutical, or otherwise.
15-17
 In using metabolomics, the goal is to 
create a detailed map of these interconnected metabolomic and genetic pathways, allowing for a 
pinpointing of the change in these processes as determined by the change in the profile itself. An 
Figure 1.1. A schematic showing the important metabolites and their related processes and interconnections. Figure reprinted 
with permission from Guimerà, R.; Amaral, L. A. N. Nature. 2005, 433, 895-900. Copyright 2005 by Nature Publishing Group. 
M3 
example map appears in Figure 1.2.
18-20
 These changes would ultimately be linked to specific 
diseases or other environmental stresses, which would allow for a quick and accurate 
determination of the cause of the stress, taking advantage of the full analytical power of the 
modern instruments used therein. 
 Metabolomics has been shown to be especially promising in disease diagnoses.
21-25
 
Diseases are well-known to disrupt various metabolic pathways, accelerating and retarding their 
rates as appropriate. These changes are seen in metabolic signatures and profiles, which, when 
analyzed via metabolomics, can be matched to the disease and thus provide diagnostic 
information. In fact, diagnostic applications of the metabolome have been made for diseases such 
as tuberculosis,
26-28
 schizophrenia,
29-30
 bipolar disorder,
31-32
 Alzheimer’s disease,33-35 coronary 
artery disease,
36-38
 hypertension,
39-40
 hemorrhages,
41-42
 type II diabetes,
43-45
 drug overdose,
46-48
 
Figure 1.2. A metabolomic map showing important metabolites and pathways in E. mutabilis. Figure reprinted 
with permission from Halter, D.; Goulhen-Chollet, F.; Gallien, S.; Casiot, C.; Hamelin, J.; Gilard, F.; Heintz, D.; 
Schaeffer, C.; Carapito, C.; Van Dorsselaer, A.; Tcherkez, G.; Arsène-Ploetze, F.; Bertin, P. N. ISME J. 2012, 6,1391-
1402. Copyright 2012 by Nature Publishing Group. 
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and preeclampsia.
49-50
 A full list of diseases appears in Table 1.1. However, metabolomics is 
probably best demonstrated in its applications to the various cancers, as discussed herein. 
 
1.2 Metabolomics and Cancer 
 As discussed, above, metabolomics has been shown to have a large impact on the ability 
to diagnose diseases, especially cancers. A full list of cancers analyzed via metabolomics, 
appears in Table 1.1. Thus, it can be stated that metabolomic approaches are well-established for 
this form of disease, allowing for a more detailed understanding of disease pathogenesis, and 
improvements in prognostic and diagnostic approaches for patient care. The ultimate goal is for 
metabolomics to become the dominant form of clinical tests for the various cancers; however, in 
Disease References 
Alzheimer’s Disease 33-35 
Bipolar Disorder 31-32 
Bladder Cancer 51-60 
Brain Cancer 61-68 
Breast Cancer 69-91 
Cervical Cancer 92-94 
Colorectal Cancer 95-111 
Coronary Artery Disease 36-38 
Head and Neck Cancer 112-124 
Esophageal Cancer 125-131 
Gastric Cancer 132-141 
Hemorrhages 41-42 
Hepatic Cancer 142-159 
Hypertension 39-40 
Leukemia 160-169 
Lung Cancer 170-183 
Ovarian Cancer 184-192 
Pancreatic Cancer 193-203 
Preeclampsia 49-50 
Prostate Cancer 204-218 
Renal Cancer 219-228 
Schizophrenia 29-30 
Tuberculosis 26-28 
Type II Diabetes 43-45 
Table 1.1. List of disease studied via metabolomics, and pertinent references. 
M5 
order to achieve that ambitious statement, all aspects of the metabolomic process, including the 
selection, preparation, analysis, and interpretation of samples must reach a certain level of 
scientific consensus, having been examined, standardized, and perfected to a degree such that all 
variation is removed and uniformity is ensured.
1,229
 This involves a focus on such minutiae as the 
type, number, collection time, storage conditions, the various levels, stages, and degrees of 
metastasis of the cancers in the patients studied.
230-231
 The variations in medications ingested and 
the length of treatment both affect metabolomic patters as well due to the processing of 
pharmaceuticals in the body. Even with this detailed treatment of data, statistical anomalies may 
still result from such factors as age, diet, sex, and even the location where the patient resides. 
Furthermore, patient-researcher interaction must be closely scrutinized to ensure no violations of 
the safety and rights of the human subjects under study are occurring, and their protection must 
remain the highest property. Generally, this is done through following the provisions of the Good 
Clinical Practice, an international quality standard for such studies.
232-235 
Though metabolomics has been shown to be well-suited to cancer analyses, as 
demonstrated by the sheer number of studies done, many challenges remain to the wide 
implementation of these techniques. Metabolites, by lieu of them being small molecules that 
participate in a wide range of metabolic processes, have an intrinsically transient nature, 
affording a large dynamic range that depends on the time of collection, endemic interindividual 
variation, and other factors that ultimately cannot be standardized.
236-238
 Metabolome variations 
can indicate diseases, but can also be due to natural physiological fluctuations, and even 
temporal and seasonal changes in diet and environment. Sample transport, freezing, and storage 
procedures, if not exactly the same between research groups, can introduce more error into the 
sample. Even further, such variations may cause usable data to be obscured from analysis as 
M6 
well, providing more opportunities for false positive or false negative diagnoses.
239-240
 Due to 
this myriad of potential issues, all metabolomic studies have to be under strict and reproducible 
conditions. As most metabolomic investigations use some form of instrumentation, such as mass 
spectrometry, nuclear magnetic resonance spectroscopy, or fluorescence spectroscopy, these 
techniques provide reproducibility, if all acquisitions are done under the same conditions of 
temperature, ionization procedure, and even on the same instrument.
241-243
 It is overwhelmingly 
crucial to painstakingly establish and follow detailed collection and preparation protocols to 
standardize all data before making any sort of conclusion. All such standard operating procedures 
(SOPs) are necessary for the highest level of accuracy in metabolomics.
244
 
Despite these drawbacks, metabolomics still provides many advantages over current 
methods. Currently, most noninvasive cancer diagnostic tests use a similar method to 
metabolomics in the application of biomarkers, larger molecules that are considered to be 
representative of a diseased state.
245-247
 They tend to be metabolites whose concentrations are 
correlated to a specific and complex physiological parameter or state, including diseases, though 
the best-known example of this is the use of the human chorionic gonadotropin hormone as a 
pregnancy test. However, many cancer biomarker tests have a large amount of variation. The 
most evident of these is the prostate-specific antigen (PSA) test, used to detect prostate 
cancer.
248-250
 In this test, the levels of PSA are detected in the blood, acting like a biomarker for 
prostate cancer. Elevated values are purported to correlate to prostate cancer; however, it can also 
indicate prostatitis or benign prostatic hyperplasia.
251
 Only 30% of patients that have elevated 
levels of PSA detected actually have prostate cancer, leading to overdiagnosis, overtreatment, 
and a screening process that is generally recommended against by most cancer agencies, 
including the American Cancer Society and the United States Preventive Services Task.
252-253
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Definitive cancer diagnosis truly only occurs after biopsies, however, in which a sample 
of the potential tumor is taken out of the patient, in a painful, invasive, and potentially expensive 
manner.
254-255
 An image of the biopsy procedure appears in Figure 1.3. For many people who 
undergo biopsies, no tumor is present, causing them undue harm and stress. Metabolomics 
improves on all of those. In using a small molecule profile, rather than just individual 
biomarkers, more accurate statements on the actual state of an individual can be made, as the 
concentration patterns in the metabolome provide both more holistic forms of analysis and have 
less variation due to stresses that may falsely elevate the concentration of a single biomarker, 
introducing error into the procedure currently in use.
1
  
As metabolomics searches for metabolite variations that differentiate between healthy 
and diseased samples, the most accurate form of diagnosis would be from comparing the 
metabolome of a healthy and diseased sample from the same person. However, as this is 
unrealistic, a standard picture of a diseased metabolome could be used in comparison to the one 
obtained from the patient, which would allow for better screening processes, preventing 
unneeded biopsies and stress on the patient.
1, 51-228
 This type of screening test would thus 
encompass the benefits of the current noninvasive diagnostic modality, while also improving on 
Figure 1.3. Depiction of the invasive nature of a 
biopsy. Copyright 2015 Mayo Foundation for 
Medical Education and Research. 
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its sensitivity, cost-effectiveness, level of patient discomfort. Furthermore, metabolomic 
techniques, due to the increase in sensitivity, catch diseases earlier in their pathophysiological 
progression, sometimes before even symptoms manifest.
256-258
 Thus, this type of diagnostic test 
would improve on all current techniques, allowing for a higher rate of survival of these cancers, 
and a better quality of life during treatment, whether chemotherapy or radiation therapy.
259-260 
Metabolomics does not limit itself to diagnostic applications, however, but also affords a 
better understanding of the underlying mechanisms of a disease through determining changes in 
metabolites, and discovering the reasons for these changes, monitoring the progress of the 
disease and giving insight into pathology while providing biomarkers that can diagnose the 
disease.
261-265
 In doing so, metabolomics is able to connect the basic science to the clinical, and 
allow for a better characterization of these deadly diseases. In understanding how these ailments 
specifically affect the human body, targeted drugs can be made to combat cancer, allowing for a 
higher rate of success in treatment and a better quality of life. In summary, metabolomics will 
have implications both in biomedical research and clinical practices, as it captures information 
with regard to the mechanism of the disease and its symptomatic results, allowing for the tracing 
of the effects on pathways, and applications in the diagnostic field.
1
  
Before medical applications can be fully realized, however, the basic principles of 
metabolomics must be established and standardized, allowing for a comprehensive method that 
would eliminate the drawbacks in metabolomics discussed above. The development of such a 
comprehensive metabolomic method, steps to which are taken in these studies, would allow for 
the definitive application of this analysis to disease diagnosis. This investigation focused on 
determining elements of a standard protocol for the metabolomic investigation of cancers at a 
general level. In determining the techniques, aspects such as reproducibility, sensitivity, and ease 
M9 
of the procedure were considered, as well as how early in the progression of cancer this 
technique could be used, especially if before metastasis. If successful, the studies herein would 
be instrumental to revolutionizing the field of oncology and the health care system as a whole, as 
they would indicate feasibility in other cancers, and potential applications to other techniques.  
 
1.4 Metabolomics Methodology 
1.4.1 Introduction to Metabolomic Methodologies 
 As metabolomic mixtures have an intrinsically large chemico-physical variation, analysis 
is extremely complicated. To deal with this variation, a plethora of techniques have been applied 
to metabolomics, including fluorescence probing and spectroscopy.
266-268
 The dominant 
techniques in metabolomics, however, remain nuclear magnetic resonance spectroscopy (NMR) 
and mass spectrometry (MS), as they maintain the necessary analytical power to overcome the 
issues inherent in metabolic mixtures, especially when combined with chromatographic 
purification techniques to reduce complexity.
269-270
 Overcoming this complexity and improving 
the overall analysis methodology is the ultimate goal of the study discussed herein, as the need 
for specialized and customized methods of statistical analysis is paramount. 
 Generally, metabolomic analysis falls into two categories: targeted and untargeted. 
Targeted approaches quantify known biomarkers for certain diseases or physiological states to 
make conclusions on the patient from whom the data originates.
271-273
 Essentially, it looks for 
something expected in the data. Untargeted approaches search for correlations between diseased 
states and experimental quantities in previously uncharacterized diseases to develop targeting 
profiles, therapeutic targets, and biochemical mechanisms of fundamental processes.
274-276
 
Current untargeted approaches have even revealed that metabolites used in biological systems 
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expand beyond canonical biochemical pathways, which allows for further pathways for 
biomarker identification to exist beyond the currently known range.
277-278
 As both methods 
acquire data similarly, they have similar limitations, which are shared with metabolomics as a 
whole. Furthermore, these techniques feed into vast, uncharacterized metabolomic databases, at a 
chemical to biochemical to even anatomical level. This is a growing research area. 
 One way in which untargeted metabolomics is improved is via meta-analysis,
279
 where 
cascades of metabolic perturbations are prioritized if unknown, even if unrelated to the disease of 
interest, revealing hundreds of alterations to pathways that may be useful in other diseases. By 
comparing the profiles of various diseases, disease pathologies can be identified, allowing for the 
further understanding of pathophysiology of both diseases.
279-280
 This data reduction allows for 
more aggressive analysis of unknown features that may be medically relevant.  
 
1.4.2 Sample Collection and Preparation 
 Samples analyzed include tissues, urine, blood, and amniotic fluid.
281-283
 However, these 
data sources contain fewer metabolites as compared to genetic materials and proteins, even fewer 
of which are detectable, depending on the sample, the analytical platform, and the goals of the 
study. Furthermore, due to natural variations in biological samples, no single method can identify 
and quantify all metabolites in a sample, needing instead a combination of applicable procedures 
to maximize the number of detected and quantified metabolites.
1
 Also, homogenization prevents 
location-based analysis, destroying information that may be able to pinpoint specific anatomical 
regions and their effects on disease. Though this procedure is not universally accepted currently, 
a typical metabolomics workflow is presented in Figure 1.4.
1
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Preparation of samples for analysis is very important in metabolomics, as the natural 
physicochemical variation in biological samples requires specific steps to standardize samples. 
For example, NMR samples require homogenization and extraction, with an appropriate solvent, 
if done in liquid phase. Tissue samples can be analyzed using solid-state NMR spectroscopy 
through magic angle spinning (MAS) or high-resolution magic angle spinning (HR-MAS) 
Figure 1.4: Overview of metabolomics methodology for NMR and MS based analysis. Figure reprinted with 
permission from Jain, N. S.; Dürr, U. H. N.; Ramamoorthy, A. Chinese Chem. Lett. 2015. In press. Copyright 2015 
Ayyalusamy Ramamoorthy. Published by Elsevier.
Acquisition of samples: Blood, urine, saliva, tissue, etc. 
Sample preparation for analytic technique: extraction, derivatization, dissolution, 
pretreatment for NMR, MS-related techniques 
Spectrometry Analysis: 1D/2D NMR Spectroscopy (
1
H, 13C, TOCSY, NOESY, HR-MAS) or 
Mass Spectrometry (LC-MS, GC-MS, UPLC-MS, DESI-MS) 
Data preprocessing: Corrections, transforms, normalizations, scaling, binning 
Statistical Analysis: PCA, PLS-DA, OPLS-DA, ANOVA 
Score Interpretation 
Identification of possible biomarkers 
Clinical Trials 
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techniques, which study tissues nondestructively.
284-285
 Neat, extracted, and incubated samples 
are used in MS analyses.
  
Specific conditions depend on the analysis being done. 
 In order to best determine the course of sample collection and preparation, the type of 
cancer and the goals of analysis must be understood in conjunction with factors such as diet, 
gender, age, ethnicity, pathophysiology, and location. Furthermore, a large number of samples, 
controls, replicates, and blanks are always preferable to ensure the broadest and most accurate 
data.
1
 To perform analysis, samples must be preserved through sample-specific techniques. 
Blood plasma and serum, samples are collected with anti-coagulants or coagulants, respectively, 
centrifuged and stored frozen. Urine storage uses the same principles, but done so at -80 °C. 
Saliva samples are preferable if not stimulated, and stored at normally -20 °C for short term use 
and – 70 °C for long term usage.286-287 Tissue samples are generally frozen at -80 °C. Sometimes, 
more drastic storage techniques, such as freezing under liquid N2, acid treatment, quenching in 
salt and methanol, or chemical protection is needed to prevent oxidation and degradation. 
Sample preparation also depends on the sample, the metabolites analyzed, and the 
analytical platform. Volatile metabolites, especially organic compounds, are difficult to use, and 
require special care to prevent sample loss. Extraction techniques can destroy metabolites, or 
alter them, which affects mass spectrometry, as MS depends on solid-phase or liquid-liquid 
extraction, or liquid and gas chromatography.
1, 288
 However, these techniques can be directly 
coupled to MS, eliminating transfer steps and allowing for analysis, while still introducing error.
  
Proper separation is one of the problems in metabolomics that this research needs to address. 
 NMR-based metabolomics uses a different sample preparation methodology, and also 
have variation on the type of NMR used, whether solution or solid-state. In solution-state NMR, 
the sample is prepared according to standard methods, desolvated, and suspended in a deuterated 
M13 
solvent for analysis. Adjustments are made for certain conditions, including a buffer to regulate 
pH or the introduction of ethylenediaminetetraacetic acid (EDTA) to eliminate salt variations.
289-
291
 This minimal sample preparation eases the use of solution NMR spectroscopy in metabolomic 
analysis. Solid-state NMR spectroscopy can be directly applied to tissues, even in vivo, and MAS 
techniques directly to bone,
292-294
 limiting sample preparation further. High throughput NMR 
techniques also exist, using a standardized flow cell for automatic sample introduction, with data 
nearly as accurate as standard methods.
295
 Research addressing peak drift in NMR spectra due to 
changes in pH or salt concentration, which can cause inaccuracies in comparing signals between 
spectra collected from different samples, as well as spectrum complexity are addressed herein. 
 
1.4.3 Nuclear Magnetic Resonance Spectroscopy and Metabolomics 
 NMR spectroscopy is a common technique applied to everything from physical 
chemistry to medicine.
296-299
 It is highly amenable to metabolomic analysis, as a wide variety of 
nuclei are NMR sensitive (Table 1.2).
1
 Furthermore, NMR does not damage or denature the 
sample, allowing for a reproduction of tests and a corroboration of results. The principle of NMR 
rests in the half-spin of the fermions that make up nuclei, namely protons and neutrons. Unpaired 
proton and neutron spin states contribute to the nuclear spin quantum number I,
300-303
 with each 
unpaired spin contributing ½ to I.  The number I is related to the magnetic moment, a measure of 
the torque a system will experience in a magnetic field, essentially representative of a transition 
Nucleus Nuclear spin Natural abundance Relative NMR sensitivity 
1H ½ 99.98% 100 
2H 1 0.02% 0.96 
13C ½ 1.1% 1.6 
15N ½ 0.366% 0.1 
19F ½ 100% 83.3 
31P ½ 100% 6.6 
Table 1.2: List of NMR-active nuclei used in metabolomics. Figure reprinted with permission from Jain, N. S.; Dürr, 
U. H. N.; Ramamoorthy, A. Chinese Chem. Lett. 2015. In press. Copyright 2015 Ayyalusamy Ramamoorthy. 
Published by Elsevier. 
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dipole moment operator. Spin states with no external magnetic field are degenerate; however, 
introducing an external field induces Zeeman splitting, creating 2I+1 split spin states, with the 
more spin aligned states stabilized, and those more antiparallel to the field destabilized.
300-303
 
This spin moment can be related to the gyromagnetic moment through the applied magnetic 
field, which is unified through shimming, locking, and spinning of the sample.  
The spin moment vector can be excited by a radiofrequency pulse, and the precession 
frequency measured, reflecting the spin transitions to the excited state.
300-303
 This motion is 
measured, and gives the Larmor frequency, which is characteristic of the chemical environment 
and the nucleus analyzed. The frequency is measured as a free induction decay, in which the 
relaxation of the spin excited states is measured as t1, affected by spin-lattice interactions, and 
the dephasing of spins, or spin-spin relaxation, in t2. Longer t1 and t2 values indicate narrower 
spectra.
304
 Performing the Fourier Transform on the free induction decay converts the time-
domain data into frequency data, which is then adjusted to the chemical shift based on the 
instrumental parameters.
305
 These shifts represent different chemical environments of the nuclei 
studying, mostly affected by electron density and matrix effects. However, as nuclei are not 
isolated, they can experience coupling, such as J-coupling, or other effects such as the nuclear 
Overhauser effect, which can be exploited in multidimensional NMR.
306 
The instrumentation of an NMR instrument is simple, yet effective. The main 
components are the cryomagnet, a probe where a sample is loaded for data collection, and a 
console that comprises of amplifiers, receivers and data processing units.
307
 A general schematic 
appears in Figure 1.5. Cooled probes, also known as cryoprobes, use liquid He and N2 to achieve 
higher sensitivities by reducing thermal noise in the probe and detector.
300-307
 The cryomagnet 
strength can be changed, and is often denoted in terms of 
1
H NMR resonance frequency, where 
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higher numbers indicate a higher sensitivity and a better resolution, giving more ppm per Hz. 
Cryomagnets as high as 1000 MHz are presently available for metabolomics studies, though 
expensive to purchase, maintain, and use.
1
 The use of an ultra-high magnetic field does afford a 
high enough sensitivity to detect low-abundant metabolites, while also giving a high enough 
resolution to simultaneously detect different types of metabolites present in a biospecimen, 
giving much better analysis.
1 
As figures of merit increase with magnetic field strength, a 500 MHz spectrometer with a 
cooled probe is the lower limit for metabolomic studies.
1
 Other limitations on the use of NMR in 
metabolomics, such as the need for an expert operator to ensure data quality, are removed by the 
automation of operation, making NMR high-throughput as used in commercially available 
quality control techniques.
308-310
 Despite reproducible and quantitative data, standardized 
procedures, ease of preparation, and automation, the relatively low sensitivity of NMR still is the 
Figure 1.5: Schematic of an NMR instrument. Reprinted with permission from Frydman, L.; Blazina, D. Nat. 
Phys. 2007, 3, 415-419. Copyright 2007 Nature Publishing Group.
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major limitation when compared to mass spectrometry.
311
 However, the use of latest approaches 
including fast data collection and cryoprobes can potentially overcome this limitation, as can 
potentially the advent of higher magnetic fields and dynamic nuclear polarization (DNP) 
techniques.
312
 
NMR experiments also can produce data in one, two, and three dimensions, allowing for 
more facets of analysis that can identify and fully characterize metabolites without any difficulty 
in reproducing the data. The Carr-Purcell-Meiboom-Gill (CPMG) sequence helps suppress peaks 
from large molecular components like proteins, clarifying data, while diffusion edited 
experiments identify lipids.
313
 Other techniques, such as total correlation spectroscopy (TOCSY) 
can be used in metabolomics to detect low concentration metabolites. Some two-dimensional 
methods reduce spectral complexity and show connectivities to increase accuracy in identifying 
metabolites, increase the time of acquisition as well.
314
 Recently introduced non-uniform 
sampling (NUS) approach can dramatically speed up the data collection process.
315
 In general, 
two-dimensional spin-spin correlation techniques such as TOCSY, heteronuclear single-quantum 
coherence, and heteronuclear multiple bond correlation are used in metabolomics. 
As discussed above, a large profile of atoms are available for metabolomic analysis. 
However, most NMR studies are carried out on 
1
H nuclei, with 
13
C and 
15
N experiments 
NMR Methods Information Advantages 
1D, presaturation, NOESY Universal detection Very quantitative, good for screening 
CPMG Selective for small molecules Easily interpreted, good for blood, HR-
MAS 
Diffusion-edited sequences Gives more large molecule peaks Simple technique, simple spectra 
2D J-RES Simplified spectra, elimination of coupling Simplifies overlapping signals 
HSQC Identifies heteromolecules connections with proton Simplifies spectra 
HMBC Identifies heteromolecules connections with proton Simplifies spectra 
TOCSY Identifies heteromolecules connections with proton Simplifies spectra, detects lower 
concentrations 
Table 1.3: List of NMR-based experiments used in metabolomics. Figure reprinted with permission from Jain, N. 
S.; Dürr, U. H. N.; Ramamoorthy, A. Chinese Chem. Lett. 2015. In press. Copyright 2015 Ayyalusamy 
Ramamoorthy. Published by Elsevier. 
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becoming more frequency. The heteronuclear experiments have resisted widespread 
implementation due to the need for and high cost of isotopically labeled samples. Combining 
1
H 
and 
13
C NMR into 2D experiments, as described above, can cut down on data collection time and 
give better analyses. The full range of NMR-based metabolomics experiments is in Table 1.3.
1
 
NMR is also done mostly on solution samples in deuterated solvents such as D2O, CDCl3, 
and CD3OD, but can be applied to solid samples as well, through solid-state NMR spectroscopy. 
However, due to the lack of motion of the sample in the solid state, there is an inherent loss of 
signal intensity, as sharp peaks in the liquid phase become broader in the solid state.
303
 Thus, 
spinning of the sample is done to ensure the uniformity of the magnetic field and reduce signal 
broadening. Spinning at the magic angle (54.7356°) allows for the acquisition of “liquid-like” 
spectra, due to the basic physical interactions between a sample and the magnetic field.
316
 
Samples can be spun up to 110 kHz for bone and rigid tissue, but soft tissue is normally spun at 5 
kHz. MAS techniques increase the avenues for metabolomic analysis, including the ability to 
study non-soluble or large metabolites, and directly analyze bacteria, cells, tissue, and viruses.
317
 
These measurements depict physiologically relevant metabolomics, giving more access to 
metabolomic profiles.
318-319
  NMR spectroscopy is established in disease
 
and drug metabolomics, 
as well as other avenues, but expanding NMR applications is an avenue for future research, and 
discussed herein. 
 
1.4.4 Mass Spectrometry in Metabolomics 
 Mass spectrometry (MS) is a highly sensitive technique for metabolomic analysis. The 
theory of MS will not be discussed in great detail here, as the instrumentation was not directly 
implemented in this investigation.
302
 A MS instrument has three main components: an ion source 
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for desolvation and ionization; a mass analyzer, which separates ions based on the mass-to-
charge ratio after acceleration and placement in a magnetic field, and a detector, which 
determines the mass-to-charge ratio. A general schematic appears in Figure 1.6.
320
 Multiple 
ionization methods exist, ranging from the harsh electron impact (EI) to softer electrospray 
ionization (ESI) and matrix-assisted laser desorption ionization (MALDI).
321-323
 Common 
analyzers include quadrupoles, ion traps, and time-of-flight analyzers, with FT-ICR and orbitraps 
for a higher resolution, around 1 ppm.
324-326
 
Metabolomics generally uses quadrupole and time-of-flight analyzers, which affords the 
most flexibility and range for analysis. A full list of all MS experiments used in metabolomics is 
provided in Table 1.5, including in multidimensional and imaging experiments.
1
 MS is beneficial 
in that it is more specific and sensitive toward a complex mixture than NMR. But, MS-based 
metabolomics has severe limitations, as it can provide irreproducible results, variations across 
research groups and methodologies, fail to identify established biomarkers, and give too complex  
Figure 1.6: Schematic of an MS instrument. Reprinted with permission from Godfrey, A. R.; Brenton, A. G. Anal. 
Bioanal. Chem. 2012, 404, 1159-1164. Copyright 2012 Springer Link Publishing.
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of a spectrum to identify an individual analyte.  In addition, unlike NMR, samples for 
measurements are not recoverable for further analyses.  These are all avenues for future research.
 
 
1.4.5 Analytical Techniques in Combination in Metabolomics 
As discussed above, these analytical techniques are not used in a vacuum, but can be 
combined with separation methodologies, such as gas chromatography (GC), liquid 
chromatography (LC), and capillary electrophoresis (CE) in so-called hyphenated 
experiments.
327-329
 Due to the combination of separations and analysis, more information is 
gleaned, as several simpler spectra are obtained as opposed to one complex spectrum, affording 
more accurate results. LC is favored in metabolomics as it is more sensitive and offers a larger 
breadth of information, as many samples are fluids that can be directly placed in the instrument 
for analysis with minimal preparation, such as the removal of proteins from sera. Furthermore, 
though advances in LC have reduced the detection limits in the systems, the methodology still is 
time-consuming. GC is also widely seen, but requires more sample preparation. Further methods 
MS Methods Information Advantages Disadvantages 
LC-MS/HPLC-
MS/UPLC-MS 
Molecules separated with liquid 
chromatography first 
Simple preparation Ion suppression can alter 
results 
GC-MS Uses gas chromatography first More sensitive, reproducible, high 
separation efficiency 
Long preparation, not 
universal technique 
2D-GC-MS Molecules separate in 2D Applicable to complex samples Long preparation, not 
universal technique 
EESI-MS Direct solution analysis method, uses 
spray sources 
No preparation Less quantitative, 
damages samples 
DESI-MS Ionization method for direct analysis Tolerates salts, no preparation Less quantitative, 
damages samples 
DART-MS Uses He gas, N2, real time info, direct 
analysis 
Sensitive, no preparation Less quantitative, 
damages samples 
TOF-MS Mass-to-charge ratio determined by 
time needed 
Unlimited mass range, fast Complex electronics, 
complicated set up 
CE-MS Samples separated by capillary 
electrophoresis 
High separation efficiency Needs higher 
concentration of samples 
Table 1.4: List of MS-based experiments used in metabolomics. Figure reprinted with permission from Jain, N. S.; 
Dürr, U. H. N.; Ramamoorthy, A. Chinese Chem. Lett. 2015. In press. Copyright 2015 Ayyalusamy Ramamoorthy. 
Published by Elsevier. 
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can be used for the separation of analytes but may require analysis or alteration of metabolites, 
affecting the data seen. Separation techniques are investigated herein as well.  
 
1.4.6 Statistical Analysis in Metabolomics 
Due to the mass of data obtained via NMR and MS spectral analysis, a large amount of 
statistical processing is needed before interpretation can even proceed. False signals, matrix 
effects, and peak drifts that cause misalignment, the removal of complexities and the revealing of 
low-abundance signals through binning and data scaling and centering are a few of the 
processing steps needed. Peak drifts are discussed in detail in this study. All these methodologies 
are at risk of fundamentally changing data, however, by eliminating real biomarkers or giving 
false positives that are artifacts of the statistical procedure. 
Spectra are aligned based on reference compounds from databases such as KnowItAll and 
Amix.
330-331
 After post-acquisition processing, direct statistical methods are used for 
interpretation. Univariate analyses, such as the students’ t-test, are used in metabolomics, but are 
not the dominate method.
332
 Commonly, multivariate methods are used due to the complexity of 
samples, which may limit the dimensionality of data to ease interpretation.  
Multivariate analysis can be performed using supervised and unsupervised methods. 
Unsupervised methods classify spectra based on given data, not external standards, in untargeted 
analysis. This is done via principal component analysis (PCA), which ranks components and 
descriptors to explain variance. Alternative methods include hierarchical cluster analysis (HCA), 
which defines natural clusters based on comparison between distances of pairs of samples, or 
variables, and K nearest neighbor analysis (KNN), which shows similarity between classes.
333
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On the other hand, supervised methods compare data against a predicted model in 
targeted analysis, used mostly as a cross-validation technique, but can force classification of 
data. Some supervised methods include partial least squares-discriminant analysis (PLS-DA),
334
 
soft independent modeling of class analogies (SIMCA), orthogonal signal correction (OSC), and 
OSC and PLS-DA combined to give OPLS-DA. Statistical validation can use permutation tests 
upward of 200, and validated findings still need secondary samples and biological validation 
before acceptance of the biomarker, as well as further clinical trials.
335 
Other statistical methods are used, including correlation methods, such as the statistical 
TOCSY used to compare NMR and MS spectra, and simply the identification of metabolites. 
PCA, NMR, and MS results are also often combined to aid the interpretation of data when two-
dimensional score plots fail to fully capture the information presented.
336-338
  
 
1.4.7 Databases used in Metabolomic Analyses 
To ease the interpretation of the vast amount of spectral data generated, databases have 
been formed to identify metabolites and provide reference values, benefitting metabolomics as a 
whole. Examples include the Human Metabolome Database (HMDB), backed by the University 
of Alberta,
339
 a free electronic database with 41,154 metabolite entries, including water-soluble, 
lipid-soluble, abundant, and rare signals. Other commonly used databases are METAGENE, 
based in the University of Tübingen,
340
 which contains genetic errors in metabolic pathways, 
giving information on the genetic fingerprint and metabolic concentrations found in a disease; 
MassBank, of Keio University,
341
 with vast amounts of MS spectra, and the Biological Magnetic 
Resonance Data Bank (BMRB) at the University of Wisconsin,
342
 which is NMR-specific and 
metabolomics specific, along with more detailed NMR data such as coupling constants, time-
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domain data, and kinetic information. One developed at the University of Michigan is MetaboID, 
an NMR-specific database used for complex mixture assignment in 1D analysis.
343
 AMIX and 
Chenomx are commercial databases that can verify small molecule structures from NMR and 
MS, and even quantify compounds accounting for conditions of analysis.
345-346
  
 
1.5 Issues in Metabolomic Analysis 
 As displayed above, there are certain issues inherent in metabolomic analysis, especially 
in NMR, the methodology chosen in this analysis. NMR was the focal point due to its 
reproducibility, ease of analysis, and potential for growth, all of which outstrip MS.
347-350
 
Furthermore, NMR is faster and requires less sample preparation, as well as is accessible to a 
wide range of metabolites. However, as discussed above, NMR suffers from low detection limits 
and can afford overly complex spectra for analysis (Figure 1.7),
351
 especially in holistic 
1
H 
analysis, the simplest form of NMR done and the method most likely to be implemented on a 
wider, diagnostic-level scale. This prevents the identification of compounds in the spectrum, and 
potentially false positives and false negatives in biomarker searches. NMR also suffers from 
inherent peak shifts, as the chemical environment is highly sensitive to the ionic strength and pH 
1.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0 ppm
Figure 1.7: 900 MHz 
1
H NMR scan of neat urine. Notice the complexity across the spectrum.
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of the surroundings. Thus, data is no longer reproducible, as a peak cannot reliably appear in the 
same position, causing a misidentification when compared between two separate patients.
1
 
Therefore, that biomarker, identified in one patient, cannot be used in the other, as the actual 
signal of the biomarker may appear as a different analyte.
1
 These two issues combined are a 
major roadblock to the widespread implementation of metabolomic analysis as a cancer 
diagnosis methodology.  
This analysis was done on urine specimen as well, rather than blood, saliva, or tissue, as 
urine offers a holistic assessment of body conditions, as all systems drain into the kidneys, 
without the protein and cellular complexities of blood, or the location specificity of tissue and 
saliva.
281-283
 Also, the liquid nature of urine allows for ease of application to NMR, with minimal 
sample preparation needed. Urine is also obtained in a noninvasive fashion, allowing for easy 
acquisition and less patient discomfort, affording larger benefits as a diagnostic technique. 
 It is the addressing of these issues that drove this investigation into metabolomic 
methodology. First, spectral complexity was tackled by applying a simple two-step phase 
separation technique, which resolved the complex NMR spectrum into two simpler spectra. 
Then, spectral drift was assessed through a simple standardization technique by which the urine 
was treated, again a two-step process which gave uniform spectra across samples from various 
different patients. By solving these issues, metabolomics would become open to a full-scale 
implementation in biomarker analysis, allowing for these analytes to be easily detected, and 
affording universal improvement of cancer diagnosis through a simple urinary biomarker test. If 
successful, this would allow for further applications to other diseases.  
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Chapter 2: 
On the Resolution of Complex NMR Spectra via Esterification and Phase 
Separation, with Applications to Urinary Metabolomics 
 
2.1 Abstract 
 Metabolomics is devoted to determining the metabolic profile of diseased and healthy 
individuals, in order to discover biomarkers that would be indicative of the selected disease, 
allowing for earlier and more accurate diagnoses. One technique used widely in metabolomics is 
nuclear magnetic resonance (NMR) spectroscopy, which exploits the intrinsic spin of nuclei. 
However, NMR has complications in metabolomics, as the human samples used, such as urine, 
contain a large variety of compounds that afford extremely complex spectra, and make 
identifying specific markers impossible. To this end, a simple esterification procedure was 
proposed, using (trimethylsilyl)diazomethane, known to react with carboxylic acids to form 
esters, followed by a phase separation to give two distinct, simple spectra from one complex 
spectrum. Though successful in providing two less complex structures, the procedure still 
requires optimization before widespread implementation can be carried out in medical diagnoses. 
 
2.2 Introduction 
 As discussed above, metabolomics is an all-encompassing science, focusing on the study 
of the metabolic byproducts of biochemical processes in the human body.
1
 By profiling these 
processes, metabolomics has been shown to be able to distinguish between healthy and diseased 
patients solely by comparing the concentrations of the metabolites profiled.
2-5
 As health care 
costs continue to rise, and diagnostic techniques for diseases such as cancer remain invasive and 
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expensive, metabolomics fills a need for more accurate, less invasive, and quicker diagnostic 
techniques, improving on the outcome of patients.
21-25
  
 Currently, metabolomics focuses on various biological samples, including blood, urine, 
and saliva,
281-283
 and differing analytical platforms, such as mass spectrometry and nuclear 
magnetic resonance (NMR) spectroscopy.
241-243
 As discussed above, each has its own benefits 
and drawbacks. Urinary analysis is especially interesting as it provides a holistic analysis of the 
body, and simultaneous screening for different diseases. This, combined with NMR, allows for 
extremely fast and accurate profiling of the patient. However, urine, as the depository fluid for 
all bodily processes, has a myriad of compounds detectable by NMR spectroscopy, which results 
in unresolvable spectra.
281-283,351
 Though higher order experiments, including two-dimensional 
spectroscopy and complex derivatization procedures, have been performed to resolve this issue, a 
simple procedure has not been found.
311-315,352 
 Such a procedure would allow for the performance of NMR-based urinary metabolomics 
by technicians of any skill level. This would allow for the full implementation of this technique 
as a diagnostic technique, as a major obstacle to metabolomics-based diagnoses is the skill 
required to operate and interpret the results. Many metabolites are carboxylic acids, such as citric 
acids, or carboxylic acid-derivatives, such as the full complement of amino acids.
2-5
 Thus, they 
are easy targets for selective esterification with a mild agent, such as 
(trimethylsilyl)diazomethane (TMSDM), which has been well-established in selective 
esterifications.
353-355
 Furthermore, in removing the carboxylic group, and replacing it with a 
methyl ester, the solubility profile of these compounds change from aqueous to organic. Thus, a 
simple phase extraction was proposed herein, allowing for the separation of the newly reacted 
compounds into a nonpolar solvent, while leaving behind polar, unreacted analytes. Subsequent 
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analyses of these solutions would then result in two spectra that are easy to understand. It was 
hypothesized that the procedure discussed above would be simply implemented and optimized, 
affording two separate, clearly understandable spectra, giving polar, nonacidic metabolites in the 
water spectrum and the esterified carboxylic acid and nonpolar metabolites in the chloroform 
spectrum. Herein is discussed the methodology development and subsequent optimization of the 
phase separation of urinary metabolites via esterification to afford resolved NMR spectra. 
 
2.3 Experimental 
2.3.1 General Considerations 
 All conversions and manipulations were done to the open air. Urine samples were 
obtained from the University of Michigan Hospital System. Samples were labeled with an ID 
number, without knowledge of the condition of the patient. All sample procedures followed 
standard safety and security practices. Urine was kept at -80 °C until use, during which it was 
kept at -10 °C. All solvents, standard amino acids, urea, and the (trimethylsilyl)diazomethane 
were purchased from Sigma-Aldrich. Deuterated solvents were purchased from Cambridge 
Isotope Laboratories. Lyophilization and centrifugation were done on the instruments provided 
by Biophysics at the University of Michigan. All spectroscopic analysis was done on a Bruker 
500 MHz instrument, with one-dimensional and two-dimensional capabilities. All matching, 
tuning, shimming, and locking of the instrument signal on the resonant proton was done by hand, 
rather than the automated function. Initial data processing was done using the Bruker interface. 
Further processing, including spectral annotation was done via ACD/NMR Labs software. All 
spectra obtained during the course of the experiment appear in the supplementary information.  
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2.3.2. Esterification Procedure. 
 Various ratios and solvents were used to optimize the esterification procedure. Each 
condition used, accounting for each change in solvent, time, and volume, is detailed in the 
supplementary information, with the general procedure outlined below. Standard carboxylic acid 
solutions were also made and analyzed, as detailed below.  
 
Standard carboxylic acid preparation: The following L-amino acids and other carboxylic acids 
were made into 0.1 M solutions, after which 25 μL of each were combined to form the standard 
solution for esterification as below: citric acid, adipic acid, trans-aconitic acid, alanine, 
phenylalanine, glycine, glutamate, and valine. 
 
General Esterification Procedure: Urine was initially thawed to room temperature. A 2 mL 
sample was combined with equal parts of methanol and acetone, and then allowed to sit at -10 °C 
for one hour. After, the sample was centrifuged at 5000 rpm for fifteen minutes, after which the 
clear yellow supernatant was taken, and the white solid discarded. This supernatant was then 
divided into four equal aliquots of 1.5 mL each, and lyophilized overnight. After lyophilization, 
the residual yellow-brown solid was reconstituted in 4 mL of 3:2 (v/v) toluene:methanol to form 
a clear, colorless solution. Next, 150 μL of (trimethylsilyl)diazomethane was added, and the 
sample was stirred vigorously until the yellow color disappeared. Gas evolution was observed. 
This occurred over the course of three hours. After, the sample was dried with N2 gas. The 
residual solid was then treated with 1:1 water:chloroform, and then centrifuged at 5000 rpm for 
five minutes. The water layer was then extracted, and dried via lyophilization overnight, while 
the chloroform layer was dried over nitrogen. The water layer was then dissolved in 500 μL D2O 
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and 50 μL phosphate buffer (10 mM phosphate, 100 mM NaCl, pH 7.4), and the chloroform 
layer in 5550 μL CDCl3, and both samples were separately analyzed via NMR spectroscopy.  
 
2.4 Results and Discussion 
2.4.1 Methodology Development 
 Initially, standard carboxylic acid solutions were made, containing citric acid, adipic acid, 
trans-aconitic acid, and the following L-amino acids: phenylalanine, alanine, glycine, valine, and 
glutamate. These compounds were treated with (trimethylsilyl)diazomethane (TMSDM), a 
known esterifying agent (Figure 2.1). This was done in a 3:2 toluene:MeOH (v/v) solution, with 
150 μL of TMSDM and a three hour reaction. After treatment with this agent, the sample was 
then separated via a nonpolar phase extraction via 1:1 H2O:CHCl3, and the two phases were 
analyzed separately via 
1
H-NMR. The samples were tracked for the peaks relevant to these acids, 
as displayed in Table 2.1.
339-346
 A representative spectrum comparing the initial, untreated urine 
and both the nonpolar and polar phases of the treated sample appears in Figure 2.2. Full spectral 
details appear in the supplementary information. 
 Based on the data presented in Figure 2.2, the esterification was successful. It is evident 
that the peaks disappear from the polar phase, and appear in the nonpolar phase. Furthermore, 
there is a large increase in peak intensity around 3.5 ppm, indicative of the addition of a new 
methyl group to the carboxylic acids. Looking at the polar phase (Figure 2.2b), it is evident that 
not all peaks went into the nonpolar phase. Most residual peaks were attributed to citric acid; as 
it has three carboxylic groups and one hydroxyl group, it is possible that the citrate did not fully  
Figure 2.1. (Trimethylsilyl)diazomethane.
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esterify and leave the polar phase for the nonpolar phase. Also, the increase in peak intensity 
from 0 to 2 ppm in the nonpolar phase is due to degradation of plastic containers used in 
centrifugation due to chloroform. 
 
2.4.2 Urinary Analysis 
 After a successful trial with the standard set of carboxylic acids, this procedure was then 
applied to urinary samples. After thawing and lyophilization, 500 μL of urine was treated with 
Compound Peaks (ppm) 
Trans-aconitic acid, 3.74, 6.93 
Adipic Acid 1.51, 2.21, 12.0 
Citric Acid 2.883, 3.011 
L-Phenylalanine 3.126, 3.286, 3.990, 7.333, 7.383, 7.428 
L-Alanine 1.482, 3.787 
Glycine 3.567 
L-Valine 0.995, 1.045, 2.260, 3.608 
L-Glutamic Acid 2.035, 2.390, 2.510, 3.896, 8.590, 13.000 
Table 2.1. List of peaks studied in standard sample.  
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Figure 2.2: 500MHz 
1
H NMR Spectra of (A) Mixture of amino acids and carboxylic acids in D2O (B) Water layer 
after esterification and (C) Chloroform layer after esterification. It is clearly seen that all the carboxylic 
containing polar mixtures becomes non polar after esterification. The reaction was done with 125 of TMSDM in 
3:2 Tol:MeOH (v/v) for three hours. Phase separation was then done with 1:1 water:chloroform. 
M30 
150 μL of TMSDM in 3:2 Tol:MeOH (v/v) for three hours. Phase separation was then done with 
1:1 water:chloroform, and the two phases separated. Though no peaks were specifically looked 
for in terms of shifting, the acids studied above were paid special attention to as bellwethers of if 
this procedure was effective, based on peaks in Table 2.1. An example spectrum of the results of 
this procedure appears in Figure 2.3. Full spectral details are in the supplementary information. 
 As seen in Figure 2.3, phase separation was achieved, to a degree. It is evident that the 
nonpolar layer has a large amount of metabolites in it, as does the polar layer. Therefore, it is 
hard to definitively state that this procedure was truly effective. It is possible that there are some 
esterified metabolites in the nonpolar layer, as evidenced by the increase of peak intensity at 3.5 
ppm, as well as some natively nonpolar metabolites that were separated into the chloroform layer 
without interaction with the esterifying agent. Furthermore, it is evident that the water layer 
contains some nonesterified reagents. Though peaks from the valine and alanine amino acids 
were quite depressed in the water layer, the amount of aromatic phenylalanine still was high, as 
23456789 ppm
Figure 2.3: 500 MHz 
1
H NMR spectra of (A) 500 µL urine showing all the metabolites (B) water layer after urine 
esterification showing only unesterified non-carboxylic containing metabolites (C) Chloroform layer showing only 
esterified carboxylic containing metabolites. The reaction was done with 125 of TMSDM in 3:2 Tol:MeOH (v/v) for 
three hours. Phase separation was then done with 1:1 water:chloroform. 
(A) 
(B) 
(C) 
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was the various other carboxylic acids present in the 3-4 ppm range, evidenced by the large 
intensity of those regions. Ideally, if this procedure were to work to its fullest extent, the relative 
intensities of peaks in the water and chloroform spectra would be roughly the same, or the 
chloroform would be greater, depending on the patient. It is evident that this is not the case. 
Therefore, this procedure was further studied to afford an optimized reaction. 
 
2.4.3 Procedure Optimization 
 After it was determined that this procedure needed to be optimized, a set of screens was 
set up to see which esterification procedure afforded the best data. TMSDM is known to esterify 
in not only the toluene and methanol mixture used above, but also in chloroform.
353-355
 Various 
times and separation techniques were used as well. The full set of conditions studied appears in 
Table 2.2, with the full set of spectra obtained in the supplementary information. Condition 
quality was graded on a scale from 1 to 10, with 10 being a fully optimized procedure. These 
grades were based on the completeness of the esterification, as seen in the comparison between 
the chloroform and water layers of the NMR spectra, as well as the quality of each individual 
spectrum. Ideally, statistical analysis would have been performed, but no available package was 
Condition Number Solvent (mL) TMSDM Volume (μL) Reaction Time (hr) Separation System Grade 
1 Tol:MeOH 3:2 (4) 150 3 1:1 H2O:CHCl3 6 
2 Tol:MeOH 3:2 (4) 150 4 8:4:3 CHCl3:MeOH:H2O 0 
3 Tol:MeOH 3:2 (4) 300 4 8:4:3 CHCl3:MeOH:H2O 2 
4 Tol:MeOH 3:2 (4) 300 4 1:1 CHCl3:0.9% NaCl 3 
5 Tol:MeOH 3:2 (4) 300 4 2:1:0.3 CHCl3:MeOH:0.9% NaCl 3 
6 Tol:MeOH 3:2 (2) 150 4 1:1 H2O:CHCl3 1 
7 Tol:MeOH 3:2 (2.5) 50 3 1:1 H2O:CHCl3 0 
8 MeOH:Et2O 10:1 (4) 150 2 1:1 H2O:CHCl3 0 
9 DCM: Et2O  1:1 (4) 150 2 1:1 H2O:CHCl3 0 
10 Tol:MeOH 3:2 (2) 150 2 1:1 H2O:CHCl3 1 
11 Tol:MeOH 3:2 (2.5) 60 3.5 1:1 H2O:CHCl3 0 
12 Tol:MeOH 3:2 (2.5) 70 3.5 1:1 H2O:CHCl3 0 
13 Tol:MeOH 3:2 (2.5) 100 18 1:1 H2O:CHCl3 5 
14 Tol:MeOH 3:2 (2.5) 125 18 1:1 H2O:CHCl3 6 
15 Tol:MeOH 3:2 (2.5) 150 18 1:1 H2O:CHCl3 7 
16 CHCl3:CD3OD 2:1 (0.6) 125 18 1:1 H2O:CHCl3 1 
17 Tol:MeOH 3:2 (2.5) 200 18 1:1 H2O:CHCl3 3 
Table 2.2. List of conditions studied for optimization. Grades were on a 1-10 scale, with 10 being the optimal 
procedure, based on the completeness of the esterification and the separation. Spectra are available in the 
Supplementary Information. 
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able to completely assess the quality of the data at the level required. These grades are in Table 2. 
 Initially, the extraction procedure was modified, keeping the same reaction conditions. 
Rather than the 1:1 CHCl3:H2O condition discussed above, a procedure of 8:4:3 
CHCl3:MeOH:H2O was used to determine if that would induce better spectra. Other separation 
techniques used were 1:1 CHCl3:0.9% NaCl and 2:1:0.3 CHCl3:MeOH:H2O. After, urine was 
acidified before treatment, to determine if that would improve the spectrum quality seen. This 
procedure was done using the conditions and techniques discussed above. The solvent system 
was also changed in the search for better data. TMSDM, though generally done in toluene and 
methanol, can be reacted in various solvent conditions, including 10:1 MeOH:Et2O and 1:1 
DCM:Et2O.
354-355
 Both these conditions were attempted with the TMSDM concentrations as 
discussed above. None of the above conditions afforded better data, as seen in Table 2.2. The full 
spectral breakdown of these conditions is in the supplementary information. 
 Based on Table 2.2, the 3:2 Tol:MeOH solvent system, with the 1:1 H2O:CHCl3 
extraction procedure was determined to be the optimal one, and the concentrations of TMSDM 
and the time of the reaction were varied instead. The full range of conditions appears in Table 2, 
and went from 60 μL to 300 μL of esterifying agent, and 2 hours to overnight reaction. A 
schematic showing the changes in NMR spectra as the TMS concentration was increased appears 
in Figure 2.4. The corresponding change in spectra due to changes in time is in Figure 2.5. As 
before, the grades of the esterification procedure quality are in Table 2.2, and a full spectral 
breakdown of these conditions appears in the supplementary information. 
 As can be seen from this data, changing the time of reaction and the amount of 
esterifying agent did not improve the spectral quality to any significant degree. The spectral 
quality did improve; however, the improvement was not meaningful enough to support the 
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validation of this technique in metabolomic analysis. Peak intensities increased across samples, 
but no new peaks were formed. Thus, though key metabolites such as adipic acid are present at 
Figure 2.4: 500 MHz 
1
H NMR spectra of CDCl3 layers of (A) Condition 13 in Table 2.2 (B) Condition 14 in Table 2.2 (C) 
Condition 15 in Table 2.2. Though the intensity of certain residues increased with the increase in TMSDM, there 
were still missing peaks corresponding to key amino acids known to esterify. Identified peaks also corresponded to 
residues that appeared at larger values in the native urine, indicative of incomplete esterification. Chloroform layers 
only are shown for simplicity. 
(A) 
(B) 
(C) 
Figure 2.5: 500 MHz 
1
H NMR spectra of CDCl3 layers of (A) Condition 1 in Table 2.2 (B) Condition 10 in Table 2.2 (C) 
Condition 15 in Table 2.2. Though the intensity of certain residues increased with the increase in reaction time, there 
were still missing peaks corresponding to key amino acids known to esterify. Identified peaks also corresponded to 
residues that appeared at larger values in the native urine, indicative of incomplete esterification. Chloroform layers 
only are shown for simplicity. 
(C) 
(B) 
(A) 
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higher TMSDM levels at higher intensities in the chloroform layer, key contributors, such as 
valine and glycine, still are missing from the esterified spectrum. Furthermore, the intensities still 
pale compare to those found in native urine (Supplementary Information), suggesting that there 
remains a large amount of these compounds in the water sample. Though the water samples were 
not analyzed to corroborate this thought, the lack of complete esterification and extraction is 
eminently clear, and none of these techniques were able to work completely. Increasing TMSDM 
levels further may help, but impede the cost-effectiveness of this technique. 
This negative result inspired an investigation into components of urine that may affect the 
mechanism of TMSDM action (Figure 2.6).
356
 Based on this mechanism, it was thought that 
components of urine, such as salt, would affect the action of TMSDM. Proteins had already been 
removed during the pretreatment of urine with methanol under cold temperature. However, a 
study of the effects of salt on TMSDM action with several standard amino acids revealed that 
there was no real influence of salt on the mechanism, and thus other components were 
investigated, such as urea, which showed no change (Supplementary Information). Similarly, 
Figure 2.6 Mechanism of TMSDM action on generic carboxylic acids. The transference of hydrogens is 
highlighted. It is possible that water or salt can contribute to quenching of this reaction. 
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acidified urine did not afford any improvement on spectra, as can be seen in the supplementary 
information as well. 
 This left many questions as to the reason why there was a lack of optimization. Based on 
the workflow presented in Figure 2.7, all steps were done with the utmost care to prevent water 
contamination of esterification, which is known to quench this reaction. It is unlikely that there 
was not enough of the esterification agent to cause this reaction to occur, as increasing the 
TMSDM concentration did not change reaction results, nor was there a kinetic barrier, as 
increasing the reaction time had little to no improvement. Studying the workflow and the 
mechanism, it is possible that a completely anhydrous environment would be needed to fully 
perform this reaction with the high concentration of metabolites in urine.
353-355
 This would not be 
necessary for the standard acid solution, as the concentration of sample would have been so low 
that any ambient water contamination would be inconsequential. As a fully anhydrous reaction 
was unable to be carried out with the facilities present, the reaction was tabled for further study. 
 Thus, though optimization of this reaction was unsuccessful, the proof of principle 
remains. This simple esterification reaction is a viable procedure for the separation of carboxylic 
acids from other polar metabolites in urinary NMR spectra, allowing for the easing of 
identification of analytes for metabolomic identification and use.  
 
Figure 2.7. The general workflow for this esterification procedure. Each step was carefully done to prevent 
error. The esterification step includes the reaction and phase separation as detailed above. 
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2.5 Conclusion 
In this study, the cumulative effect of a simple esterification procedure performed by 
(trimethylsilyl)diazomethane and a solvent phase extraction to simplify NMR spectra for urinary 
metabolomics was investigated. Initial standard carboxylic acid solutions were shown to esterify 
quickly and effectively, causing a near-complete phase transition. However, applications to urine 
samples were more complex, mainly due to the complex nature of urine samples, in terms of salt, 
concentration of metabolites, and other issues. Various solvent conditions were investigated, as 
were differing concentrations of TMSDM and reaction times, and even different extraction 
procedures. However, none afforded a fully optimized sample, as both the water layer and the 
chloroform layer showed signs of carboxylic acid analytes, even after esterification. A study of 
the mechanism of the reaction and the workflow of the esterification procedure was done to 
determine where error could be introduced. It was believed that esterification was prevented by 
water contamination in the samples, which could not be removed by the accessible facilities. 
Therefore, the procedure could not be fully optimized. Thus, though the principle of the reaction 
was shown to be successful and effective, the procedure performed above is not ready for 
widespread use. Many questions and challenges remain before this esterification workflow can 
be fully implemented. Future directions for this line of thought would be the full optimization of 
this procedure such that it is effective to its fullest extent. Next, statistical calculations would be 
performed, to see if this procedure truly does improve metabolite detection. A new method would 
need development, as current ones do not fully detail the desired information. After optimization, 
implementation for biomarker development would follow, with hopes of improvements on 
current disease biomarker identification modalities for full clinical applications. 
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Chapter 3: 
A Method of Minimizing Ionic Strength to Reduce Chemical Shift Variance in 
NMR-Based Urinary Metabolomics 
3.1 Abstract 
As NMR-based metabolomics gains popularity as a potential diagnostic technique, the 
exact mechanisms of the procedure need to be optimized. Though extremely quick and simple, 
NMR is sensitive to subtle changes in pH and ionic strength, which can cause peaks to shift, 
creating inconsistencies in peak assignment between patients, and thus unreliable biomarker 
identification. The standardization of sample conditions was investigated herein, through a 
simple methodology. It was found that the addition of decanoic acid removed salt and proteins, 
as shown by the narrowing of the chemical shift of creatinine, citrate, and glycine. Thus, this 
procedure was shown to be effective, allowing for improvements on technique and the further 
detection of biomarkers for the treatment of various diseases. 
 
3.2 Introduction 
As discussed above, metabolomics is the study of the entirety of a metabolic profile of a 
given biological structure or compartment, or a representative subgroup therein.
1-5
 It identifies 
and uses the chemical fingerprints of cellular processes to develop real-time profiles of the state 
of a biological system, representing the total unity of the metabolites and chemical byproducts in 
a cell, tissue, organ, or organism, depending on the scale under study, allowing for various 
diagnostic and prognostic applications.
21-25
 Metabolomics fills a need for a faster, more accurate, 
and cheaper diagnostic test for diseases such as the various cancers, due to their previously 
established utility in metabolomics. 
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As metabolomic samples generally are body fluids, many choices are present as to the 
best form. Urine samples provide the advantage of being easily acquired and also a holistic 
representation of the subject at large.
281-283
 Furthermore, multiple analytical platforms exist. 
NMR is in many ways superior to MS, as it affords more reproducible data, and can be 
quantified easily. It gives faster data acquisition and more flexible experiments.
347-350
 However, 
challenges remain to the expansion of NMR-based metabolomic experiments. Peaks in NMR 
spectra can change chemical shift values based on salt concentration and pH, causing metabolites 
to appear at different position on spectra from different samples.
357
 This is especially a problem 
for metabolomic analysis, as metabolites are intrinsically changing and individuals have various 
salt and pH levels, which change the spectra seen. This prevents the standardization of data from 
sample to sample, as samples can appear in one location for one person, and another for the 
next.
268-238
 Thus, the determination of biomarkers for accurate diagnoses would be impossible, 
preventing approaches that can apply to all patients and alleviate health care costs. 
This issue needs to be addressed before metabolomics can be fully implemented as a 
diagnostic technique. Previous attempts have focused on the use of ethylenediaaminetetraacetic 
acid (EDTA), known to be strong chelator to the cations that affect peak shifts in solution.
289-291
 
However, this molecule introduces new peaks into the sample in metabolomically relevant 
regions, and must persist in the sample during spectral acquisition. Thus, it obscures potentially 
useful data, complicating interpretations further. Other computational techniques result in 
artifacts appearing in data, misaligning spectra and giving false positives and negatives. 
In order to maximize the applicability of metabolomic analysis, these issues need to be 
addressed. Toward this goal, it was proposed that peak shift standardization would be achievable 
by treating urine with decanoic acid to remove the salt from the solution. This procedure is seen 
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on an industrial scale with regards to producing drinking water from brine, which demonstrated 
that the mixing of decanoic acid and brine at 80 °C caused a salt layer to settle to the bottom, and 
afforded a removable decanoic acid, resulting in the recovery of pure water. 
358 
This procedure 
was adapted to suit urinary metabolomics. As the decanoic acid is removed from the solution 
before analysis, it does not have the peak-obscuring issues of EDTA. It was hypothesized that 
this method will reduce the peak shifts as measured by the standard deviation of the chemical 
shift, an established measure of sample variation,
348
 of three major metabolites, glycine, creatine, 
and citric acid. Herein we discuss the applications of decanoic acid-based salt precipitation in 
urinary NMR-based metabolomics. 
 
3.3 Experimental 
3.3.1 General Considerations 
 All conversions and manipulations were done to the open air. Urine samples were 
obtained from the University of Michigan Hospital System. Samples were labeled with an ID 
number, without knowledge of the condition of the patient. All sample procedures followed 
standard safety and security practices. Urine was kept at -80 °C until use, during which it was 
kept at -10 °C. All solvents, citrate, and decanoic acid were purchased from Sigma-Aldrich. 
Deuterated solvents were purchased from Cambridge Isotope Laboratories. Lyophilization and 
centrifugation were done on the instruments provided by Biophysics at the University of 
Michigan. All spectroscopic analysis was done on a Bruker 500 MHz instrument, with one-
dimensional and two-dimensional capabilities. All matching, tuning, shimming, and locking of 
the instrument signal on the resonant proton was done by hand, rather than the automated 
function. Initial data processing was done using the Bruker interface. Further processing, 
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including spectral annotation was done via ACD/Labs software. All spectra obtained during the 
course of the experiment appear in the supplementary information.  
 
3.3.2. Decanoic Acid Procedure. 
Pure decanoic acid (200 μL) was melted at 80 °C and maintained at that temperature in a 
water bath. To this sample, 600 μL of urine was added. This mixture turned cloudy, and was then 
mixed at room temperature intermittently over the course of an hour, while the temperature was 
maintained at 80 °C. After mixing was completed, the mixture stood in the water bath for an 
additional ten minutes. The top 700 μL formed a clear solution, which was transferred to a 
separate vial, and allowed to settle into two distinct layers. The top layer was removed and 
discarded, while the bottom was lyophilized, reconstituted in 500 μL D2O and 50 μL phosphate 
buffer (10 mM phosphate, 100 mM NaCl, pH 7.4) and analyzed via 
1
H-NMR. 
 
3.4. Results and Discussion 
3.4.1 Decanoic Acid Studies 
 Initial decanoic acid procedures followed that seen for industrial-scale removal of salt 
from brine.
358
 Acid was melted and mixed with neat urine samples in a heat bath. After, the 
supernatant was removed, the decanoic acid separated, and the urine dried and analyzed. This 
procedure is outlined in Figure 3.1. After, NMR spectra were taken of each urine sample, and 
overlaid with that of the native and with each other. This is displayed in the supplementary 
information. The spectra were monitored for three key metabolites: creatinine, citrate, and 
glycine. These appear in in Figure 3.2, and a table of standard peaks for them is in Table 3.1.
86-92 
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This technique was then applied to fifteen separate urine samples. Each native sample 
was analyzed, as were two treated samples. The creatine, citrate, and glycine peaks were tracked, 
and recorded, as seen in Table 3.1. Representative spectra appear in Figure 3.3. Based on 
obtained spectra, the native urine gave the following data (ppm): 3.02±0.02 and 4.02±0.02 for 
creatinine; 2.68±0.02, 2.65±0.02, 2.54±0.02, 2.70±0.02, and 2.50±0.02 for citrate; and 3.54±0.03  
for glycine. Treated urine, on the other hand, gave the following peaks (ppm): 3.021±0.009 and 
4.03±0.01 for creatinine; 2.68±0.01, 2.65±0.01, 2.55±0.02, 2.509±0.008, and 2.70±0.02 for 
citrate; and 3.538±0.008 for glycine. This data is summarized in Table 3.1, and given in detail in 
the supplementary information. 
 Decanoic acid was chosen for this investigation due to the fact that it is removed during 
the procedure, and that its NMR spectrum does not interfere with the metabolomic-relevant 
region. An image of decanoic acid appears in Figure 3.4, along with its NMR peaks.
342
 As a 
 Decanoic acid was chosen for this investigation due to the fact that it is removed during 
the procedure, and that its NMR spectrum does not interfere with the metabolomic-relevant 
region. An image of decanoic acid appears in Figure 3.4, along with its NMR peaks.
342
 As a 
majority of metabolomics focuses on the aromatic region and the region between 2.5-4.5 ppm, 
the decanoic acid procedure does not come into that region. Furthermore, decanoic acid is a solid 
Dissolve in pH 7.2 
phosphate buffer 
Extract supernatant (700 μL)  
and remove decanoic acid 
Salt and protein 
precipitation 
Aligned NMR spectra for 
statistical analysis 
Separation into 
two layers 
 
Dry with N
2
 gas 
Decanoic Acid (200 μL)  
353 K, 1 hour, mixing 
Collect Data: 
 1D 
1
H NMR  
(298 K, 500 MHz, 256 scans) 
  
Urine (600 μL)  
Figure 3.1. The general workflow for the decanoic acid procedure.  
Figure 3.2. Representative structures of glycine (left), citric acid (middle), creatinine (right). 
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at room temperature; therefore, it forms an easily removed film on top of the urine sample after 
cooling, and before drying, giving great separation from the tested water layer. 
Based on the peaks presented above, a comparison of the standard deviations of the peaks 
before and after treatment was done to determine if the variance in the peak location dropped. 
This data is also presented in Table 3.1. For creatinine, the standard deviation dropped by 62.9% 
for the upfield peak and 72.2% for the downfield peak. For glycine, the peak variation dropped 
Metabolite Standard Peak 
Value (ppm) 
Average Untreated 
Peak (ppm) 
Untreated Std. 
Dev. (ppm) 
Average Treated 
Peak (ppm) 
Treated Std. Dev. 
(ppm) 
Percent Lowered Standard 
Deviation 
Creatinine 3.03 3.020 0.024 3.021 0.009 62.9 
 4.05 4.018 0.038 4.033 0.010 72.2 
Citrate 2.67 2.684 0.021 2.678 0.014 33.2 
 2.64 2.654 0.020 2.647 0.012 41.5 
 2.54 2.541 0.024 2.546 0.023 7.5 
 2.51 2.503 0.019 2.509 0.009 54.9 
Glycine 3.54 3.542 0.023 3.538 0.008 73.2 
Table 3.1. Table of analytes studied, with standard values, untreated peak locations and standard deviations, 
and treated averages and standard deviations. The percent lowered standard deviation represents the 
narrowing of the variance in peaks after treatment, and are in red for emphasis. All treatments were done with 
the decanoic acid treatment as detailed above. 
A) Native 
B) Treated 
B) Native  
C) Treated 
1
C) Native 
A) Treated 
Figure 3.3. Representative spectra of treated and 
untreated urine, with treatment via the decanoic acid 
method detailed above. The spectra are divided up as 
follows: A) Aromatic region. B) Hydroxyl Region. C) 
Aliphatic region. For all regions, spectral overlays are of 
the three same urine samples, with the native samples 
on the bottom, and the treated ones on top. It is 
obvious from a simple visual examination that there is 
an increase in alignment between the samples when 
the top, as opposed to the bottom, are studied. 10 
different samples were studied, with treatment done in 
duplicate. 
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by 73.2%. For citrate, on the other hand, the change in standard deviation varied from 7.5% to 
54.9%. This data is to be expected. Citrate, due to its carboxylic nature, is highly sensitive to salt 
variations in solution, being used as a chelating agent and a salt probe previously.
359-360
 
Therefore, any small amount of salt would cause peak shifts to occur. Residual salt not removed 
by the decanoic acid procedure would still cause peak shifts to occur. However, for the other two 
amino acids studied, the drop in standard deviation was remarkable, as they were quite large 
 Furthermore, the peaks stayed close to the standard value of the metabolites studied. This 
is important in that there were no artifacts or other false positives inherent in the statistical 
alignment methods. Also, a comparison of the native to the treated spectra showed that no 
evident new peaks were formed in the treated sample, indicating that the decanoic acid layer was 
removed and did not affect the spectra quality or obscure peaks, while still allowing for high 
Figure 3.4. Decanoic acid spectrum. Spectrum from the BioMagResBank. Ulrich, E. L.; Akutsu, H.; Doreleijers, J. 
F.; Harano, Y.; Ioannidis, Y. E.; Lin, J.; Livny, M.; Mading, S.; Maziuk, D.; Miller, Z.; Nakatani, E.; Schulte, C. F.; 
Tolmie, D. E.; Wenger, R. K.; Yao, H.; Markley, J. L. Nuc. Acids Res. 2008, 36, 402-408. Copyright 2008 Oxford 
University Press. 
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quality salt removal. Thus, this improves on the EDTA technique, as no new peaks were added to 
further complicate data. This salt removal procedure was not perfect, however, as there were still 
variations in the peak position. Peak variation is not only due to salt concentration but can also 
be due to the relative concentrations of the various metabolites in solution. Thus, it is not to be 
expected that all peak variation would disappear. Lowering this variance, however, to a point 
such that peaks can be consistently identified, as presented above, would be diagnostically 
useful. 
 Based on the data presented above, the decanoic acid procedure was successful for these 
three metabolites. A full statistical analysis needs to be performed before full implementation of 
this procedure, but its easy process and evident results make it a likely candidate to replace 
EDTA and statistical methods for peak alignment. 
 
3.5. Conclusion 
In this study, the effect of using decanoic acid to lower the ionic strength of solutions to 
standardize NMR chemical shift values was investigated, with applications to urinary 
metabolomics of cancers. Creatinine, glycine, and citric acid were chosen for their applicability 
to metabolomics. It was shown that the decanoic acid procedure worked extremely well for 
creatinine and glycine, and not quite as well for citric acid, due to the sensitivity of citrate to salt 
concentrations in solution. Furthermore, decanoic acid did not introduce any novel peaks in 
regions of the spectrum related to metabolomic analysis, improving on the previously established 
methodologies based around ethylenediaminetetraacetic acid. Also, peaks remained in their 
expected regions, removing the false positives and negative seen from statistical alignment 
procedures. Furthermore, the decanoic acid was a simple procedure, able to be done at all levels 
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of technical proficiency, affording widespread implementation. This decanoic acid procedure was 
not perfect, however, as peak variation from other sources still existed, but the improvement seen 
allows for the improvement of biomarker identification and consistency between patient 
analyses. Future directions for this procedure involve optimization for a high-throughput method, 
along with a full statistical analysis to determine the degree to which all peaks decrease in 
variance. Implementation for biomarker development would follow to determine improvements 
to disease biomarker identification for full clinical applications. 
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Chapter 4 
Concluding Remarks and Future Directions 
 
 As metabolomics has grown as a science, its applications to studying major diseases, 
such as the various cancers. Metabolomics-related methods have the ability to alter clinical 
diagnoses for not only these diseases, but a wide profile. As seen above, the potential impact for 
medical applications is ever-expanding, as the litany of research being done in the various 
cancers only adds to the general knowledge about how diagnoses can be improved, and raises the 
likelihood of discovering a definitive biomarker. Thus, metabolomics maintains a positive 
outlook, improving diagnostic accuracy of current detection techniques upon expanded usage, 
limiting medical issues and extending lifespans. Furthermore, metabolomics, once established in 
cancers, can expand to other diseases such as diabetes, cardiovascular disease, pulmonary 
disease, and even bipolar disorder, though this analysis is still under development.  
 However, as displayed in this analysis, metabolomic techniques have a large ability to 
improve on current methodologies, supplying many avenues of future research before even 
reaching the stage of biomarker development. Metabolomics is not quite as high-throughput as 
desired. Designing new methodologies and machinery to aid in this would be a large step 
forward to increasing the power of metabolomics, improving both the speed and accuracy of data 
collection. This could include synthesizing separation techniques, MS, and NMR analysis, or 
even finding a methodology to simplify the preparation of each sample, whether by determining 
optimal samples for each technique or helping techniques such as MS improve on their solid 
state analysis.  
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Specific analytical techniques also pose their own problems, which need to be addressed, 
especially in relation to NMR. Current techniques give overly complex spectra for proton 
analysis. Though higher order experiments could be performed to improve on the spectral 
quality, this adds another layer of complexity in the experimental design, preventing the 
widespread implementation of the technique and impeding its diagnostic capability. These were 
addressed above by introducing a selective esterification procedure. As displayed above, the 
esterification procedure proposed showed some promising results. Though optimization is 
needed, there still exists the potential for the improvement of separations, resulting in a more 
accurate metabolomic procedure, as biomarkers would be easily identified on simplified spectra.  
NMR is also sensitive to peak shifts between different samples mainly due to pH and salt 
concentrations. These variations are characteristic of metabolomic samples, and are due to 
variations in age, weight, gender, location, diet, pharmacology, and other subject-specific factors. 
These changes must be taken into account for accurate metabolomic analysis, whether by 
statistical or chemical treatment. As shown above, this was dealt with through a simple decanoic 
acid procedure, which allowed for the removal of salt from the sample, and a narrowing of the 
variance of chemical shifts across samples from different patients, as determined by the standard 
deviation of the peaks. A full statistical analysis is needed, but this procedure allows for the 
standardization of samples without the introduction of new peaks, as with EDTA, or the 
propagation of false positives and negatives, à la statistical alignment, and affords more 
consistent detection of analytes for more accurate biomarker development and diagnoses. 
NMR-based metabolomics can also benefit from unification with MS data. As discussed 
above, this can be through the synthesis of NMR and MS instrumentation for high-throughput 
and simultaneous data acquisition. Improvements to mass spectra would also help support the 
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conclusions made from NMR data. This can be done by creating standard operating procedures 
for the type of ionization, the settings of the mass analyzer, and so forth, to remove variation 
among research groups and afford unified spectra, which would allow for biomarker 
identification, and remove a major obstacle to metabolomic analysis. 
These improvements on metabolomic analysis, however, do not lose sight of the overall 
goal of this type of analysis; that is, all these methodology improvements are made to better the 
biomarker detection of this technique.  As seen the various cancers, there still is a need for better 
means to detect diseases. Metabolomics is one of the best candidates to fill this void, but its lack 
of standardization and difficulty of interpretation prevents it from reaching its clinical potential. 
The improvements to metabolomics methodology presented in this investigation represent steps 
toward reaching that potential. Being able to consistently and accurate locate potential 
biomarkers will allow for the detection of metabolites indicative of diseases. Once these analytes 
can be detected, they can be compiled and used for diagnoses. This process is the single most 
important step. Once the procedure is optimized, clinical applications will follow. 
 With the improvements in methodology above, metabolomics will become the most 
sensitive and convenient approach for early disease diagnosis. Though these procedures still need 
optimization, early results have been promising. Thus, the five-year outlook is extremely strong 
for metabolomics, given rapid recent developments and easily discernible areas of improvement 
that promise to fix current problems and provide a definitive platform by which diseases can be 
accurately and specifically detected, diagnosed, and treated. 
  
M49 
Appendix A.1: 
References 
 
1. Jain, N. S.; Dürr, U. H. N.; Ramamoorthy, A. Chinese Chem. Lett. 2015. In press. Portions of the text were reprinted in 
this work with permission. Copyright 2015 Ayyalusamy Ramamoorthy. Published by Elsevier. 
2. Krug, S.; Kastenmüller, G.; Stückler, F.; Rist, M. J.; Skurk, T.; Sailer, M.; Raffler, J.; Römisch-Margl, W.; Adamski, J.; 
Prehn, C.; Frank, T.; Engel, K.-H.; Hofmann, T.; Luy, B.; Zimmermann, R.; Mortiz, F.; Schmitt-Kopplin, P.; Krumsiek, J.; 
Kremer, W.; Huber, F.; Oeh, U.; Theis, F. J.; Szymczak, W.; Haunner, H.; Suhre, K.; Daniel, H. FASEB J 2012, 26, 2607-
2619. 
3. Rist, M. J.; Muhle-Goll, C.; Görling, B.; Bub, A.; Heissler, S.; Watzl, B.; Luy, B. Metabolites 2013, 3, 243-258. 
4. Assflaq, M.; Bertini, I.; Colangiuli, D.; Luchinat, C.; Schäfer, H.; Schütz, B.; Spraul, M. Proc. Natl. Acad. Sci. U. S. A. 
2008, 105, 1420-1424. 
5. Madsen, R.; Lundstedt, T.; Trygg, J. Anal. Chim. Acta. 2010, 669, 23-33. 
6. Guimerà, R.; Amaral, L. A. N. Nature. 2005, 433, 895-900. 
7. Kaddurah-Daouk, R.; Ranga Rama Krishnan, K. Neuropsychopharmacol. 2009, 34, 173-186. 
8. Schmidt, C.. J. Nat. Cancer Inst. 2004, 96, 732-734. 
9. Nagaraj, N. S. Briefings in Functional Genomics and Proteomics 2009, 8, 49-59. 
10. Lay, J. O.; Liyanage, R. TrAC Trends Anal. Chem. 2006, 25, 1045-1056. 
11. Chandramouli, K.; Qian, P.-Y. Hum. Genomics Proteomics. 2009. Online. 
12. Alkan, C.; Sajjadian, S.; Eichler, E. E. Nat. Methods. 2011, 8, 61-65. 
13.  Ceres, Inc. http://www.ceres-inc.com/techno/platforms/ metab.html. 
14 . Wink M. Theor Appl Genet. 1988, 75, 225-233. 
15. Sidransky, D. Nat. Rev. Cancer 2002, 2, 210-219. 
16. Shah, S. H.; Kraus, W. E.; Newgard, C. B. Basic Sci. Clinic. 2012, 126, 1110-1120. 
17. Cha, M. H.; Kim, M. J.; Jung, J.; Kim, J. H.; Lee, M. S.; Kim, M. S. Evid. Based Complement Alternat. Med. 2015, 
2015, 453423. 
18. Deda, O.; Gika, H. G.; Wilson, I. D.; Theodoridis, G. A. J. Pharm. Biomed. Anal. 2015. In press. 
19. Calabrese, V.; Dattilo, S.; Petralia, A.; Parenti, R.; Pennisi, M.; Koverech, G.; Calabrese, V.; Graziano, A.; Monte, I.; 
Maiolino, L.; Ferrerri, T.; Calabrese, E. J. Free Radic. Res. 2015. In Press. 
20. Halter, D.; Goulhen-Chollet, F.; Gallien, S.; Casiot, C.; Hamelin, J.; Gilard, F.; Heintz, D.; Schaeffer, C.; Carapito, C.; 
Van Dorsselaer, A.; Tcherkez, G.; Arsène-Ploetze, F.; Bertin, P. N. ISME J. 2012, 6,1391-1402. 
21. Johnson, A. R.; Makowski, L. J. Nutr. 2015. In press. 
22. Ogodorova, L. M.; Fedorova, O. S.; Sripa, B.; Mordvinov, V. A.; Katohkin, A. V.; Keiser, J.; Odermatt, P.; Brindley, P. 
J.; Mayboroda, O. A.; Velavan, T. P.; Freidin, M. B.; Sazonov, A. E.; Saltykova, I. V.; Pakharukova, M. Y.; Kovshirina, Y. 
V.; Kalouilis, K.; Krylova, O. Y.; Yazdanbaksh, M. PloS Negl. Trop. Dis. 2015. In press. 
23. Lee, S. Y.; Kim, M.; Jung, S.; Lee, S. H.; Lee, J. H. PLoS One. 2015.  
24. Xu, J.; Jiang, H.; Li, J.; Cheng, K. K.; Dong, J.; Chen, Z. PLoS One. 2015. 
25. Su, L.; Li, H.; Xie, A.; Liu, D.; Rao, W.; Lan, L.; Li, X.; Li, F.; Xiao, K.; Wang, H.; Yan, P.; Li, X.; Xie, L. PLoS One. 
2015. 
26. Somashekar, B. S.; Amin, A. G.; Tripathi, P.; MacKinnon, N.; Rithner, C. D.; Shanley, C. A.; Basaraba, R.; Henao-
Tamayo, M.; Kato-Maeda, M.; Ramamoorthy, A.; Orme, I. M.; Ordway, D. J.; Chatterjee, D. J. Proteome Res. 2012, 10, 
4873-4884. 
27. Somashekar, B. S.; Amin, A. G.; Rithner, C. D.; Troudt, J.; Basaraba, R.; Izzo, A.; Crick, D. C.; Chatterjee, D. J. 
Proteome Res. 2011, 10, 4186-4195. 
28.  Zhou, A.; Ni, J.; Xu, Z.; Wang, Y.; Lu, S.; Sha, W.; Karakousis, P. C.; Yao, Y.-F.vJ. Proteome Res.,  2013, 12, 4642-
4649. 
29. McClay, J. L.; Vunck, S. A.; Batman, A. M.; Crowley, J. J.; Vann, R. E.; Beardsley, P. M.; van den Oord, E. J. J. 
Neuroimmune Pharmacol. 2015. In press. 
30. Pickard, B. S. J. Psychopharmacol. 2015. In press. 
31. Villaseñor, A.; Ramamoorthy, A.; Silva Dos Santos, M.; Lorenzo, M. P.; Laje, G.; Zarate, J. C.; Barbas, C.; Wainer, I. 
W. J. Pharmacol. 2014, 171, 2230-2242. 
32. Lorenzo, M. P.; Villaseñor, A.; Ramamoorthy, A.; Garcia, A. Electrophoresis 2013, 34, 1701-1709. 
33. Li, N.; Zhou, L.; Li, W.; Liu, Y.; Wang, J.; He, P. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 2015. In press.  
34. Ellis, B.; Hye, A.; Snowden, S. G. J. Alzheimer’s Dis. 2015. In press. 
35. Graham, S. F.; Chevallier, O. P.; Elliott, C. T.; Hölscher, C.; Johnston, J.; McGuinness, b.; Kehoe, P. G.; Passmore, A. 
P.; Green, B. D. PLoS One. 2015. 
36. Qui, Q.; Li, C.; Wang, Y.; Xiao, c.; Li. Y.; Lin, Y.; Wang, W. BMC Complement Altern. Med. 2014, 12, 232. 
M50 
37. Kramer, P. A.; Chacko, B. K.; Ravi, S.; Johnson, M. S. Mitchell, T.; Barnes, S.; Arabshahi, A.; Dell’Italia, L. J.; 
George, D. J.; Steele, C.; George, J. F.; Darley-Usmar, V. M.; Melby, S. J. Lab Invest. 2015, 95, 132-141. 
38. Basak, T.; Varshney, S.; Hamid, Z.; Ghosh, S.; Seth, S.; Sengupta, S. J. Proteomics. 2015. In press.  
39. Van Deventer, C. A.; Lindeque, J. Z.; van Rensburg, P. J.; Malan, L.; van der Westheuizen, F. H.; Louw, R. J. Am. Soc. 
Hypertens. 2015, 9, 104-114. 
40. Lewis, G. D. Pulm. Circ.2014, 4, 417-423. 
41. Nevzati, E.; Shafighi, M.; Bakhtian, K. D.; Treiber, H.; Fandino, J.; Fathi, A. R. Acta Neurochir. Suppl. 2015, 120, 141-
145. 
42. Sjöberg, R. L.; Bergenheim, T.; Mörén, L.; Antti, H.; Lindgren, C.; Naredi, S.; Lindvall, P. Neurocrit. Care. 2015. In 
press. 
43. Piccolo, B. D.; Comerford, K. B.; Karakas, S. E.; Knotts, T. A.; Fiehn, O.; Adams, S. H. J. Nutr. 2015, 145, 691-700. 
44. Sood, R. F.; Gu, H.; Djukovic, D.; Deng, L.; Ga, M.; Muffley, L. A.; Raftery, D.; Hocking, A. M. Wound Repair Regen. 
2015. In press. 
45. Fahrmann, J.; Grapoy, D.; Yang, J.; Hammock, B.; Fiehn, O.; Bell, G. I.; Hara, M. Am. J. Physiol. Endorcinol. Metab. 
2015. In press. 
46. McGill, M. R..; Li, F.; Sharpe, M. R.; Williams, C. D.; Curry, S. C.; Ma, X.; Jaeschke, H. Arch. Toxicol. 2014, 88, 391-
401. 
47. Lu, Y.; Sun, J.; Petrova, K.; Yang, X.; Greenhaw, J.; Salminen, W. F.; Beger, R. D.; Schnackenberg, L. K. Food Chem. 
Toxicol. 2013, 62, 707-721. 
48. Coen, M. Drug Metab. Rev. 2014. In press. 
49. Hart, N. R. Pregnancy Hypertens. 2015, 5, 132. 
50. Bond, L.; Nolan, C.; Hyland, K.; Lenaerts, C.; Baker, P. N.; Kenny, L. C.; Tuytten, R. Pregnancy Hypertens. 2015, 5, 
82. 
51.  Tripathi, P.; Somashekar, B. S.; Ponnusamy, M.; Gursky, A.; Dailey, S.; Kunju, P.; Lee, C. T.; Chinnaiyan, A. M.; 
Rajendiran, T. M.; Ramamoorthy, A. J. Proteome Res. 2013, 12, 3519-3528. 
52. Issaq, H. J.; Nativ, O.; Waybright, T.; Luke, B.; Veenstra, T. D.; Issaq, E. J.; Kravstov, A.; Mullerad, M. J. Urol. 2008, 
179, 2422-2426. 
53. Putluri, N.; Shojaie, A.; Vasu, V. T.; Vareed, S. K.; Nalluri, S.; Putluri, V.; Thangjam, G. S.; Panzitt, K.; Tallman, C. T.; 
Butler, C.; Sana, T. R.; Fischer, S. M.; Sica, G.; Brat, D. J.; Shi, H.; Palapattu, G. S.; Lotan, Y.; Weizer, A. Z.; Terris, M. 
K.; Shariat, S. F.; Michailidis, G.; Sreekumar, A. Cancer Res. 2011, 71, 7376-7386. 
54. Pasikanti, K. K.; Esuvaranathan, K.; Ho, P. C.; Mahendran, R.; Kamaraj, R.; Wu, Q. H.; Chiong, E.; Chan, E. C. J. 
Proteome Res. 2010, 9, 2988-2995. 
55.  Huang, Z.; Lin, L.; Gao, Y.; Chen, Y.; Yan, X.; Xing, J.; Hang, W. Mol. Cell Proteomics.2011, 10, 1074. 
56. Kim, J.-W.; Lee, G.; Moon, S.-M.; Park, M.-J.; Hong, S. K.; Ahn, Y.-H.; Kim, K.-R.; Paik, M-J. Metabolomics. 2010, 
6, 202-206. 
57. Jobu, K.; Sun, C.; Yoshioka, S.; Yokota, J.; Onogawa, M.; Kawada, C.; Inoue, K.; Shuin, T.; Sendo, T.; Miyamura, M. 
Biol. Pharm. Bull.2012, 35, 639-642. 
58.  Chen, Y.-T.; Chen, H.-W.; Domanski, D.; Smith, D. S.; Liang, K.-H.; Wu, C.-C.; Chen, C.-L.; Chung, T.; Chen, M.-C.; 
Chang, Y.-S.; Parker, C. E.; Borchers, C. H.; Yu, J.-S. J. Proteomics 2012, 75, 3529-3545. 
59. Srivastava, S.; Roy, R.; Singh, S.; Kumar, P.; Dalela, D.; Sankhwar, S. N.; Goel, A.; Sonkar, A. A. Cancer Biomark 
2010, 6, 11-20. 
60. Cao, M.; Zhao, L.; Chen, H.; Xue, W.; Lin, D. Anal. Sci. 2012, 28, 451-456. 
61. Monleon, D.; Morales, J. M.; Gonzalez-Darder, J.; Talamantes, F.; Cortes, O.; Gil-Benso, R.; Lopez-Gines, C.; Cerda-
Nicolas, M.; Celda, B. J. Proteome Res. 2008, 7, 2882-2888. 
62. Erb, G.; Elbayed, K.; Piotto, M.; Raya, J.; Neuville, A.; Mohr, M.; Maitrot, D.; Kehrli, P.; Namer, I. J. Magn. Reson. 
Med. 2008, 59, 959-965. 
63. Aria Tzika, A.; Cheng, L. L.; Goumnerova, L.; Madsen, J. R.; Zurakowski, D.; Astrakas, L. G.; Zarifi, M. K.; Scott, 
M.; Anthony, D. C.; Gonzalez, R. G.; M., Black. P.  J. Neurosurg. 2002, 96, 1023-1031 
64. Gleissman, H.; Yang, R.; Martinod, K.; Lindskog, M.; Serhan, C. N.; Johnsen, J. I.; Kogner, P. FASEB J. 2010, 24, 
906-915. 
65. Reitman, Z. J.; Jin, G.; Karoly, E. D.; Spasojevic, I.; Yang, J.; Kinzler, K. W.; He, Y.; Bigner, D. D.; Vogelstein, B.; 
Yan, H. Proc. Natl. Acad. Sci. 2011, 108, 3270-3275. 
66. Maxwell, R. J.; Martinez-Perez, I.; Cerdan, S.; Cabanas, M. E.; Arus, C.; Moreno, A.; Capdevila, A.; Ferrer, E.; 
Bartomeus, F.; Aparicio, A.; Conesa, G.; Roda, J. M.; Carceller, F.; Pascual, J. M.; Howells, S. L.; Mazucco, R.; Griffiths, 
J. R. Magn. Reson. Med. 1998, 39, 869-877. 
67. Lehnhardt, F. G.; Rohn, G.; Ernestus, R. I.; Grune, M.; Hoehn, M. NMR Biomed. 2001, 14, 307-317. 
68. Maletić-Savatić, M.; Vingara, L. K.; Manganas, L. N.; Li, Y.; Zhang, S.; Sierra, A.; Hazel, R.; Smith, D.; Wagshul, M. 
E.; Henn, F.; Krupp, L.; Enikolopov, G.; Benveniste, H.; Djurić, P. M.; Pelczer, I. Cold Spring Harb. Symp. Quant. Biol. 
2008, 73, 389-401. 
M51 
69. Sitter, B.; Lundgren, S.; Bathen, T. F.; Halgunset, J.; Fjosne, H. E.; Gribbestad, I. S. NMR Biomed. 2006, 19, 30-40. 
70. Bathen, T. F.; Jensen, L. R.; Sitter, B.; Fjösne, H. E.; Halgunset, J.; Axelson, D. E.; Gribbestad, I. S.; Lundgren, S. 
Breast Cancer Res. Treat. 2007, 104, 181-189. 
71. Sitter, B.; Sonnewald, U.; Spraul, M.; Fjönse, H. E.; Gribbestad, I. S. NMR Biomed. 2002, 15, 327-337. 
72. Giskeødegård, G. F.; Grinde, M. T.; Sitter, B.; Axelson, D. E.; Lundgren, S.; Fjøsne, H. E.; Dahl, S.; Gribbestad, I. S.; 
Bathen, T. F. J. Proteome Res. 2010, 9, 972-979. 
73. Borgan, E.; Sitter, B.; Linjærde, O. C.; Johnsen, H.; Lundgren, S.; Bathen, T. F.; Sørlie, T.; Børresen-Dale, A.-L.; 
Gribbestad, I. S. BMC Cancer. 2010, 10, 628. 
74. Wei, S.; Liu, L.; Zhang, J.; Bowers, J.; Nagana Gowda, G. A.; Seeger, H.; Fehm, T.; Neubauer, H. J.; Vogel, U.; Clare, 
S. E.; Raftery, D. Mol. Oncol. 2013, 7, 297-307. 
75. Li, M.; Song, Y.; Cho, N.; Chang, J. M.; Koo, H. R.; Yi, A.; Kim, H.; Park, S.; Moon, W. K. PLoS One 2011, 6. 
76. Sugimoto, M.; Wong, D. T.; Hirayama, A.; Soga, T.; Tomita, M. Metabolomics. 2010, 6, 78-95. 
77. Gu, H.; Pan, Z.; Xi, B.; Asiago, V.; Musselman, B.; Raftery, D. Anal. Chim. Acta. 2011, 686, 57-63. 
78. Nam, H.; Chung, B. C.; Kim, Y.; Lee, K.; Lee, D. Bioinformatics 2009, 25, 3151-3157. 
79. Asiago, V. M.; Alvarado, L. Z.; Shanaiah, N.; Nagana Gowda, G. A.; Owusu-Sarfo, K.; Ballas, R. A.; Raftery, D. 
Cancer Res. 2010, 70, 8309. 
80. Kim, Y.; Koo, I.; Jung, B. H.; Chung, B. C.; Lee, D. BMC Bioinform. 2010, 11, S4. 
81. Budczies, J.; Denkert, C.; Müller, B. M.; Brockmöller, S. F.; Klauschen, F.; Györffy, B.; Dietel, M.; Richter-
Ehrenstein, C.; Marten, U.; Salek, R. M.; Griffin, J. L.; Hilvo, M.; Orešič, M.; Wohlgemuth, G.; Fiehn, O. BMC Genomics. 
2012, 13, 334. 
82. Miyagi, Y.; Higashiyama, M.; Gochi, A.; Akaike, M.; Ishikawa, T.; Miura, T.; Saruki, N.; Bando, E.; Kimura, H.; 
Imamura, F.; Moriyama, M.; Ikeda, I.; Chiba, A.; Oshita, F.; Imaizumi, A.; Yamamoto, H.; Hiyano, H.; Horimoto, K.; 
Tochikubo, O.; Mitsushima, T; Yamakado, M; Okamoto, N. PLoS One. 2011, 6. 
83. Brockmöller, S. F.; Bucher, E.; Müller, B. M.; Budczies, J.; Hilvo, M.; Griffin, J. L.; Orešič, M.; Kallioniemi, O.; Iljin, 
K.; Loibl, S.; Darb-Esfahani, S.; Sinn, B. V.; Klauschen, F.; Prinzler, J.; Bangemann, N.; Ismaeel, F.; Fiehn, O.; Dietel, M.; 
Denkert, C. J. Proteome Res. 2012, 11, 850-860. 
84. Oakman, C.; Tenori, L.; Biganzoli, L.; Santarpia, L.; Cappadona, S.; Luchinat, C.; Di Leo, A. Int. J. Biochem. Cell. 
Biol. 2010. 
85. Gribbestad, I. S.; Petersen, S. B.; Fjosne, H. E.; Kvinnsland, S.; Krane, J. NMR Biomed 1994, 7, 181-194. 
86. Beckonert, O.; Monnerjahn, J.; Bonk, U.; Leibritz, D. V. NMR Biomed 2003, 16, 1-11. 
87. Slupsky, C. M.; Steed, H.; Wells, T. H.; Dabbs, K.; Schepansky, A.; Capstick, V.; Faught, W.; Sawyer, M. B. Clin. 
Cancer Res. 2010, 16, 5835. 
88. Tenori, L.; Oakman, C.; Claudino, W. M.; Bernini, P.; Cappadona, S.; Nepi, S.; Biganzoli, L.; Arbushites, M. C.; 
Luchinat, C.; Bertini, I.; Di Leo, A. Mol. Oncol 2012, 6, 437-444. 
89. Weljie, A. M.; Bondareva, A.; Zang, P.; Jirik, F. R. J. Biomol. NMR 2011, 49, 185-193. 
90. Bayet-Robert, M.; Lim, S.; Barthomeuf, C.; Morvan, D. Biochem. Pharmacol. 2010, 80, 1170-1179. 
91. Oakman, C.; Tenori, L.; Claudino, W. M.; Cappadona, S.; Nepi, S.; Battaglia, A.; Bernini, P.; Zafarana, E.; Saccenti, 
E.; Fornier, M.; Morris, P. G.; Biganzoli, L.; Luchinat, C.; Bertini, I.; Di Leo, A. Ann. Oncol. 2011, 22, 1295-1301. 
92. Sitter, B.; Bathen, T.; Hagen, B.; Arentz, C.; Skjeldestad, F. E.; Gribbestad, I. S. Magma 2004, 16, 1741-1781. 
93. De Silva, S. S.; Payne, G. S.; Thomas, V.; Carter, P. G.; Ind, T. E.; deSouza, N. M. NMR Biomed. 2009, 22, 191-198. 
94. Woo, H. M.; Kim, K. M.; Choi, M. N.; Jung, B. H.; Lee, J.; Kong, G.; Nam, S. J.; Kim, S.; Bai, S. W.; Chugn, B. C. 
Clin.Chim. Acta. 2009, 400, 63-69. 
95. Bertini, I.; Cacciatore, S.; Jensen, B. V.; Schou, J. V.; Johansen, J. S.; Kruhøffer, M.; Luchinat, C.; Nielsen, D. L.; 
Turano, P. Cancer Res. 2012, 72, 356. 
96. Chan, E.C.; Koh, P.K.; Mal, M.; Cheah, P. Y.; Eu, K.W.; Backshall, A.; Cavill, R.; Nicholson, J. K.; Keun, H. C. J. 
Proteome Res. 2009, 8, 352-361. 
97. Jordan, K. W.; Nordenstam, J.; Lauwers, G. Y.; Rothenberger, D. A.; Alavi, K.; Garwood, M.; Cheng, L. L. Disease. 
Colon Rectum. 2009, 52, 520-525. 
98. Hirayama, A.; Kami, K.; Sugimoto, M.; Sugawara, M.; Toki, N.; Onozuka, H.; Kinoshita, T.; Saito, N.; Ochiai, A.; 
Tomita, M.; Esumi, H.; Soga, T. Cancer Res. 2009, 69, 4918. 
99. Kondo, Y.; Nishiumi, S.; Shinohara, M.; Hatano, N.; Ikeda, A.; Yoshie, T.; Kobayashi, T.; Shiomi, Y.; Irino, Y.; 
Takenawa, T.; Azuma, T.; Yoshia, M. Biomark. Med. 2011, 5, 451-460. 
100. Ma, Y.; Zhang, P.; Wang, F.; Liu, W.; Yang, J.; Qin, H. Ann. Surg. 2012, 255, 720-730. 
101. Nishiumi, S.; Kobayashi, T.; Ikeda, A.; Yoshie, T.; Kibi, M.; Izumi, Y.; Okuno, T.; Hayashi, N.; Kawano, S.; 
Takenawa, T.; Azuma, T.; Yoshida, M. PLoS ONE 2012, 7. 
102. Qiu, Y.; Cai, G.; Su, M.; Chen, T.; Liu, Y.; Xu, Y.; Ni, Y.; Zhao, A.; Cai, S.; Xu, L. X.; Jia, W. J. Proteome Res. 2010, 
9, 1627-1634. 
103. Qiu, Y.; Cai, G.; Su, M.; Chen, T.; Zheng, X.; Xu, Y.; Ni, Y.; Zhao, A.; Xu, L. X.; Cai, S.; Jia, W. J. Proteome Res. 
2009, 8, 4844-4850. 
M52 
104. Ma, Y.-L.; Qin, H.-L.; Liu, W.-J.; Peng, J.-Y.; Huang, L.; Zhao, X.-P.; Cheng, Y.-Y. Dig. Dis. Sci. 2009, 54, 2655-
2662. 
105. Mal, M.; Koh, P. K.; Cheah, P. Y.; Chan, E. C. Y. Metabotyping of human colorectal cancer using two-dimensional 
gas chromatography mass spectrometry. Anal. Bioanal. Chem. 2012, 403, 483-493. 
106. Denkert, C.; Budczies, J.; Weichert, W.; Wohlgemuth, G.; Scholz, M.; Kind, T.; Niesporek, S.; Noske, A.; 
Buckendahl, A.; Dietel, M.; Fiehn, O. Molecular Cancer 2008, 7, 72. 
107. Ritchie, S. A.; Ahiahonu, P. W. K.; Jayasinghe, D.; Heath, D.; Liu, J.; Lu, Y.; Jin, W.; Kavianpour, A.; Yamazaki, Y.; 
Khan, A. M.; Hossain, M.; Su-Myat, K. K.; Wood, P. L.; Krenitsky, K.; Takemasa, I.; Miyake, M.; Sekimoto, M.; Monden, 
M.; Matsubara, H.; Nomura, F.; Goodenowe, D. B. BMC Medicine 2010, 8, 13. 
108. Feng, B.; Yue, F.; Zheng, M. H. Adv. Clin. Chem. 2009, 47, 45-57. 
109. Moreno, A.; Arus, C. NMR Biomed 1996, 9, 33-45. 
110. Monléon, D.; Morales, J. M.; Barrasa, A.; López, J. A.; Vázquez, C.; Celda, B. NMR in Biomedicine 2009, 22, 342-
348. 
111. Ludwig, C.; Ward, D. G.; Martin, A.; Viant, M. R.; Ismail, T.; Johnson, P. J.; Wakelam, M. J. O.; Günther, U. L. Mag. 
Reson. Chem. 2009, 47, S68-S73. 
112. Yonezawa, K.; Nishiumii, S.; Kitamoto-Matsuda, J.; Fujita, T.; Morimoto, K.; Yamashita, D.; Saito, M.; Otsuki, N.; 
Irino, Y.; Shinohara, M.; Yoshida, M.; Nibu, K.-I. Cancer Genom. Proteom. 2013, 10, 233-238.  
113. Xie, G. X.; Chen, T. L.; Qui, Y. P.; Shi, P.; Zheng, X. J.; Su, M. M.; Zhao, A. H.; Zhou, Z. T.; Jia, W. Metabolomics 
2012, 8, 220-231. 
114. Wei, J.; Xie, G.; Zhou, Z.; Shi, P.; Qui, Y.; Zheng, X.; Chen, T.; Su, M.; Zhao, A.; Jia, W. Int. J. Cancer 2011, 129, 
2207-2217. 
115. Yan, S.-K..; Wei, B.-J.; Lin, Z.-Y.; Yang, Y.; Zhou, Z.-T.; Zhang, W.-D. Oral Oncol. 2008, 44, 477-483. 
116. Bezabeth, T.; Odlum, O.; Nason, R.; Kerr, P.; Sutherland, D.; Patel, R.; Smith, I. C. P. Am. J. Neuroadiol. 2005, 26, 
2108-2113. 
117. Shukla-Dave, A.; Poptani, H.; Loevner, L. A.; Mancuso, A.; Serrai, H.; Rosenthal, D. I.; Kilger, A. M.; Nelson, D. S.; 
Zalkan, K. L.; Arlas-Mendoza, F.; Rijpkema, M.; Koutcher, J. A.; Brown, T. R.; Heerschap, A.; Glickson, J. D. Acad. 
Radiol. 2002, 9, 688-694. 
118. Mukherji, S. K.; Schiro, S.; Castillo, M.; Kwock, L.; Muller, K. E.; Blackstock, W. Am. J. Neuroadiol. 1997, 18, 
1057-1072. 
119. Zhou, J.; Xu, B.; Huang, J.; Jia, X.; Xue, J.; Shi, X.; Xiao, L.; Li, W. Clin. Chim. Acta. 2009, 401, 8-13. 
120. Tiziani, S.; Lopes, V.; Günther, U. L. Neoplasia 2009, 11, 269-276. 
121. Aimetti, M.; Cacciatore, S.; Graziano, A.; Tenori, L. Metabolomics 2012, 8, 465-474. 
122. Srivastava, S.; Roy, R.; Gupta, V.; Tiwari, A.; Srivastava, A. N.; Sonkar, A. A. Metabolomics 2011, 7, 278-288. 
123. Somashekar, B. S.; Kamarajan, P.; Danciu, T.; Kapila, Y. L.; Chinnaiyan, A. M.; Rajendiran, T. M.; Ramamoorthy, A. 
J. Proteome Res. 2011, 10, 5232-5241. 
124. Torregrossa, L.; Shintu, L.; Chandran, J. N.; Tintaru, A.; Ugolini, C.; Magalhães, A.; Basolo, F.; Miccoli, P.; 
Caldarelli, S. J. Proteome Res. 2012, 33, 3317-3325. 
125. Zhang, J.; Bowers, J.; Liu, L.; Wei, S.; Nagana Gowda, G. A.; Hammoud, Z.; Raftery, D. PLoS ONE 2012. 
126. Xu, J.; Chen, Y.; Zhang, R.; Song, Y.; Cao, J.; Bi, N.; Wang, J.; He, J.; Bai, J.; Dong, L.; Wang, L.; Zhan, Q.; Abliz, Z. 
Mol. Cell Proteom. 2013, 12, 1306-1318. 
127. Wu, H.; Xue, R.; Lu, C.; Deng, C.; Liu, T.; Zeng, H.; Wang, Q.; Shen, X. J. Chromatograph. B. 2009, 877, 3111-
3117. 
128. Kumar, S.; Huang, J.; Cushnir, J. R.; Španěl, P.; Smith, D.; Hanna, G. B. Anal. Chem. 2023, 84, 9550-9557.  
129. Hasim, A.; Ma, H.; Mamtimin, B.; Abudula, A.; Miyaz, M.; Zhang, L.-W.; Anwer, J.; Sheyhidin, I. Mol. Biol. Rep. 
2012, 39, 8955-8964. 
130. Zhang, J.; Liu, L.; Wei, S.; Nagana Gowda, G. A.; Hammoud, Z.; Kesler, K. A.; Raftery, D. Gen. Thor. Surg. 2011, 
141, 469-475. 
131. Davis, V. W.; Schiller, D. E.; Eurich, D.; Sawyer, M. B. World J. Surg. Oncol. 2012, 10, 271-282. 
132. Tugnoli, V.; Mucci, A.; Schenetti, L.; Righi, V.; Calabrese, C.; Fabbri, A.; Di Febo, G.; Tosi, M. R. Oncol. Rep. 2006, 
16, 543-553. 
133. Wu, H.; Xue, R.; Tang, Z.; Deng, C.; Liu, T.; Zeng, H.; Sun, Y.; Shen, X. Anal. Bioanal. Chem 2010, 396, 1385-1395. 
134. Ikeda, A.; Nishiumi, S.; Shinohara, M.; Yoshie, T.; Hatano, N.; Okuno, T.; Bamba, T.; Fukusaki, E.; Takenawa, T.; 
Azuma, T.; Yoshida, M. Biomed. Chromatogr. 2012, 26, 548-558. 
135.  Hu, J.-D.; Tang, H.-Q.; Zhang, Q.; Fan, J.; Hong, J.; Gu, J.-Z.; Chen, J.-L. World J. Gastroenterol . 2011, 17, 727-
734. 
136. Chen, J.-L.; Tang, H.-Q.; Hu, J.-D.; Fan, J.; Hong, J.; Gu, J.-Z. World J. Gastroenterol. 2010, 16, 5874-5880. 
137. Song, H.; Peng, J.-S.; Yao, D.-S.; Yang, Z.-L.; Liu, H.-L.; Zeng, Y.-K.; Shi, X.-P.; Lu, B.-Y. Braz J Med Biol Res 
2012, 45, 78-85. 
M53 
138. Cai, Z.; Zhao, J.-S.; Li, J.-J.; Peng, D.-N.; Wang, X.-Y.; Chen, T.-L.; Qui, Y.-P.; Chen, P.-P.; Li, W.-J.; Xu, L.-Y.; Li, 
E.-M.; Tam, J. P. M.; Qi, R. Z.; Jia, W.; Xie, D. Mol. Cell Proteomics. 2010, 9, 2617-2628. 
139. Yoshida, M.; Hatano, N.; Nishiumi, S.; Irino, Y.; Izumi, Y.; Takenawa, T.; Azuma, T. J. Gastroenterol. 2012, 47, 9-20. 
140. Morita, Y.; Ikegami, K.; Goto-Inoue, N.; Hayasaka, T.; Zaima, N.; Tanaka, H.; Uehara, T.; Setoguchi, T.; Sakaguchi, 
T.; Igarashi, H.; Sugimura, H.; Setou, M.; Konno, H. Cancer Sci. 2010, 101, 267-273. 
141. Kim, K.-B.; Yang, J.-Y.; Kwack, S. J.; Park, K. L.; Kim, H. S.; Ryu, D. H.; Kim, Y.-J.; Hwang, G.-S.; Lee, B. M. J. 
Toxicol. Environ. Health 2010, 73. 
142. Yang, Y.; Li, C.; Nie, X.; Feng, X.; Chen, W.; Yue, Y.; Tang, H.; Deng, F. J. Proteome Res 2007, 6, 2605-2614. 
143. Patterson, A. D.; Maurhofer, O.; Beyoğlu, D.; Lanz, C.; Krausz, K. W.; Pabst, T.; Gonzalez, F. J.; Dufour, J.-F.; Idle, 
J. R. Cancer Res. 2011, 71, 6590. 
144. H., W.; Xue, R.; Dong, L.; Liu, T.; Deng, C.; Zeng, H.; Shen, X. Anal. Chim. Acta. 2009, 648, 98-104. 
145. Li, S.; Liu, H.; Jin, Y.; Lin, S.; Cai, Z.; Jiang, Y. J. Chromatograph. B. 2011, 879, 2369-2375. 
146. Soga, T.; Baran, R.; Suematsu, M.; Ueno, Y.; Ikeda, S.; Sakurakawa, T.; Kakazu, Y.; Ishikawa, T.; Robert, M.; 
Nishioka, T.; Tomita, M. J. Biol. Chem. 2006, 281, 16768-16776. 
147. Soga, T.; Sugimoto, M.; Honma, M.; Mori, M.; Igarashi, K.; Kashikura, K.; Ikeda, S.; Hirayama, A.; Yamamoto, T.; 
Yoshida, H.; Otsuka, M.; Tsuji, S.; Yatomi, Y.; Sakuragawa, T.; Watanabe, H.; Nihei, K.; Saito, T.; Kawata, S.; Suzuki, H.; 
Tomita, M.; Suematsu, M.  J. Hepatol. 2011, 55, 896-905. 
148. Tan, Y.; Yin, P.; Tang, L.; Xing, W.; Huang, Q.; Cao, D.; Zhao, X.; Wang, W.; Lu, X.; Xu, Z.; Wang, H.; Zu, G. Mol. 
Cell Proteomics.2012, 11. 
149. Ressom, H. W.; Xiao, J. F.; Tuli, L.; Varghese, R. S.; Zhou, B.; Tsai, T.-H.; Nezami Ranjbar, M. R.; Zhao, Y.; Wang, 
J.; Di Poto, C.; Cheema, A. K.; Tadesse, M. G.; Goldman, R.; Shetty, K. Anal. Chim. Acta. 2012, 743, 90-100. 
150. Cao, H.; Huang, H.; Xu, W.; Chen, D.; Yu, J.; Li, J.; Li, L. Anal. Chim. Acta. 2011, 691, 68-75. 
151. Chen, J.; Wang, W.; Lv, S.; Yin, P.; Zhao, X.; Lu, X.; Zhang, F.; Xu, G. Anal. Chim. Acta. 2009, 650, 3-9. 
152. Zhang, A.; Sun, H.; Yan, G.; Han, Y.; Ye, Y.; Wang, X. Clin. Chim. Acta. 2013, 418, 86-90. 
153. Xue, R.; Lin, Z.; Deng, C.; Dong, L.; Liu, T.; Wang, J.; Shen, X. Rapid. Comm. Mass. Spec. 2008, 22, 3061-3068. 
154. Zhou, L.; Wang, Q.; Yin, P.; Xing, W.; Wu, Z.; Chen, S.; Lu, X.; Zhang, Y.; Lin, X.; Xu, G. Anal. Bioanal. Chem. 
2012, 403, 203-213. 
155. Chen, T.; Xie, G.; Wang, X.; Fan, J.; Qiu, Y.; Zheng, X.; Qi, X.; Cao, Y.; Su, M.; Wang, X.; Xu, L. X.; Yen, Y.; Liu, P.; 
Jia, W. Mol. Cell Proteomics. 2011, 10. 
156. Wang, X.; Zhang, A.; Han, Y.; Wang, P.; Sun, H.; Song, G.; Dong, T.; Yuan, Y.; Yuan, X.; Zhang, M.; Xie, N.; Zhang, 
H.; Dong, H.; Dong, W. Mol. Cell Proteomics. 2012, 11, 370-380. 
157. Wen, H.; Yoo, S. S.; Kang, J.; Kim, H. G.; Park, J.-S.; Jeong, S.; Lee, J. I.; Kwon, H. N.; Kang, S.; Lee, D.-H.; Park, 
S. J. Hepatol. 2010, 52, 228-233. 
158.  Wei, S.; Suryani, Y.; Nagana Gowda, G. A.; Skill, N.; Maluccio, M.; Raftery, D. Metabolites 2012, 2, 701-716. 
159. Nagana Gowda, G. A.; Shanaiah, N.; Cooper, A.; Maluccio, M.; Raftery, D. Lipids 2009, 44, 27-35. 
160. Mizuno, H.; Tsuyama, N.; Date, S.; Harada, T.; Masujima, T. Live Anal. Sci. 2008, 24. 
161. Tiziani, S.; Kang, Y.; Harjanto, R.; Axelrod, J.; Piermarocchi, C.; Roberts, W.; Paternostro, G. Metabolomics of the 
Tumor Microenvironment in Pediatric Acute Lymphoblastic Leukemia. PLoS One 2013, 8. 
162. Wang, Y.; Gao, D.; Chen, Z.; Li, S.; Gao, C.; Cao, D.; Liu, F.; Liu, H.; Jiang, Y. PLoS One 2013, 8. 
163. A, J.; Qian, S.; Wang, G.; Yan, B.; Zhang, S.; Huang, Q.; Ni, L.; Zha, W.; Liu, L.; Cao, B.; Hong, M.; Wu, H.; Lu, H.; 
Shi, J.; Li, M.; Li, J. PLoS One 2010, 5. 
164. MacIntyre, D. A.; Jiménez, B.; Lewintre, E. J.; Martín, C. R.; Schäfer, H.; Ballesteros, C. G.; Mayans, J. R.; Spraul, 
M.; García-Conde, J.; Pineda-Lucena, A. Leukemia 2010, 24, 788-797. 
165. Rainaldi, G.; Romano, R.; Indovina, P.; Ferrante, A.; Motta, A.; Indovina, P. L.; Santini, M. T. Radiat. Res. 2008, 169, 
170-180. 
166. Miccheli, A.; Tomassini, A.; Puccetti, C.; Valerio, M.; Peluso, G.; Tuccillo, F.; Calvani, M.; Manetti, C.; Conti, F. 
Biochimie 2006, 88, 437-448. 
167. Dewar, B. J.; Keshari, K.; Jeffires, R.; Dzeja, P.; Graves, L. M.; Macdonald, J. M. Metabolomics 2010, 6, 439-450. 
168. Cano, K. E.; Li, L.; Bhatia, S.; Bhatia, R.; Forman, S. J.; Chen, Y. J. Proteome Res. 2011, 10, 2873-2881. 
169. Tiziani, S.; Lodi, A.; Khanim, F. L.; Viant, M. R.; Bunce, C. M.; Günther, U. L. Metabolomic Profiling of Drug 
Responses in Acute Myeloid Leukaemia Cell Lines. PLoS One 2009, 4. 
170. Chen, W.; Zu, Y.; Huang, Q.; Chen, F.; Wang, G.; Lan, W.; Bai, C.; Lu, S.; Yue, Y.; Deng, F. Magn. Reson. Med. 2011. 
171. Rocha, C. M.; Barros, A. S.; Gil, A. M.; Goodfellow, B. J.; Humpfer, E.; Spraul, M.; Carreira, I. M.; Melo, J. B.; 
Bernardo, J.; Gomes, A.; Sousa, V.; Carvalho, L.; Duarte, I. F. J. Proteome Res. 2010, 9, 319-332. 
172. Fan, T. W. M.; Lane, A. N.; Higashi, R. M.; Farag, M. A.; Gao, H.; Bousamra, M.; Miller, D. M. Mol. Cancer. 2009, 
8, 41. 
173. Fan, T. W. M.; Bandura, L. L.; Higashi, R. M.; Lane, A. N. Metabolomics 2005, 1, 325-339. 
174. Jordan, K. W.; Adkins, C. B.; Su, L.; Halpern, E. F.; Mark, E. J.; Christiani, D. C.; Cheng, L. L. Lung Cancer 2010, 
68, 44-50. 
M54 
175. Fan, T. W. M.; Lane, A. N.; Higashi, R. M.; Yan, J. Metabolomics 2011, 7, 257-269. 
176. An, Z.; Chen, Y.; Zhang, R.; Song, Y.; Sun, J.; He, J.; Bai, J.; Dong, L.; Zhan, Q.; Abliz, Z. J. Proteome Res. 2010, 9, 
4071-4081. 
177. Dong, J.; Cai, X.; Zhao, L.; Xue, X.; Zou, L.; Zhang, X.; Liang, X. Metabolomics 2010, 6, 478-488. 
178. Wedge, D. C.; Allwood, J. W.; Dunn, W.; Vaughan, A. A.; Simpson, K.; Brown, M.; Priest, L.; Blackhall, F. H.; 
Whetton, A. D.; Dive, C.; Goodacre, R. Anal. Chem. 2011, 83, 6689-6697. 
179. Maeda, J.; Higashiyama, M.; Imaizumi, A.; Nakayama, T.; Yamamoto, H.; Daimon, T.; Yamakado, M.; Imamura, F.; 
Kodama, K. BMC Cancer 2010, 10, 690. 
180. Hori, S.; Nishiumi, S.; Kobayashi, K.; Shinohara, M.; Hatakeyama, Y.; Kotani, Y.; Hatano, N.; Maniwa, Y.; Nishio, 
W.; Bamba, T.; Fukusaki, E.; Azuma, T.; Takenawa, T.; Nishimura, Y.; Yoshida, M. Lung Cancer 2011, 74, 284-292. 
181. Hanaoka, H.; Yoshioka, Y.; Ito, I.; Niitu, K.; Yasuda, N. Magn. Reson. Med. 1993, 29, 436-440. 
182. Carrola, J.; Rocha, C. M.; Barros, A. S.; Gil, A. M.; Goodfellow, B. J.; Carreira, I. M.; Bernardo, J.; Gomes, A.; 
Sousa, V.; Carvalho, l.; Duarte, I. F.. J. Proteome Res. 2011, 10, 221-230.  
183. Rocha, C.; Carrola, J.; Barros, A. S.; Gil, A. M.; Goodfellow, B. J.; Carreira, I. M.; Bernardo, J.; Gomes, A.; Sousa, 
V.; Carvalho, L.; Duarte, I. F. J. Proteome Res. 2011, 10, 4314-4324. 
184. Guan, W.; Zhou, M.; Hampton, C. Y.; Benigno, B. B.; Walker, L. D.; Gray, A.; F., M. J.; Fernández, F. M. BMC 
Bioinformatics 2009, 10, 259. 
185. Chen, J.; Zhang, X.; Cao, R.; Lu, X.; Zhao, S.; Fekete, A.; Huang, Q.; Schmitt-Kopplin, P.; Wang, Y.; Xu, Z.; Wan, 
X.; Wu, X.; Zhao, N.; Xu, C.; Zu, G. J. Proteome Res. 201, 10, 2625-2632. 
186. Denkert, C.; Budczies, J.; Kind, T.; Weichert, W.; Tablack, P.; Sehouli, J.; Niesporek, S.; Könsgen, D.; Dietel, M.; 
Fiehn, O. Mass Spectrometry–Based Metabolic Profiling Reveals Different Metabolite Patterns in Invasive Ovarian 
Carcinomas and Ovarian Borderline Tumors. Cancer Res. 2006, 66, 10795. 
187. Fong, M. Y.; McDunn, J.; Kaker, S. S. PLoS ONE 2011. 
188. Zhang, T.; Wu, X.; Ke, C.; Yin, M.; Li, Z.; Fan, L.; Zhang, W.; Zhang, H.; Zhao, F.; Zhou, X.; Lou, G.; Li, K.  J. 
Proteome Res. 2013, 12, 505-512. 
189. Zhou, M.; Guan, W.; Walker, L. D.; Mezencev, R.; Benigno, B. B.; Gray, A.; Fernández, F. M.; McDonald, J. M. 
Cancer Epidemiol Biomarkers Prev. 2010, 19., 2262. 
190. Zhang, T.; X., W.; Yin, M.; Fan, L.; Zhang, H.; Zhao, F.; Zhang, W.; Ke, C.; Zhang, G.; Hou, Y.; Zhou, X.; Lou, G.; 
Li, K. Clin. Chim. Acta. 2012, 413, 861-868. 
191. Odunsi, K.; Wollman, R. M.; Ambrosone, C. B.; Huston, A.; McCann, S. E.; Tammela, J.; Geisler, J. P.; MIller, G.; 
Sellers, T.; Cliby, W.; Qian, F.; Keitz, B.; Intengan, M.; lele, S.; Alderfer, J. L. Int. J. Cancer 2005, 113, 782-788. 
192. Garcia, E.; Andrews, C.; Hua, J.; Kim, H. L.; Sukumaran, D. K.; Szyperski, T.; Odunsi, K. J. Proteome Res. 2011, 10, 
1765-1771. 
193. Fang, F.; He, X.; Deng, H.; Chen, Q.; Lu, J.; Spraul, M.; Yu, Y. Cancer Sci. 2007, 98, 1678-1682. 
194. Urayama, S.; Zou, W.; Brooks, K.; Tolstikov, V. Rapid. Commun. Mass Spectrom. 2010, 24, 613-620. 
195. Nishiumi, S.; Shinohara, M.; Ikeda, A.; Yoshie, T.; Hatano, N.; Kakuyama, S.; Mizuno, S.; Sanuki, T.; Kutsumi, H.; 
Fukusaki, E.; Azuma, T.; Takenawa, T.; Yoshida, M. Metabolomics 2010, 6, 518-528. 
196. Lane, A. N.; Fan, T. W. M.; Higashi, R. M.; Tan, J.; Bousamra, M.; Miller, D. M. Exp. Mol. Pathol. 86, 86, 165-173. 
197. Ohmine, K.; Kawaguchi, K.; Ohtsuki, S.; Motoi, F.; Egawa, S.; Unno, M.; Terasaki, T. Pharm Res 2012, 29, 2006-
2016. 
198. Liu, H.; Huang, D.; McArthur, D. L.; Boros, L. G.; Nissen, N.; Heaney, A. P. Cancer Res. 2010, 70, 6368. 
199. Bathe, O. F.; Shaykhutdinov, R.; Kopciuk, K.; Weljie, A. M.; McKay, A.; Sutherland, F. R.; Dixon, E.; Dunse, N.; 
Sotiropoulous, D.; Vogel, H. J. Cancer Epidemiol. Biomarkers Prev. 2011, 20, 140. 
200. OuYang, D.; Xu, J.; Huang, H.; Chen, Z. Appl. Biochem. Biotechnol. 201, 165, 148-154. 
201. Beger, R. D.; Shnackenberg, L. K.; Holland, R. D.; Li, D.; Dragan, Y. Metabolomics 2006, 2, 125-134. 
202. Zyromski, N. J.; Mathur, A.; Nagana Gowda, G. A.; Murphy, C.; Swartz-Basile, D. A.; Wade, T. E.; Pitt, H. A.; 
Rafter, D. Pancreatology 2009, 9, 410-419. 
203. Chaika, N. V.; Gebregiworgis, T.; Lewallen, M. E.; Purohit, V.; Radharishnan, P.; Liu, X.; Zhang, B.; Mehla, K.; 
Brown, R. B.; Caffrey, T.; Yu, F.; Johnson, K. R.; Powers, R.; Hollingsworth, M. A.; Singh, P. K. Proc. Acad. Natl. Sci. 
2012, 109, 13787-13792. 
204. Tessem, M. B.; Swanson, M. G.; Keshari, K. R.; Albers, M. J.; Joun, D.; Tabatabai, Z. L.; Simko, J. P.; Shinohara, K.; 
Nelson, S. J.; Vigneron, D. B.; Gribbestad, I. S.; Kurhanewicz, J. Magn. Reson. Med. 2008, 60, 510-516. 
205. Cheng, L. L.; Burns, M. A.; Taylor, J. L.; He, W.; Halpern, E. F.; McDougal, W. S.; Wu, C. L. Cancer Res. 2005, 65, 
3030-3034. 
206. MacKinnon, N.; Khan, A. P.; Chinnaiyan, A. M.; Rajendiran, T. M.; Ramamoorthy, A. Metabolomics 2012, 8, 1026-
1036. 
207. Maxeiner, A.; Adkins, C. B.; Zhang, Y.; Taupitz, M.; Halpern, E. F.; McDougal, W. S.; Wu, C.-L.; Cheng, L. L. The 
Prostate 2010, 70, 710-717. 
M55 
208. McDunn, J. E.; Li, Z.; Adam, K.-P.; Neri, B. P.; Wolfert, R. L.; Milburn, M. V.; Lotan, Y.; Wheeler, T. M. The 
Prostate 2013, 73, 1547-1560. 
209. Cao, D.-L.; Ye, D.-W.; Zhang, H.-L.; Zhu, Y.; Wang, Y.-X.; Yao, X.-D. The Prostate 2011, 71, 700-710. 
210. Wu, H.; Liu, T.; Ma, C.; Xue, R.; Deng, C.; Zeng, H.; Shen, X. Anal. Bioanal. Chem. 2011, 401. 
211. Thysell, E.; Surowiec, I.; Hörnberg, E.; Crnalic, S.; Widmark, A.; Johansson, A. I.; Stattin, P.; Bergh, A.; Moritz, T.; 
Antti, H.; Wikström, P. PLoS One 2010, 5. 
212. Cao, D.-L.; Ye, D.-W.; Zhu, Y.; Zhang, H.-L.; Wang, Y.-X.; Yao, X.-D. Prost. Cancer Prost. Diseases 2011, 14, 166-
172. 
213. Putluri, N.; Shojaie, A.; Vasu, V. T.; Nalluri, S.; Vareed, S. K.; Putluri, V.; Vivekanandan-Giri, A.; Byun, J.; Pennathur, 
S.; Sana, T. R.; Fischer, S. M.; Palapattu, G. S.; Creighton, C. J.; Michailidis, G.; Sreekumar, A. PLoS One 2011, 6. 
214. Fowler, A. H.; Pappas, A. A.; Holder, J. C.; Finkbeiner, A. E.; Dalrymple, G. V.; Mullins, M. S.; Sprigg, J. R.; 
Komoroski, R. A. Magn. Reson. Med. 1992, 25, 140-147. 
215. Raina, K.; Serkova, N. J.; Agarwal, R. Cancer Res. 2009, 69, 3731. 
216. Wu, C.-L.; Jordan, K. W.; Ratai, E. M.; Sheng, J.; Adkins, C. B.; DeFeo, E. M.; Jenkins, B. G.; Ying, L.; McDougal, 
W. S.; Cheng, L. L. Sci. Transl. Med. 2010, 2. 
217. Serkova, N. J.; Gamito, E. J.; Jones, R. H.; O'Donnell, C.; Brown, J. L.; Green, S.; Sullivan, H.; Hedlund, T.; 
Crawford, E. D. The Prostate 2008, 68, 620-628. 
218. Albers, M. J.; Bok, R.; Chen, A. P.; Cunningham, C. H.; Zierhut, M. L.; Zhang, V. Y.; Kohler, S. J.; Tropp, J.; Hurd, 
R. E.; Yen, Y.-F.; Nelson, S. J.; Vigneron, D. B.; Kurhanewicz, J. Cancer Res. 2008, 68, 8607. 
219. Tate, A. R.; Foxall, P. J.; Holmes, E.; Moka, D.; Spraul, M.; Nicholson, J. K.; Lindon, J. C. NMR Biomed 2000, 13, 
64-71. 
220. Righi, V.; Mucci, A.; Schenetti, L.; Tosi, M. R.; Grigioni, W. F.; Corti, B.; Bertaccini, A.; Franceschelli, A.; 
Sanguedolce, F.; Schiavina, R.; Martorana, G.; Tugnoli, V. Anticancer Res 2007, 27, 3195-3204. 
221. Kim, K.; Taylor, S. L.; Ganti, S.; Guo, L.; Osier, M. V.; Weiss, R. H. OMICS 2011, 15, 293-303. 
222. Perroud, B.; Lee, J.; Valkova, N.; Dhirapong, A.; Lin, P.-Y.; Fiehn, O.; Kültz, D.; Weiss, R. H. Molecular cancer 
2006, 5. 
223. Lin, L.; Huang, Z.; Gao, Y.; Yan, X.; Xing, J.; Hang, W. J. Proteome Res. 10, 1396-1405. 
224. Ganti, S.; Taylor, S. L.; Aboud, O. A.; Yang, J.; Evans, C.; Osier, M. V.; Alexander, D. C.; Kim, K.; Weiss, R. H. 
Cancer res. 2012, 72, 3471-3479. 
225. Ganti, S.; Taylor, S. L.; Kim, K.; Hoppel, C. L.; Guo, L.; Yang, J.; Evans, C.; Weiss, R. H. Int. J. Cancer 2012, 130, 
2791-2800. 
226. Catchpole, G.; Platzer, A.; Weikert, C.; Kempkensteffen, C.; Johannsen, M.; Krause, H.; Jung, K.; Miller, K.; 
Willmitzer, L.; Selbig, J.; Weikert, S. J. Cell. Molec. Medicine 2011, 2011, 109-118. 
227. Kim, K.; Aronov, P.; Zakharkin, S. O.; Anderson, D.; Perroud, B.; Thompson, I. M.; Weiss, R. H. Mol. Cell. 
Proteomics 2009, 8, 558-570. 
228. Kind, T.; Tolstikov, V.; Fiehn, O.; Weiss, R. H. Anal. Biochem. 2007, 363, 185-195. 
229. Sansone, S.-A.; Fan, T.; Goodacre, R.; Griffin, J. L.; Hardy, N. W.; Kaddurah-Daouk, R.; Kristal, B. S.; Lindon, J.; 
Mendes, P.; Morrison, N.; Nikolau, B.; Robertson, D.; Sumner, L. W.; Taylor, C.; van der Werf, M.; van Ommen, B.; Fieh, 
O. Nat. Biotechnol. 2007, 25, 846-848. 
230. Kullgren, A.; Jutfelt, F.; Fontanillas, R.; Sundell, K.; Samuelsson, L.; Wiklander, K.; Kling, P.; Koppe, W.; Larsson, 
D. G.; Björnsson, B. T.; Jönsson, E. Comp. Biochem. Physiol. A. Mol. Integr. Physiol. 2013, 164, 44-53. 
231.  Defernez, M.; Colguhoun, I. J. Phytochemistry. 2003, 62, 1009-1017. 
232. Yao, W.; Dai, J.; Zheng, C.; Bao, B.; Cheng, H.; Zhang, L.; Ding, A.; Li, W. J. Sep. Sci. 2015. In press. 
233. Sun, M.; Gao, X.; Zhang, D.; Ke, C.; Hou, Y.; Fan, L.; Zhang, R.; Liu, H.; Li, K.; Yu, B. Mol. Biosyst. 2013, 9, 3059-
3067. 
234. Feng, B.; Wu, S. M.; Ly, S.; Liu, F.; Chen, H. S.; Gao, Y.; Dong, F. T.; Wei, L. BMC Gastroenterol. 2009, 99, 9-99. 
235. Vijverberg, S. J.; Hilvering, B.; Raaijmakers, J. A.; Lammers, J. W.; Maitland-van der Zee, A. H.; Koenderman, L. 
Biologics. 2013, 7, 199-210. 
236. Vielhauer, O.; Zakhartsev, M.; Horn, T.; Takors, R.; Reuss, M. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 
2011, 879, 3859-3870. 
237. Watson, D. G. Comput. Struct. Biotechnol. J. 2013, 4, 1005. 
238. Gika. H. G.; Wilson, I. D.; Theododoris, G. A. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 2014, 966, 1-6. 
239. Cloarec, O.; Dumas, M. E.; Trygg, J.; Craig, A.; Barton, R. H.; Lindon, J. C.; Nicholson, J. K.; Holmes, E. Anal. 
Chem. 2005, 77, 517-526. 
240. Halouska, S.; Powers, R. J. Magn. Reson. 2006, 178, 88-95. 
241. Tomita, R.; Todoroki, K.; Machida, K.; Nishida, S.; Marouka, H.; Yoshida, H.; Fujioka, T.; Nakashima, M.; 
Yamaguchi, M.; Nohta, H. Anal. Sci. 2014, 30, 751-758. 
242. Kocabas, F.; Zheng, J.; Zhang, C.; Sadek. H. A. Methods Mol. Biol. 2014, 1185, 155-164. 
M56 
243. Griesser, M.; Weingart, G.; Schoedl-Hummel, K.; Neumann, N.; Becker, M.; Varmuzza, K.; Liebner, F.; 
Schuhmacher, R.; Forneck, A. Plant Physiol. Biochem. 2015. In press. 
244. Yin, P.; Lehmann, R.; Xu, G. Anal. Bioanal. Chem. 2015. In press. 
245. Rizos, E.; Siafakas, N.; Katasantoni, E.; Skourti, E.; Salpeas, V.; Rizos, I.; Tsoporis, J. N.; Kastania, A.; 
Filippopoulou, A.; Xiros, N.; Margaritis, D.; Parker, T. G.; Papgeorgiou, C.; Zoumpourlis, V. PLoS One. 2015.  
246. Mishra, A.; Verma, M. Cancers. 2010, 2, 190-208. 
247.Behne, T.; Copur, M. Int. J. Hepatol. 2012, 1-7.  
248. Ménez, R.; Michel, S.; Muller, B. H.; Bossus, M.; Ducancel, F.; Jolivet-Reynaud, C.; Stura, E. A. J. Mol. Biol. 2008, 
376¸1021-1033. 
249. Balk, S. P.; Ko, Y. J.; Bubley, G. J. J. Clin. Oncol. 2003, 21, 383-391. 
250. Velonas, V. M.; Woo, H. H. Remedios. C. G.; Assinder, S. J. Int. J. Mol. Sci. 2013, 14, 11034-11060. 
251. Catalona, W. J.; Richie, J. P.; Ahmann, F. R.; Hudson, M. A.; Scardino, P. T.; Flanigan, R. C.; Dekernion, J. B.; 
Ratliff, T. L.; Kavoussi, L. R.; Dalkin, B. L. J. Urol. 1994, 151, 1283-1290. 
252. Carter, H. B. N. Engl. J. Med. 2004, 350, 2292-2294. 
253. Catalona, W. J.; Smith, D. S.; Ratliff, T. L.; Dodds, K. M.; Coplen, D. E.; Yuan, J. J.; Petros, J. A.; Andriole, G. L. N. 
Engl. J. Med. 1991, 324, 1156-1161. 
254. Moka, D.; Vorreuther, R.; Schicha, H.; Spraul, M.; Humpfer, E.; Lipinski, M.; Foxall, P. J. D.; Nicholson, J. K.; 
Lindon, J. C. J. Pharm. Biomed. Anal. 1998, 17, 125-132. 
255. Iglesias-Garcia, J.; Dominguez-Munoz, E.; Lozano-Leon, A.; Abdulkader, I.; Larino-Noia, J.; Antunez, J.; Forteza, J. 
World J. Gastroenterol. 2007, 13, 289-293  
256. Johnson, S. R.; Lange, B. M. Front. Bioeng. Biotechnol. 2015. In press. 
257. Addie, R. D.; Balluff, B.; Bovée, J. V.; Morreau, H.; McDonnell, L. A. Anal. Chem. 2015. In press. 
258. Nielsen, K. F. Larsen, T. O. Front. Microbiol. 2015. In press. 
259. Heim, M. Pain Res. Treat. 2015. In press. 
260. Di Santo, S.; Trignani, M.; Neri, M.; Milano, A.; Innocenti, P.; Taraborrelli, M.; Augurio, A.; Vinciguerra, A.; Di 
Tommaso, M.; Ursini, L. A.; Di Pilla, A.; Di Nicola, M.; Genovesi, D. Rep. Pract. Oncol. Radiother. 2014, 20, 128-134. 
261. Kwon, H.; Oh, S.; Jin, X.; An, Y. J.; Park, S. Arch. Pharm. Res. 2015, 38, 372-380. 
262. Chandrasekaran, S.; Rittschof, C. C.; Djukovic, D.; Gu, H.; Raftery, D.; Prince, N. D.; Robinson, G. E. Genes Brain 
Behav. 2015, 14, 158-166. 
263. Stäubert, C.; Bhuiyan, H.; Lindahl, A.; Broom, O. J.; Zhu, Y.; Islam, S.; Linnarsson, S.; Lehtiö, J.; Nordström, A. J. 
Biol. Chem. 2015, 290, 8348-8359. 
264. Gu, H.; Du, J.; Carnevale Neto, F.; Carroll, P. A.; Turner, S. J.; Chiorean, E. G.; Eisenman, R. N.; Raftery, D. Analyst. 
2015, 140, 2726-2734. 
265. Holst, S.; Wuhrer, M.; Rombouts, Y. Adv. Cancer Res. 2015, 126, 203-256. 
266. Amantonico, A.; Urban, P. L.; Zenobi, R. Anal. Bioanal. Chem. 2010, 396, 2493-2504. 
267. Kraly, J. R.; Holcomb, R. E.; Guan, Q.; Henry, C. S. Anal. Chim Acta. 2009, 663, 23-36. 
268. Kubota, K.; Fukushima, T.; Yuji, R.; Miyano, H.; Hirayama, K.; Santa, T.; Imai, K. Biomed. Chromatogr. 2005, 19, 
788-795. 
269. Oedit, A.; Vulto, P.; Ramautar, R.; Lindenburg, P. W.; Hankemeier, T. Curr. Opin. Biotechnol. 2015, 31, 79-85. 
270. Wolfender, J. L.; Marti, G.; Thomas, A.; Bertrand, S. J. Chromatogr. A. 2015, 1382,  136-164. 
271. Sanchez, E. L.; Lagunoff, M. Virology. 2015. In press. 
272. Albright, J. C.; Henke, M. T.; Soukup, A. A.; McClure, R. A.; Thomson, R. J.; Keller, N. P.; Kelleher, N. L. ACS 
Chem. Biol. 2015. In press. 
273. Li, J.; Niu, X.; Pei, G.; Sui, X.; Zhang, X.; Chen, L.; Zhang, W. Bioresour. Technol.2015. In press. 
274. Garg, N.; Kapono, C.; Lim, Y. W.; Koyama, N.; Vermeij, M. J.; Conrad, D.; Rohwer, F.; Dorrestein, P. C. Int. J. Mass 
Spectrom. 2015, 377, 717-719. 
275. Paiva, C.; Amaral, A.; Rodriguez, M.; Canyellas, N.; Correig, X.; Ballescá, J. L.; Ramalho-Santos, J.; Oliva, R. 
Andrology. 2015. In press. 
276. Bean, H. D.; Hill, J. E.; Dimandja, J. M. J. Chromatogr. A. 2015. In press. 
277. Yanes, O.; Tautenhahn, R.; Patti, G. J.; Siuzdak, G. Anal. Chem. 2015, 83, 2152-2161. 
278. Keurentjes, J. J. B. Curr. Opin. Plant Biol.2009, 12, 223-230. 
279. Joseph, B.; Atwell, S.; Corwin, J. A.; Li, B.; Kliebenstein, D. J. Front. Plant Sci. 2014.  
280. Patti, G. J.; Tautenhahn, R.; Johannsen, D.; Kalisiak, E.; Ravussin, E.; Brüning, J. C.; Dillin, A.; Siuzdak, G. 
Metabolomics. 2014, 10, 737-743. 
281. Lin. C. Y.; Wu, H.; Tjeerdema, R. S.; Viant, M. R. Metabolomics. 2007, 3, 55-67. 
282. Jonsson, P.; Johansson, A. I.; Gullberg, J.; Trygg, J.; A, J.; Grung, B.; Marklund, S.; Sjöström, M.; Antti, H.; Moritz, 
T. Anal. Chem.2005, 77, 5635-5642. 
283 Goodacre, R.; Vaidyanathan, S.; Dunn, W. B.; Harrigan, G. G.; Kell, D. B. Trends Biotechnol.2004, 22, 245-262. 
284. Viant, M. R. Biochem. Biophys. Res. Comm.2003, 310, 943-948. 
M57 
285. Wu, H.; Southam, A. D.; Hines, A.; Viant, M. R. Anal. Biochem.2008, 372, 204-212. 
286. Vuckovic, D. Anal. Bioanal. Chem.2012, 403, 1523-1548. 
287. Bruce, S. J.; Tavazzi, I.; Parisod, V.; Rezzi, S.; Kochhar, S.; Guy, P. A. Anal. Chem.2009, 81, 3285-3296. 
288. Chen, H.; Pan, Z.; Talaty, N.; Raftery, D.; Cooks, R. G. Rapid. Comm. Mass Spectrom. 2006, 20, 1577-1584. 
289. Asiago, V. M.; Nagana Gowda, G. A.; Zhang, S.; Narasimhamurthy, S.; Clark, J.; Raftery, D. Metabolomics. 2008, 4, 
328-336. 
290. Wishart, D. S. TrAC Trends Anal. Chem.2008, 27, 228-237. 
291. Kruger, N. J.; Troncoso-Ponce, M. A.; Ratcliffe, R. G. Nat. Protoc.2008, 3, 1001-1012. 
292. Mroue, K. H.; MacKinnon, N.; Xu, J.; Zhu, P.; McNerny, E.; Kohn, D. H.; Morris, M. D.; Ramamoorthy, A. J. Phys. 
Chem. B. 2012, 116, 11656-11661. 
293. Mroue, K. H.; Zhang, R.; Zhu, P.; Kohn, D. H.; Morris, M. D.; Ramamoorthy, A. J. Magn. Reson. 2014, 244, 90-97. 
294. Xu, J.; Zhu, P.; Gan, Z.; Sahar, N.; Tecklenburg, M.; Morris, M. D.; Kohn, D. H.; Ramamoorthy, A. J. Am. Chem. 
Soc. 2010, 132, 11504-11509. 
295. Da Silva, L.; Godejohann, M.; Martin, F. P.; Collino, S.; Bürkle, A.; Moreno-Villanueva, M.; Bernhardt, J.; Toussaint, 
O.; Grubeck-Loebenstein, B.; Gonos, E. S.; Sikora, E.; Grune, T.; Breusing, N.; Franceschi, C.; Hervonen, A.; Spraul, M.; 
Moco, S. Anal. Chem. 2013, 12, 5801-5809. 
296. Claridge, T. D. W. High-Resolution NMR Techniques in Organic Chemistry; Elsevier: Oxford, 2009.  
297. Harris, D. C. Quantitative Chemical Analysis; W. H. Freeman: New York, 2010. 
298. Chachaty, C. Prog. Nuc. Magn. Reson. Spect. 1987, 19, 183-222. 
299. Damadian, R.; Goldsmith, M.; Minkoff, L. Physiol. Chem. Phys.1977, 9, 97-100. 
300. Skoog, D. A.; Holler, F. J.; Crouch, S. R. Principles of Instrumental Analysis; Thomson: California, 2007. 
301. Harris, R. K. Nuclear Magnetic Resonance Spectroscopy; Longman: Essex, 1986.  
302. Mukamel, S. Principles of Nonlinear Optical Spectroscopy; Oxford University; Oxford, 1995.  
303. Sanders, J. K. M.; Hunter, B. K. Modern NMR Spectroscopy: A Guide for Chemists; Oxford University: Oxford, 
1993. 
304. Abragam, A. Principles of Nuclear Magnetism; Oxford University: Oxford, 1961. 
305. Stein, E.; Shakarchi, R. Fourier Analysis: An Introduction; Princeton University: Princeton, 2003. 
306. Hahn, E. L.; Maxwell, D. E. Phys. Rev. 1952, 88, 1070-1084. 
307. Frydman, L.; Blazina, D. Nat. Phys. 2007, 3, 415-419. 
308. Godelmann, R.; Fang, F.; Humpfer, E.; Schütz, B.; Bansbach, M.; Schäfer, H.; Spraul, M. J. Agric. Food. Chem. 
2013, 23, 5610-5619. 
309. Spraul, M.; Schütz, B.; Rinke, P.; Koswig, S.; Humpfer, E.; Schäfer, H.; Mörtter, M.; Fang, F.; Marx, U. C.; Minoja, A 
Nutrients 2009, 2, 148-155. 
310. Beckonert, O.; Keun, H. C.; Ebbels, T. M.; Bundy, J.; Holmes, E.; Lindon, J. C.; Nicholson, J. K. Nat. Protoc. 2007, 
2, 2692-2703. 
311.  Fujiwara, T.; Ramamoorthy, A. Ann. Rep. NMR Spectrosc. 2006, 58, 155-175. 
312. Maciel, G. E.; Davis, M. F. J. Magn. Reson. 1986, 64, 356-360. 
313. Wu, D.; Chen, A.; Johnson, C. S.  J. Magn. Reson. 1995, 115, 260-264. 
314. Sandusky, P.; Raftery, D. Anal. Chem. 2005, 77, 2455-2463. 
315. Xi, Y.; de Ropp, J. S.; Viant, M. R.; Woodruff, D. L.; Yu, P. Metabolomics 2006, 2, 221-233. 
316. Sitter, B.; Bathen, T. F.; Tessem, M. B.; Gribbestad, I. S. Prog. Nucl. Magn. Reson. Spectrosc. 2009, 54, 239-254. 
317. Beckonert, O.; Coen, M.; Keun, H. C.; Wang, Y.; Ebbels, T. M.; Holmes, E.; Lindon, J. C.; Nicholson, J. K. Nat. 
Protoc. 2010, 5, 1019-1032. 
318. Merz, A. L.; Serkova, N. J. Biomark. Med. 2009, 3, 289-306. 
319. Smith, I. C.; Baert, R. IUBMB Life. 2003, 55, 273-277. 
320. Godfrey, A. R.; Brenton, A. G. Anal. Bioanal. Chem. 2012, 404, 1159-1164. 
321. Yuan, M.; Breitkopf, S. B.; Yang, Z.; Asara, J. M. Nat. Protoc. 2012, 7, 872-881. 
322. Brown, S. C.; Kruppa, G.; Dasseux, J. L. Mass Spectrom. Rev. 2005, 24, 223-231. 
323. Lu, W.; Clasquin, M. F.; Melamud, E.; Amador-Noguez, D.; Caudy, A. A.; Rabinowitz, J. D. Anal Chem 2010, 82, 
3212-3221. 
324. Wang, J.; Christison, T. T.; Misuno, K.; Lopez, L.; Huhmer, A. F.; Huang, Y.; Hu, S. Anal. Chem. 2014, 86, 5116-
5124. 
325. Ma, S.; Chowdhury, S. K.; Alton, K. B. Curr. Durg. Metab. 2006, 7, 503-523. 
326. Diamandis, E. P. Mol. Cell. Proteomics 2004, 3, 367-378. 
327. Cody, R. B.; Laramee, J. A.; Durst, H. D. Anal. Chem. 2005, 77, 2297-2302. 
328. Struck-Lewicka, W.; Kordaelwska, M.; Bujak, R.; Yumba Mpanga, A.; Markuszewski, M.; Jacyna, J.; Matuszweski, 
M.; Kaliszan, R.; Markuszweski, R. J. J. Pharm. Biomed. Anal. 2015. In press. 
329. Shubhakar, A.; Reiding, K. R.; Gardner, R. A.; Spencer, D. I.; Fernandes, D. L.; Wuhrer, M. Chromatographia. 2015, 
78, 321-333. 
M58 
330. KnowItAll. http://www.bio-rad.com/en-us/product/spectroscopy-software/knowitall-enterprise-server. 
331.  O’Sullivan, A.; Avizonis, D.; German, J. B.; Slupsky, C. M. eMagRes 2011. 
332. Vinaixa, M.; Samino, S.; Saez, I.; Duran, J.; Guinovart, J. J.; Yanes, O. Metabolites. 2012, 2, 775-795. 
333. Johnson, R. A.; Wichern, D. W. Applied Multivariate Statistical Analysis; Prentice Hall: NJ, 1999. 
334. Barker, M.; Rayens, W. J. Chemom. 2003, 17, 166-173. 
335. Beckwith-Hall, B. M.; Brindle, J. T.; Barton, R. H.; Coen, M.; Holmes, E.; Nicholson, J. K.; Antti, H. Analyst 2002, 
127, 1283-1288. 
336. Cloarec, O.; Dumas, M. E.; Craig, A.; Barton, R. H.; Trygg, J.; Hudson, J.; Blancher, C.; Gauguier, D.; Lindon, J. C.; 
Holmes, E.; Nicholson, J. Anal. Chem. 2005, 77, 1282-1289. 
337. Crockford, D. J.; Holmes, E.; Lindon, J. C.; Plumb, R. S.; Zirah, S.; Bruce, S. J.; Rainville, P.; Stumpf, C. L.; 
Nicholson, J. K.. Anal. Chem. 2006, 78, 363-371. 
338. Chen, H. W.; Pan, Z.; Talaty, N.; Raftery, D.; Cooks, R. G. Rapid Commun. Mass Spectrom. 2006, 20, 1577-1584. 
339. HMBD. http://www.hmdb.ca/. 
340. METAGENE. http://www.metabolomicssociety.org/databases. 
341. Horai, H.; Arita, M.; Kanaya, S.; Nihei, Y.; Ikeda, T.; Suwa, K.; Ojima, Y.; Tanaka, K.; Tanaka, S.; Aoshima, K.; Oda, 
Y.; Kakazu, Y.; Kusano, M.; Toghe, T.; Matsuda, F.; Sawada, Y.; Hirai, M. Y.; Nakanishi, H.; Ikeda, K.; Akimoto, N.; 
Maoka, T.; Takahashi, H.; Ara, T.; Sakurai, N.; Suzuki, H.; Shibata, D.; Neumann, S.; Iida, T.; Tanaka, K.; Funatsu, K.; 
Mastuura, F.; Soga, T.; Taguchi, R.; Saito, K.; Nishioka, T. J. Mass Spectrom. 2010, 45, 703-714. 
342. Ulrich, E. L.; Akutsu, H.; Doreleijers, J. F.; Harano, Y.; Ioannidis, Y. E.; Lin, J.; Livny, M.; Mading, S.; Maziuk, D.; 
Miller, Z.; Nakatani, E.; Schulte, C. F.; Tolmie, D. E.; Wenger, R. K.; Yao, H.; Markley, J. L. Nuc. Acids Res. 2008, 36, 
402-408. 
343. MacKinnon, N.; Somashekar, B. S.; Tripathi, P.; Ge, W.; Rajendiran, T. M.; Chinnaiyan, A. M.; Ramamoorthy, A. J. 
Magn. Reson. 2013, 226, 93-99. 
345. AMIX. http://www.bruker.com/products/mr/nmr/nmr-software/software/amix/overview.html. 
346. CHENOMX. http://www.chenomx.com/software/software.php?pageID=65. 
347. Emwas, A. H. Methods Mol. Biol. 2015, 1277, 161-193. 
348. Parsons, H. M.; Ekman, D. R.; Collette, T. W.; Viant, M. R. Analyst.2009, 134, 478-485. 
349. Pan, Z.; Raftery, D. Anal. Bioanal. Chem. 2007, 387, 525-527. 
350. Fan, T. W.-M.; Higashi, R. M.; Lane, A. N.; Jardetzky, O. Biochim. Biophys. Acta. Gen. Subj. 1986, 882, 154-167. 
351. Nicholson, J. K.; Lindon, J. C.; Holmes, E. Xenobiotica. 1999, 29, 1181-1189. 
352. Shanaiha, N.; DeSilva, M. A.; Nagana Gowda, G. A.; Raftery, M. A.; Halnline, B. E.; Raftery, D. Proc. Natl. Acad. 
Sci. U. S. A. 2007, 104, 11540-11544. 
353. Kühnel, E.; Laffan, D. D. P.; Lloyd-Jones, G. C.; Martínez del Campo, T.; Shepperson, I. R.; Slaughter, J. L. Angew. 
Chem. Int. Ed. 2007, 46, 7075-7078. 
354. Leggio, A.; Liguori, A.; Perri, F.; Siciliano, C.; Caterina Visconi, M. Chem. Biol. Drug. Des. 2009, 73, 287-297. 
355. Presser, A.; Hüfner, A. Monat. Chem.2004, 135, 1015-1022. 
356. Kühnel, E.; Laffan, D. D. P.; Lloyd-Jones, G. C.; Martínez del Campo, T.; Shepperson, I. R.; Slaughter, J. L. Angew. 
Chem. Int. Ed. 2007, 46, 7075-7078. 
357. Moench, S. J.; Shi, T. M.; Satterlee, J. D. Eur. J. Biochem.1991, 197, 631-641. 
358. Bajpayee, A.; Luo, T.; Muto, A.; Chen, G. Energy Environ. Sci. 2011, 4, 1672-1675. 
359. Swartz, R.; Pasko, D.; O’Toole, J.; Starmann, B. Clin. Nephrol. 2004, 61, 134-143. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
M59 
Appendix B.1: 
Supplementary Information 
 
All spectra are available online at http://www-
personal.umich.edu/~nirbs/jain_supplementary_information_section_1.pdf 
 
For the spectra related to the analyses done in Chapter 2, please see pages S1-S136 
 
For the spectra related to the analyses done in Chapter 3, please see pages S137-S206 
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Introduction:  
 
5.1 Alzheimer’s Disease 
5.1.1 Introduction to Alzheimer’s disease 
Alzheimer’s disease (AD) is a debilitating neurodegenerative disease that is the leading 
cause of dementia, accounting for up to 70% of all cases seen.
1-3
 As with other dementia 
diseases, AD is characterized by a decrease in the ability of an individual to think and remember 
to such an extent that the quality of daily life of the patient is negatively impacted. Though the 
consciousness of the person may not be affected, there can be issues with emotions, language, 
and motivation.
4-6
 These problems may develop as part of the aging process, but only truly 
become a form of dementia when they outstrip what may be expected to be a natural byproduct 
of aging.
7 
The rapidity of the onset of AD can vary from patient to patient, but body functions 
degrade to an extent that death is seen generally three to nine years after diagnosis.
8-10
 
Alzheimer’s disease was found in about 35 million people worldwide in the year 2010, causing 
486,000 deaths, making it one of the most widespread diseases seen.
11
 Furthermore, this disease 
tends to affect the elderly, being more common in people above the age of 65, though those 
younger may suffer from a form known as early-onset AD.
12
 As it stands, AD is the single most 
expensive disease to treat in developed countries.
13-15
 This fact, coupled with the large burden 
not only on the patient but on their caregivers, such as family, friends, and medical staff, greatly 
expands the impact of this disease beyond the individual to other societal, psychological, 
Aβ2 
physical, and economic extents. Institutions such as nursing homes and long-term care help 
support the caregivers, but costs can range up to $77,500 per year in the United States.
13
  
Despite the widespread nature of this disease, a solid understanding of its origins is 
severely lacking.
16
 Many factors are thought to be at the root of AD, including genetics,
17-19
 head 
injuries,
20-21
 depression,
22
 hypertension,
23-25
 cerebral plaques,
26-29
 obesity,
30
 and others. As 
symptoms are normally mistaken as natural byproducts of aging, this disease can go undiagnosed 
for years. Furthermore, there are no generally accepted procedures to lower one’s risk for AD, 
nor is there a treatment to stop the progression of this dementia.
31-33
 As displayed above, the cost 
of AD treatment is extremely high. Coupling this cost with the growing age of the baby boomer 
generation, and the general economic strain accompanying them, indicates that there is a great 
need for a better understanding of this disease.
34
 A mechanistic understanding from studying the 
molecular nature of AD would allow for more knowledge of how it functions, and thus how to 
treat it. 
 
5.1.2 Signs and Symptoms 
AD is generally split into four phases: pre-dementia, early, middle, and late.
35
 The pre-
dementia stage is generally conflated with natural processes of aging or stress, such as an 
increase in forgetfulness, short-term memory loss, a loss of planning ability and abstract 
thinking, apathy, mild depression, and other slight cognitive impairments.
36
 Though these 
symptoms may affect the most complex of daily life activities, they do not change the everyday 
enough such that the patient is aware of the potential for AD. 
Early onset AD is the stage in which most diagnoses are made.
37
 There may be some 
difficulties with language or perception, or even movement, along with an increase in memory 
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impairment. Fine motor tasks become more difficult, and sufferers may require assistance with 
more complex tasks, or at least supervision. 
At the moderate stage of AD, independence tends to be eliminated, as sufferers struggle 
with even the most common daily tasks.
38
 Difficulties in speech increase as well, causing word-
substitutions and a general drop in vocabulary, accompanied by functional illiteracy. Long-term 
memory, not affected in the early onset stage, becomes damaged here, along with personality 
changes and delusion. There are some physical effects as well, including incontinence, and it is 
at this stage that many patients are moved to long-term facilities. 
In the last stage, known as advanced, the patient is completely dependent on their 
caregiver for all aspects of life, being able to communicate only in short phrases or single 
words.
39
 Aphasia eventually occurs. Though emotional communication is still possible, apathy is 
the dominant feeling. Muscle mass and motility disappear, and the body is open to more 
diseases, leading to death. The cause of death is not AD itself, but rather ulcers or pneumonia, 
which only became deadly due to the effects of Alzheimer’s.40-41 
 
5.1.3 Diagnostic Techniques 
Diagnosis of AD can only be definitively done from a histological brain analysis, but 
factors such as medical and family history, computed tomography, magnetic resonance imaging, 
single-photon emission computed tomography, or positron emission tomography are studied in 
connection with functionality tests.
42-47
 These tests all follow rigorous guidelines established by 
the Alzheimer’s Association, which have a strong correlation with AD diagnoses.48 However, as 
neurological examinations may provide normal results or even support other forms of dementia, 
corroboration with blood tests and thyroid function tests are used. Early-onset cases are generally 
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not diagnosed; however, as the signs of AD may seem like normal stages of aging, and thus are 
ignored by the patient, before true cognitive impairment leads to the need for a diagnosis.
49-50 
Some metabolite screening procedures have been developed, using cerebrospinal fluid to 
test for β-amyloid or tau proteins, but must be done in conjunction with neuroimaging techniques 
before a diagnosis be truly trusted.
51-53
  
 
5.1.4 Pathophysiology 
Generally, AD is characterized by neurodegeneration and atrophies of affected cerebral 
areas.
54-58
 This degradation progresses as the disease progresses, and is generally accompanied 
with amyloid plaques, made up of insoluble collections of β-amyloid peptide, and neurofibrillary 
tangles, comprised of tubular tau proteins. This protein misfolding may disrupt basic cellular 
processes, including calcium ion homeostasis, enzyme function, and glucose usage, resulting in 
apoptosis.
55
 This is normally seen in conjunction with inflammatory responses, which help 
induce neural degeneration. All these processes, however, essentially lead to neuronal cell death, 
which is the root of AD, though the exact trigger that starts killing cells is unknown.
59 
 
5.1.5 Prevention, Treatment, and Prognosis 
No clear prevention or treatment plan for AD exists, and the prognosis remains poor.
31-33
 
However, theories abound on how to best combat this disease. One such theory is that 
cardiovascular risk factors correlate to a higher rate of AD.
23-25
 However, statins and anti-
inflammatory drugs have had minimal effects in preventing and treating the disease. Intellectual 
activities and physical fitness, along with diet, have some potential as preventative techniques, 
but this link remains weak.
60-62
 Compounds such as caffeine and flavonoids, along with certain 
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vitamins, cannabinoids, and curcumin, have shown some potential positive activity, but these 
correlations remain under further investigation.
63-66 
Various acetylcholinesterase inhibitors have also been developed to combat AD, as well 
as glutamate and other antipsychotic drugs.
67-69
 Further psychological techniques have all been 
suggested as psychosocial alternatives to pharmaceutical therapy. However, as a whole, none of 
these potential treatments have been shown to be effective. In fact, their main usage has been as 
symptom management or palliative care, but has not stopped the onset of the disease, nor 
prevented death from complications due to Alzheimer’s disease.  
As discussed above, the symptom progression of AD will eventually lead to death, being 
the underlying cause of death for 68% of patients, generally due to complications of AD that lead 
to pneumonia, dehydration.
11
 Though the rate of cancer is lower in AD patients, the mean life 
expectancy is six years, with less than 5% of patients surviving over fourteen years. With this 
poor prognosis, AD is among the deadlier of diseases. 
 
5.1.6 Causes 
The cause of AD is unknown.
59
 Though the actual mechanism of cell death is fairly well-
characterized, the reason for the process to begin is a mystery. Genetic factors have been 
identified, which result in mutations in the amyloid polypeptide (APP) and presenilins that cause 
the production of amyloid-β to increase, resulting in plaque formation (Figure 5.1).70-73 Other 
hypotheses include the cholinergic hypothesis, in which a reduction of acetylcholine leads to AD, 
though this has been generally rejected due to the lack of effectiveness of cholinergic 
pharmaceuticals.
74-75
 The tau hypothesis tends to focus on the tau protein as the initiator of this 
disease, in which tau protein microtubules degrade the neuronal cytoskeleton and thus the 
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neuron.
76-77
 More esoteric beliefs include metallic causes of AD, mediated by changes in the 
homeostatic concentrations of Fe, Cu, Zn, and Al.
78-79
 Electromagnetic fields,
80
 smoking,
81
 
autoimmune factors,
82
 myelin breakdown,
83
 oxidative stress,
84
 and air pollution
85
 have all been 
suggested as potential causes, but none have been shown to be the true source of AD. A full 
diagram of all potential AD causes appears in Figure 5.2.
75-88
 The most evident cause of this 
Figure 5.1. A schematic showing the effects of amyloid-β on Alzheimer’s disease. Figure reprinted with permission from 
Blennow, K.; Hampel, H.; Weiner, M.; Zetterberg, H. Nat. Rev. Neurol. 2010, 6, 131-144. Copyright 2010 Macmillan 
Publishers Ltd. 
Genetic: 
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APP and presenilins 1 and 2 
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Mutations in 
acetylcholine synthesis 
Amyloid: 
Aggregation of amyloid-β peptide 
leading to neual degeneration 
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Tau protein abnormalities leading to 
the degredation of neural membranes 
Herpes 
Autoimmune 
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degeneration ALZHEIMER’S 
DISEASE 
Environmental: 
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Figure 5.2. A schematic showing the various theories of the cause of Alzheimer’s Disease. The prevailing theory, the 
amyloid cascade hypothesis, is highlighted in red and blue at the bottom. 
Ion Channel: 
Ion influx induces 
apoptosis 
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disease remains the amyloid hypothesis,
86-88
 discussed further below. 
 
5.2 The Amyloid Cascade Hypothesis and Amyloid-β 
5.2.1 Introduction to the Amyloid Cascade Hypothesis and Amyloid-β 
The amyloid cascade hypothesis is the most generally accepted cause for AD, stating that 
extracellular deposits of amyloid-β (Aβ) are the underlying cause of the disease,86-88 as well as 
other diseases such as Parkinson’s disease,89-90 Huntington’s disease,91-92 and type II diabetes.93-94 
This hypothesis gained support through the fact that the APP gene is present on chromosome 21, 
and those with trisomy 21 (Down’s syndrome) present AD by the age of 40.95 Furthermore, 
identified genetic risk factors correlate to APP and Aβ buildup.96-98 
Based on the amyloid cascade hypothesis, however, it is not the native form of Aβ that 
causes AD, but rather an aggregated form, which has been recently developed to exclude the 
fibrillar, amyloid state of the aggregate, focusing instead on the oligomer as the toxic species.
86-88
 
Native Aβ find their origin in APP (Figure 5.3), which is proteolytically processed to form Aβ by 
cleavage via a copper metalloprotein and a secretase.
99-100
 This yields fragments ranging from 
39-43 residues, with the most common alloforms having 40 and 42 residues (Figure 5.4).
99,101-104
 
Figure 5.3. A representation of APP in the membrane, showing the location of the amyloid-β peptide within this 
larger peptide. Reprinted with permission from Savelieff, M. G.; Lee, S.; Liu, Y.; Lim, M. H. ACS Chem. Biol. 2013, 8, 
856-865. Copyright 2013: American Chemical Society. 
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Both alloforms oligomerize and ultimately fibrilize, however, the Aβ(42) case is clinically 
correlated, while the 40 case is more commonly formed. A general schematic showing the stages 
of fibrilization and the effects on the cell to lead to AD appears in Figure 5.5.
99 
The amyloid hypothesis suggests that Aβ aggregates are the pathogenic source of AD, 
and the signal that commences the chain of physiological effects leading to cell death, especially 
when in the oligomer form, rather than the insoluble, fully fibrilized form.
105
 Though fibers may 
retain toxic activity, the oligomers are the truly dangerous species. Oligomers are formed through 
the aggregation of individual monomeric peptides, in which the random coil peptide, with some 
intrinsic β-sheet and α-helix conformations, interact such that the hydrophilic N-termini and the 
hydrophobic C-termini are aligned in a parallel β-sheet structure.106-108 Oligomerization 
heightened in the 42-residue species, causing it to have more inherent toxic ability.
99
  
Figure 5.4. Various representations of amyloid-β. a) Amyloid-β as a partially folded structure in the presence of 50 
mM NaCl, with residues 13 to 23 forming a 310 helix. Reprinted with permission from Vivekanandan, S.; Brender, J. 
R.; Lee, S. Y.; Ramamoorthy, A. Biochem. Biophys. Res. Commun. 2011, 411, 312-316. Copyright 2011 Elsevier. b) 
Solution NMR structure of a 0.05% SDS-stabilized pre-globulomer of amyloid-β(42) (top) compared with the basic 
fold of the fibrils of amyloid-β(42) (bottom). Adapted with permission from Yu, L.; Edalji, R.; Harlan, J. E.; Holzman, 
T. F.; Lopez, A. P.; Labkovsky, B.; Hillen, H.; Barghorn, S.; Ebert, U.; Richardson, P. L.; Miesbauer, L.; Solomon, L.; 
Bartley, D.; Walter, K.; Johnson, R. W.; Hajduk, P. J.; Olejnicazk, E. T. Biochemistry. 2009, 48, 1870-1877. Copyright 
2009 American Chemical Society. (c) Structural schematic of amyloid-β balls formed at low pH in the absence (top) 
and presence (bottom) of DSS. These structures both show a pinwheel or micelle-like arrangement of monomers. 
Reprinted with permission from Laurents, D. V.; Gorman, P. M.; Guo, M.; Rico, M.; Chakrabartty, A.; Bruix, M. J. 
Biol. Chem. 2005, 280, 3675-36853. Copyright 2005 Journal of Biological Chemistry. d) The sequence of amyloid-
β(42), with labels as follows: black, flanking APP residues that are not in amyloid-β; red, putative Cu2+-binding 
residues; blue, hydrophilic residues; green, hydrophobic residues; underlined, self-recognition region. The terminal I 
and A residues are not in amyloid-β(40). Reprinted with permission from Savelieff, M. G.; Lee, S.; Liu, Y.; Lim, M. H. 
ACS Chem. Biol. 2013, 8, 856-865. Copyright 2013: American Chemical Society. 
a) b) c) 
d) 
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The mechanism of fiber growth is known as a nucleated growth mechanism (Figure 
5.5).
99, 105
 In this proposed mechanism a critical nucleating species is formed that triggers the 
formation of protofibrillar aggregates. The formation of protofibrils is followed by secondary 
nucleation and elongation to an eventual plateau at which point the fibers are formed and the 
system reaches its kinetic equilibrium. This is generally modeled as a sigmoidal curve and can be 
measured via fluorescent techniques. Fibril shape and size is dependent on a wide variety of 
factors, including monomer conformation, solution pH, salt concentration, peptide concentration, 
the presence of exogenous species, temperature, agitation, and others.
109-111 
Aggregates take on a β-sheet conformation, which act as seeds to further aggregation, and 
arise in a variety of morphologies with differing toxic abilities, though these links are not fully 
understood.
106-108,112
 Most studies point to oligomers of Aβ eliciting toxicity through membrane 
interactions, such as binding and insertion into membranes to various degrees, causing entry of 
calcium ions into the cell and disrupting ionic homeostasis by forming ion-channel like pores.
113-
115
 This type of membrane disruption to be correlated with smaller, annular oligomers, before full 
Figure 5.5. Representation of the aggregation of amyloid-β. Left: a diagram representing the three phases of 
amyloid-β aggregation, including monomer to β-sheet oligomerization and then platueau at a insoluble plaque. 
Reprinted with permission from Savelieff, M. G.; Lee, S.; Liu, Y.; Lim, M. H. ACS Chem. Biol. 2013, 8, 856-865. 
Copyright 2013: American Chemical Society. Right: A diagram representing the effects of each stage of amyloid-β 
aggregation on the size of oligomers and on the cell, with the consequences for Alzheimer’s disease. The membrane 
disruption stage, thought to be the key location of the signal that starts Alzheimer’s disease and neural 
degeneration, is highlighted. Reprinted with permission from Kotler, S. A.; Walsh, P.; Brender, J. R.; Ramamoorthy, 
A. Chem. Soc. Rev. 2014, 43, 6692-6700. 
Aβ10 
fibril formation, and leads to apoptosis of the cell in the ion channel hypothesis.
116-119
 Elongation 
of the fiber to large, spherical aggregates, can change conductance on the cell surface, and lead to 
the recruitment of cellular factors, oxidative stress, and apoptosis.
105, 120-121
 Furthermore, 
oligomers have shown inherent binding abilities to surface receptors, which could result in a loss 
of neuronal plasticity and neuronal function.
122
 However, in vitro studies have failed to display 
the same level of toxicity as in vivo studies.
123-125
 Thus, there may be further modifications or 
interactions in vivo, as well as other types of oligomers that underlie the toxicity of this protein. 
Thus, though a wealth of information that displays the connections between AD and Aβ via the 
amyloid hypothesis exists, the exact details are unknown.
126 
 
5.2.2 The Two-Step Mechanism 
The ion channel hypothesis of Aβ discussed above is one of the dominant explanations of 
the amyloid cascade hypothesis, but does not explain the full morphological effects seen in 
cellular fragmentation and the toxicity of large aggregates.
127
 Much of the evidence for the Aβ 
channel rests largely on findings through studies utilizing atomic force microscopy (AFM), 
electron microscopy, molecular dynamics simulations, and single channel conductance 
measurements.
95-127
 While the Aβ channel hypothesis is well characterized, it unsatisfactorily 
describes how large aggregates, such as protofibrils or amyloidospheroids. In the case of large 
aggregates, it is difficult to fathom how they could form the smaller Aβ aggregates comprising 
the channel-like structures discussed above. A recent study demonstrated how such large 
aggregate structures could contribute to membrane disruption through a non-specific 
mechanism.
128
  This study from Sciacca, et al, proposed a two-step mechanism of membrane 
disruption (Figure 5.6).
128
 In this mechanism, initial aggregation of Aβ on the cellular surface 
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leads to pore formation, in which ion channels are formed via amyloid insertion into the 
membrane. This stage of the mechanism is characterized by calcium influx. Channels have been 
shown to be permeable to calcium, but blocked by zinc. Thus, this step explains the ion channel 
hypothesis outlined above.
128 
However, this is not the only means by which amyloids affect the cell membrane. In this 
mechanism, the pore formation step is followed by a fiber-dependent form of membrane 
disruption step resulting in fragmentation of the lipid bilayer via a detergent-like mechanism. 
This phase is characterized by the leakage of large dyes from the interior of the cellular 
membrane, which only appear after fibrillary Aβ structures are formed.128 Though pores were 
found to appear almost immediately after introduction of Aβ and initial aggregation, the 
membrane fragmentation was only found after the oligomers were allowed to form full fibers. 
This membrane disruption is fundamentally different from the pore formation stage in that it is 
nonselective, being permissible to positive and negative species, as well as species of various 
sizes. This lack of permittivity indicates that the integrity of the membrane is lost, further 
supported by the appearance of micelle-like structures.
128
 This stage also required the presence of 
fiber formation and their continued polymerization. Once fibers were fully formed, 
Figure 5.6. A representation of the aggregation of amyloid-β. a) Amyloid-β binding to the membrane and forming 
ion channel-like pores. b) Appearance of amyloid-β pores increased by the presence of ganglioside content, 
mediating a fiber-dependent step to induce membrane disruption. c) Membrane fragmentation. Reprinted with 
permission from Kotler, S. A.; Walsh, P.; Brender, J. R.; Ramamoorthy, A. Chem. Soc. Rev. 2014, 43, 6692-6700. 
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fragmentation stopped. Though the steps in this procedure are not known to be separate phases or 
connected, this two-step mechanism explains many strange activities of Aβ and membrane 
interactions, namely the transient nature of pore formation and membrane disruption. This 
mechanism is promising, but merits further investigation before full acceptance.
128 
 
5.3 Membrane Modulations and its Effects on Amyloid-β and Alzheimer’s Disease 
5.3.1  Gangliosides, the Membrane and Amyloid-β 
 Though many membrane studies have been carried out with Aβ, the role of specific 
membrane components and their effects on Aβ are still not well-understood. One such 
component is monosialotetrahexosylganglioside, better known as GM1.
129-131
 It is a 
glycosphingolipid with a sialic acid linked to the sugar chain, known to be a component of 
cellular membranes in domains known as lipid rafts, especially in neuronal membranes. GM1 is 
known to have important applications in neuronal plasticity and the release of neurotrophins in 
the brain, as well as being a binding site for both the Cholera toxin and the E. coli toxin.
132-133
  
Recently, GM1 has been demonstrated to be a signaling point for Aβ aggregation and AD 
onset.
134-136
 Initially, it was found that GM1 influences the structure of the Aβ fibril during 
aggregation, mediated by the Aβ:GM1 ratio.137 At a low ratio, the α-helix is dominant, but 
increasing the amount of Aβ per GM1 causes more fibrillization. Furthermore, the potential for 
the formation of amyloid aggregates from Aβ is controlled by GM1, as this effect is increased by 
the introduction of lipid rafts containing GM1.
138
 This binding may be due to the sialic acid 
moiety on the GM1 molecule, as confirmed by various studies. 
139-142 
The process of ganglioside-Aβ binding is known to be a multi-stage event, involving 
electrostatic interactions with the N-terminus, and further hydrophobic driving forces allowing 
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for C-terminus insertion within the membrane.
138-142
 This is amplified by the fact that GM1 
carries a negative charge, helping to facilitate the interaction of the N-terminus with the sugar, 
allowing for the orienting of the peptide for easy insertion.
143
 However, this mechanism still 
remains in question, and requires further investigation before it can be fully described. 
The action of GM1 in the context of the two-step mechanism, however, is less 
controversial. As discussed above, the cytotoxic nature of Aβ is not fully known, but the two-step 
mechanism, involving initial pore formation, followed by gross membrane disruption, is one 
possibility within the framework of the amyloid cascade hypothesis.
128
 It was displayed that this 
mechanism is entirely dependent on the presence of gangliosides in the membrane, as GM1-free 
membranes displayed only pore formation, but not gross membrane disruption. Given the fact 
that gangliosides are a generally accepted factor in Aβ aggregation,144-145 the fact that it has such 
demonstrable effects on membrane disruption is further support of the two-step mechanism as 
the source of amyloid toxicity in AD. 
Though gangliosides have been universally recognized as a factor in AD progression, its 
role still remains clouded. The place of ganglioside in the two-step mechanism has not been 
established in the presence of other important membrane contributors, such as cholesterol and 
other components of lipid rafts, and the specific nature of its interaction with Aβ is unknown. 
This remains an area of further study. 
 
5.3.1 Cholesterol, the Membrane and Amyloid-β 
Another important membrane component is cholesterol, a major membrane lipid, as well as 
the main source of lipid rafts.
146-149
 The role of cholesterol in membranes remains 
controversial.
150-152
 It is known to contribute to membrane fluidity by modulating the phase 
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transition temperature of the lipid membrane.
153
 Three main types of phases exist: gel phases, in 
which there is little lateral diffusion of the membrane components;
154-155
 liquid ordered, in which 
lateral diffusion occurs in distinct clusters;
156-157
 and liquid disordered, in which lateral diffusion 
occurs in random structures, maximizing entropy.
158-159
 Cholesterol is believed to decrease the 
fluidity of liquid ordered membranes and increase the fluidity of gel ordered membranes,
160-162
 
while also creating microdomains of liquid ordered regions in an area of complete disorder, 
enriched in cholesterol, sphingolipid, ganglioside, and other proteins known as lipid rafts.
146-149
 
These rafts are considered to be signals for Aβ binding due to the fact that they contain 
gangliosides known to promote oligomerization, such as GM1.
163-167 
 Cholesterol has been shown to modulate lipid-Aβ interaction, with recent studies 
showing that the gel phase interacts with Aβ at the highest level, indicative of the lowest 
fluidity.
168-169
 This is corroborated by the effects of cholesterol in the membrane itself, where its 
increased fluidity allow for the sealing of pores and fragments which may be caused by Aβ 
aggregation, and result in apoptosis.
170-172
 This also agrees with other studies in which Aβ affects 
membrane fluidity.
173-175
 Though this effect is not well-characterized, the connection is still 
evident. Due to this connection, the role of cholesterol in the two-step mechanism, especially 
with ganglioside, merits further investigation and discussion. 
 This is especially important due to the fact that connections have been made between 
cholesterol and AD.
176-179
 Though the direct connection between cholesterol and AD remains 
tenuous at best, it has been shown that increased cardiovascular risks, such as higher levels of 
cholesterol,
23-25
 do correlate to increased risks for Alzheimer’s. Furthermore, cholesterol may 
interact with many important compounds that affect brain activity, such as hydroxymethyl 
glutaryl-coenzyme A, eventually helping promote AD, resulting in higher risk levels.
180-181
 In 
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fact, lipids such as cholesterol have been shown to modulate the amyloidogenic processing of 
APP, which leads to the formation of Aβ and AD. There is also an epidemiological connection 
between higher cholesterol and higher rates of AD incidence.
182-184 
However, neuronal cholesterol content has also been shown to prevent AD. Neurons are 
comprised of, on average, 30% cholesterol,
185
 which has been displayed to prevent peptide 
insertion, reduce fibrillization, and prevent membrane disruption.
186-188
 These results are in direct 
conflict with that discussed above in terms of dietary and plasma cholesterol. The difference here 
may be that cellular cholesterol, rather than dietary cholesterol, has a protective effect toward 
AD, whereas dietary cholesterol has a damaging effect.
189-190
 This connection requires further 
research, and remains a flashpoint for AD studies. 
 
5.4 The TK9 Anti-Amyloid-β Peptide 
Given the support for the amyloid hypothesis, it is only natural that investigations into the 
prevention of Aβ aggregation have been performed. A class of these anti-amyloid therapeutic 
agents is self-assembling peptide chains, which have inherent amyloidogenic properties 
themselves.
191
 These peptides have been studied as models for amyloid aggregation, in order to 
simplify the analysis as well as probe specific interactions between peptides in assemblies before 
translation to the larger amyloid system.
192-193
 Self-assembling peptides from amyloids 
themselves, such as NFGAIL in human islet APP (hIAPP) and KLVFF in Aβ have shown to have 
inhibitory pathways, affording valuable information as to the aggregation pathway and acting as 
potential therapeutic agents.
194-195 
Another characterized agent is TK9, a nine residue peptide taken from the carbonyl 
terminus of the SARS corona virus envelope protein (Figure 5.7).
196
 This enveloped region is 
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thought to be the cause of such diseases as the common cold, severe acute respiratory syndrome 
(SARS, caused by the source virus), bronchitis, and others.
197-198
 This envelope is a long peptide 
chain of up to 108 amino acids with flexibility at both ends and an α-helix in its transmembrane 
region, with known changes to its secondary structure upon contact with a membrane, as 
demonstrated previously with hIAPP.
196 
This peptide has established self-assembly characteristics, forming a β-sheet structure in 
solution. It has also been demonstrated to inhibit the aggregation of APP, which, as discussed 
above, is the source of Aβ.196 The effect of TK9 on Aβ aggregation has been demonstrated 
previously (Figure 5.8), but further study on this initial peptide could open up the field of self-
assembly proteins as therapeutic agents. A positive result would not only give great insight into 
the mechanism of Aβ aggregation but also allow for further testing of other peptides, such as 
NF11, leading to the customization of these peptides and pharmaceutical development for the 
eventual treatment of amyloidogenic diseases. 
Figure 5.7. The SARS corona virus sequece and cartoon, with the TK9 sequence highlighted in both. Reprinted with 
permission from Ghosh, A.; Pithadia, A. S.; Bhat, J.; Bera, S.; Midya, A.; Fierke, C. A.; Ramamoorthy, A.; Bhunia, A. 
Biochemistry. 2015, 54, 2249-2261. 
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5.5 Methodology of Analysis 
5.5.1 Sample Preparation 
5.5.1.1 Amyloid-β Preparation 
In order to prevent aggregation before introduction to sample conditions, the Aβ peptide 
must be prepared carefully. The peptide is normally stored as a powder under -20 °C 
conditions.
128
 Upon thawing, it is then dissolved in a solution of 190 μL millipure water and 10 
μL 1% ammonium hydroxide, to break up any preformed aggregated. The concentration is then 
standardized through measuring the absorbance of Aβ at 280 nm.128 Absorbance spectroscopy is 
a form of ultraviolet-visible spectroscopy in which the amount of photons absorbed by a 
molecule is measured through determining the difference in incident and transmitted light 
intensity.
199
 This absorbance value is proportional to the concentration of the analyte via the 
Beer-Lambert law.
200
 Absorbance is greatly affected by the physical nature of the sample, 
Figure 5.8. To the left is a two-dimensional 
heteronuclear single quantum coherence 
spectrum of amyloid-β(40) and TK9 (red 
peaks), overlaid with a spectrum of simple 
amyloid-β(40) (blue peaks). The red 
arrows indicate peaks that appeared  or 
greup only upon the introduction of the 
TK9 spectrum. Blue arrows indicate those 
that disappeared or receded upon the 
addition of TK9. 
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including various excitation modes available, as well as the chemical environment. After 
determining the concentration of peptide in the sample, it is set aside until introduction into the 
analysis as needed.  
Generally, investigations are done with the 40-residue peptide, rather than the 42 residue 
one. This is due to the increase in aggregation rate seen with the 42-residue peptide.
101-104
 Its 
faster oligomerization rate obscures many details of Aβ interaction evident with the 40-residue 
one. Furthermore, the 40-residue peptide is more common in the body, and thus is more 
physiologically relevant.
103
 Thus, the 40-residue peptide was used for all investigations herein. 
 
5.5.1.2 Lipid Membrane Composition 
Various choices exist for the model membrane used in analysis. A common combination 
used is 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphoserine (POPS). This lipid system affords data that models eukaryotic cell 
composition, as opposed to the phosphoglycerols (PG) and the phosphoinositols (PI), as well as 
the dimyristoyl (DM) or dilauroyl (DL) lipids.
128,201-203
 Furthermore, these lipids can be 
modulated to include gangliosides and cholesterols. The GM1 source generally used is porcine, 
due to the eukaryotic cell and the close resemblance to human gangliosides. Cholesterol is the 
general molecule, synthesized as such. Furthermore, studies can be performed on brain extract 
lipids, which are lipid membranes formed from neurons of an animal, generally pigs or cows.
204
 
These contain a full complement of gangliosides, sphingomyelin, cholesterol, and other 
compounds that would be expected in a neuron, and afford the best model for true interaction in 
neuronal cells possible. Lipids are all purchased from Avanti Polar Lipids, Inc (Athens, GA), 
which is the literature standard for such research.
128 
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5.5.1.3 Extrusion and Membrane Formation 
Lipid samples are kept in chloroform at -20 °C when not in use. When prepared for 
membrane formation, the desired lipids are chosen and mixed in the appropriate ratio. The 
solvent is then removed under nitrogen gas, and the resulting film is lyophilized to remove any 
extraneous solvent molecules.
128
 The sample is then reconstituted in the buffer or dye-solution, if 
dye encapsulation is desired, of choice. Upon dissolution in an aqueous solution, the lipids 
spontaneously form multilamellar vesicles, which are essentially globular structures with many 
layers of lipid, like an onion.
205
 This structure does not accurately represent the phospholipid 
bilayer in a cell, and thus the lipids are passed through a membrane filter in a process known as 
extrusion, where the excess layers are stripped off of the vesicle until one remains, forming a 
large unilamellar vesicle (LUV), which is a lipid vesicle with a single bilayer.
206-207
 At this point, 
the lipid is ready for further experimentation. 
 
5.5.1.4 Dye-Filled Vesicle Experiments and the Stewart Assay 
It is possible to secure dye molecules within a membrane if extrusion is done with a dye 
solution, rather than a dye-free buffer. With the dye encapsulated in the membrane, 
characteristics of membrane integrity can be analyzed in dye-filled vesicle experiments. 
However, dye still remains in the vesicle solution, which must be removed.
128
 This is done 
through the use of gravity-based column chromatography, in which the dye-filled vesicles come 
off the column first, due to their large size, in a solution free of external dye molecules. 
To assess the concentration of the lipid obtained off the column, the Stewart assay is 
employed.
208
 This assay uses ammonium ferrothiocyanate to bind to phospholipid head groups. 
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As this metal complex absorbs light at 461 nm, the absorbance can be used as a measure of the 
amount of ammonium ferrothiocyanate bound to the lipid head groups, and thus a representation 
of the amount of lipid present in the sample, given known values. At this point, with the 
concentration known, the sample is ready for further investigations. 
 
5.5.2 Fluorescence Experiments 
5.5.2.1 Introduction to Fluorescence 
Fluorescence is another form of visible spectroscopy used in amyloid analysis. It is based 
on the interconversion of states upon the absorption of a photon.
209
 Once a molecule absorbs a 
photon, it can relax in a variety of forms. The excited state can relax directly to the ground state, 
emitting radiation at the same energy as that which was absorbed.
210
 Molecules also release heat 
after excitation via nonradiative relaxation processes, within the first excited state manifold.
211
 If 
this were to be followed by radiative relaxation, the photon emitted would be slightly lower in 
energy as compared to that absorbed, affording a redshifted spectrum. This process is 
fluorescence. Common fluorophores are conjugated molecules that are easily excited, with many 
relaxation modes.
212
 The redshift that the photon observes is known as a Stokes shift, which 
tends to be nonradiative relaxation within the excited state manifold, but depends on the 
environment, fluorophore, and wavelength of excitation and emission.
213-214
 It is generally 
characteristic of the fluorophore and sample conditions.
215
 Furthermore, the amount of photons 
emitted, and thus the intensity of the signal seen, is proportional to the concentration of the 
fluorophore in the solution, and thus is a quantitative measure of the relative amount of 
fluorophore.
215 
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The quality of a fluorophore, and its fluorescence, is measured in quantum yield, a 
measure of the efficiency of the fluorescence process.
216
 This quantum yield can be affected by 
nonradiative forms of relaxation that return the fluorophore to the ground state, known as 
quenching. This can be due to various interactions, such as collisions, energy transfer, or 
reactions, between the fluorophore and another element in the sample, known as the quencher, or 
even itself, at high enough concentrations.
217
 Due to quenching, fluorescence intensity and 
quantum yield decrease. Intermolecular quenching, due to collisions, is the dominant form, and 
is dependent on fluorophore and quencher concentration. 
Fluorescence is analyzed via fluorescence spectroscopy techniques, and related 
procedures. Typically, excitation wavelengths are scanned in order to give the maximum 
absorption.
218
 After determination of the maximum absorption, the emission spectrum is scanned 
to determine the optimal fluorescent wavelength for detection. This procedure is used to 
maximize the quantum yield of the fluorophore detected, improving signal intensity and 
sensitivity.
 
For many commonly used fluorophores, however, these values are known and 
standardized across research groups. Fluorescence is the main means by which amyloid 
aggregation and membrane interaction is studied, being the quickest and most effective 
characterization of qualitative Aβ mechanisms.128 
 
5.5.2.2 Thioflavin-T 
The most common tool used to study amyloid aggregation is the Thioflavin-T (ThT) 
assay.
219-220
 ThT (Figure 5.9) is a fluorophore of the thioflavin family used to identify amyloid 
fibers. The maximum absorbance of ThT in Aβ-free solution is at 340 nm, with an emission 
wavelength at 445 nm. However, upon binding to β-rich amyloid sheets, the fluorescent nature of 
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the dye changes. Instead of the spectrum discussed above, the absorbance maximum shifts 
toward 440 nm, and the emission maximum to 480 nm. Furthermore, the quantum yield of this 
dye increases greatly upon binding to an amyloid-like structure. Monitoring this shift in the 
emission spectrum allows for the use of ThT as an indicator of the presence of aggregated 
amyloids, and thus is a useful monitor of Aβ fibrilization. As the intensity of the signal seen is 
proportional to the amount of dye bound to fiber, the signal intensity is actually a measure of the 
amount of fibrilization, and gives the clear sigmoidal curve, with distinct lag, elongation, and 
plateau phases characteristic of Aβ aggregation, as shown in Figure 5.10.128 
   
5.5.2.3 Carboxyfluorescein 
Another dye commonly used in Aβ experiments is carboxyfluorescein (Figure 5.11).221-222 
A larger dye, carboxyfluorescein has an excitation maximum at 494 nm and an emission 
wavelength of 520 nm. As a member of the fluorescein family of dyes, carboxyfluorescein has 
the distinct quality of self-quenching, in which high local concentrations of the dye causes the 
quantum yield to go down drastically. Thus, the dye changes color depending on its 
concentration from a bright green when dilute to a damp, dull orange when concentrated. Thus, 
carboxyfluorescein is used in amyloid analyses as a measure of membrane integrity in a dye-
Figure 5.9. Thioflavin-T as 
used in fluorescence 
experiments 
Figure 5.10. Example thioflavin-T spectra, as used in fluorescence 
experiments. Reprinted with permission from Sciacca, M. F. M.; Kotler, 
S. A.; Brender, J. R.; Chen, J.; Lee, D.-k.; Ramamoorthy, A. Biophys. J. 
2012, 103, 702-710. Copyright 2012 Elsevier. 
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filled vesicle experiment. Trapped within a membrane, the dye exhibits a low level of 
fluorescence. However, if the membrane were to be degraded, then the dye would be released out 
into solution, lowering the local concentration, and thus increasing the quantum yield and 
fluorescence signal. Therefore, monitoring the change in signal at the 520 nm peak allows for a 
characterization of the integrity of the membrane being studied, and is a good indicator of the 
second stage of the two-step mechanism. An example spectrum is in Figure 5.12. 
 
5.5.2.4 Fura-2 
Much like carboxyfluorescein, Fura-2 is a dye used to probe the integrity of the 
membrane studied (Figure 5.13).
223-224
 A large, acidic dye, Fura-2 has an excitation peak at 380 
nm, with an emission spectrum at its maximum at 510 nm. However, upon binding to calcium or 
zinc ions, the excitation spectrum shifts its maximum to 340 nm, while not affecting the emission 
spectrum. The 340:380 ratio of fluorescence intensity is proportional to the amount of calcium or 
zinc binding to the dye. Thus, this dye can be used in dye-filled vesicle experiments to monitor 
the entrance of these ions via the monitoring of the change of this ratio. Upon pore formation, as 
in the first step of the two-step mechanism, calcium influx would cause the ratio to shift greatly. 
In fact, given the changes in size between calcium and zinc, this dye can be used to determine if 
the membrane disruption is due to pore formation or gross disruption. If zinc does not cause any 
Figure 5.11. The 6-carboxyfluorescein 
dye as used in fluorescence 
experiments 
Figure 5.12. Example 6-carboxyfluorescein spectra, as used in 
fluorescence experiments. Reprinted with permission from Sciacca, M. 
F. M.; Kotler, S. A.; Brender, J. R.; Chen, J.; Lee, D.-k.; Ramamoorthy, A. 
Biophys. J. 2012, 103, 702-710. Copyright 2012 Elsevier. 
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change, then it is a simple pore formation, as hypothesized by the two-step mechanism. An 
example spectrum appears in Figure 5.14 for both calcium and zinc. 
 
5.5.3 Nuclear Magnetic Resonance Experiments 
5.5.3.1 Nuclear Magnetic Resonance and Amyloids 
A full discussion of nuclear magnetic resonance (NMR) can be found in Chapter 1.4.3: 
Nuclear Magnetic Resonance and Metabolomics. It is sufficient here to state that NMR is a 
technique that exploits the inherent spin state of nuclei through the application of magnetic 
field,
225
 and has been demonstrated to be highly useful in analyzing Aβ in both the solution and 
the solid state.
226-228
 Upon excitation of the spin states, the relaxation time is measured, which is 
converted to frequencies normalized for the instrument into the chemical shift.
229
 This shift gives 
information on the environmental conditions of the nucleus studied. Important nuclei for amyloid 
analysis are 
1
H, 
13
C, 
15
N, 
19
F, and 
31
P, though the first and the last are the only to be discussed in 
great detail.
227
 Furthermore, amyloid data benefits from both one-dimensional and especially 
two-dimensional data, as the detail and specifics afforded therein are highly useful.
226-228 
NMR is not the only spectroscopic tool available for amyloid analysis, however, as two-
dimensional infrared spectroscopy is gaining popularity in this field.
230-233
 However, this 
Figure 5.13. The fura-2 dye as used in 
fluorescence experiments 
Figure 5.14. Example fura-2 spectra, as used in fluorescence 
experiments. Reprinted with permission from Sciacca, M. F. M.; 
Kotler, S. A.; Brender, J. R.; Chen, J.; Lee, D.-k.; Ramamoorthy, A. 
Biophys. J. 2012, 103, 702-710. Copyright 2012 Elsevier. 
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technique remains laborious, preventing its implementation on a wider scale, and the theoretical 
implications of amyloid analysis are not fully characterized. Furthermore, it is less sensitive than 
NMR, and affords more complex spectra, requiring a skilled interpreter. NMR remains the 
superior and the widely used technique. Other options, such as mass spectrometry
234-235
 and 
atomic force microscopy,
236-237
 exist, but come with flaws such as limited interpretation and 
experimental flexibility, and destruction of sample, preventing an accurate time-course 
measurement. All discussed experiments can be done in the solution- or solid-state, as needed. 
 
5.5.3.2 1D and 2D 1H-NMR and Amyloids 
Amyloid analysis via 
1
H-NMR is done from many angles. One such form of analysis is a 
simple one-dimensional proton analysis, which has been demonstrated specifically with APP 
studies.
196
 This technique, however, has the drawback of affording highly complex spectra. 
Though easy to acquire, interpretation remains a challenge in the one-dimensional field. It is best 
used for amyloids on its own to track aggregation rates through the appearance of new and 
broader peaks, rather than in contact with lipids, cholesterol, gangliosides, or other 
compounds.
196 
Two-dimensional spectroscopy, on the other hand, overcomes many of these limitations. 
In 2D spectroscopy, correlations between nuclei are analyzed, whether 
1
H-
1
H, 
13
C-
1
H, or 
15
N-
1
H. 
These are probed through complex pulse sequences and methods such as spin magnetization 
energy transfer, in which the excitation energy of one sample is transferred to another, coupled 
nucleus via quantum interactions, causing that interaction to be measured.
238-240
 This is 
analogous to saturation transfer difference NMR spectroscopy, another useful amyloid analysis 
technique, in which certain protons can be saturated such that they give no signal in the 
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spectrum. The coupled protons to the initial ones will also have depressed signals, indicative of 
some sort of interaction, especially between receptors and ligands. Essentially, 2D spectroscopy 
comes down to the determination of various coupling modes between nuclei in a sample.
238-240 
Common 
1
H-
1
H 2D techniques used in protein analysis include correlation spectroscopy 
(COSY), in which α and β protons that are coupled via bonds are detected. Detection is seen via 
cross-peaks on the 2D spectrum, where excitation at the α proton causes a signal to be seen at 
both the α and the β proton, resulting in the α-α diagonal peak and the α-β cross peak.241-242 
COSY can be expanded to total correlation spectroscopy (TOCSY), where the coupled α, β, γ, δ, 
ε, and beyond protons are all detected upon excitation of the α proton.243-244 Another one used is 
nuclear Overhauser effect spectroscopy (NOESY), in which protons related through space, rather 
than bonds, are detected.
245-256 
More important to amyloid analysis is heteronuclear correlation spectroscopy, such as 
heteronuclear single quantum coherence (HSQC), performed with 
15
N or 
13
C. The HSQC 
magnetization is prepared on the proton and subsequently transferred to the bound heteronucleus, 
after which the magnetization is allowed to evolve in the heteronuclear frequency, and 
transferred back to the bound proton for measurement.
 247-248
 Thus, the direct measurement of the 
proton is coupled with the indirect measurement of the heteronucleus and a single peak in a two-
dimensional spectrum is indicative of a single 
1
H-
15
N or 
1
H-
13
C bond.. Spectra are plotted such 
that one axis is the proton and the other either nitrogen or carbon, and peaks thus appear in two 
dimensions. This allows for the separation of similar proton peaks from each other based on the 
differences in heteronuclear environments. An example spectrum of amyloid-β(40) with and 
without membrane binding is in Figure 5.15.
249 
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NMR experiments utilizing proton magnetization are quite useful in tracking aggregation 
rates of the amyloid, as well as determining binding of the amyloid to a membrane, other 
proteins or components in the sample, and so on. In fact, HSQC data can reveal, with residue 
specificity in the amyloid, the formation of distinct binding sites through the depletion of peak 
intensity and changes in chemical shift.
 247
 Thus, important structural and kinetic information is 
obtained from these spectra in a time course fashion, without degradation of the sample or an 
overly complex setup.  

5.5.3.3 31P-NMR and Amyloids 
One-dimensional spectroscopy is not limited to hydrogen, however, but can also be 
performed on phosphorus nuclei. The principle is much the same as with hydrogen nuclei, but 
attuned to a different characteristic frequency. As 
31
P is a component of membrane head groups, 
analysis of it can be used to study membrane quality. Thus, changes in the 1D spectrum are 
representative of different lipid membrane structures, such as the formation of micelle-like 
structures or interaction with peptide.
128,250
 Furthermore, paramagnetic ions such as Mn
2+
 ions, 
Figure 5.15. To the right is an example two-
dimensional heteronuclear single quantum coherence 
spectrum of amyloid-β(40) (black) and amyloid-β(40) 
with a potential anti-oligomerization compounds 
(red). Reprinted with permission from Hindon, S. S.; 
Mancino, A. M.; Braymer, J. J.; Liu, Y.; Vivekanandan, 
S.; Ramamoorthy, A.; Lim, M. H. J. Am. Chem. Soc. 
2009, 131, 16663-16665. 
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with its five unpaired electrons, can give rise to an effect known as paramagnetic relaxation 
enhancement when in close proximity to the lipid head group and the 
31
P nucleus.
128
 When a 
nucleus is exposed to a paramagnetic ion it causes quenching of the signal, and can be used as an 
indicator of phospholipid head groups are exposed to the environment.
128
 Thus, this is a 
diagnostic technique for the integrity of a membrane. If the membrane is intact, then only the 
outer surface would be exposed and quenched, and the inner membrane would supply a signal as 
before. If the membrane was not intact, then the entire membrane would be quenched, and the 
phosphorus signal would not be detected.
128, 250-251
  
 
5.6 Areas of  Potential Growth 
As well-demonstrated above, there is a wealth of information on the aggregation of 
amyloid-β; yet, for every fact known, there is a corresponding unknown fact. Thus, Aβ studies 
can go in any desired direction, probing any mechanism or hypothesis. As all techniques are well 
established, little methodology analysis can be done. It is the actual mechanism of action of the 
sample that needs further study. With the importance of membranes in the mechanism of 
interaction, that idea was pursued in this investigation. 
The two moieties chosen to probe membrane analysis were cholesterol and anti-amyloid 
peptides, due to their controversial nature, in the case of cholesterol, and their potential benefits, 
in the case of TK9. Though they represent two different aspects of Aβ-membrane interaction, 
they both afford important data toward the full understanding of the mechanism of Aβ-membrane 
interactions, and potentially give insight into the pathophysiology of Alzheimer’s disease. 
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Chapter 6: 
Effects of Membrane Compositions on Amyloid-β Aggregation 
 
6.1 Abstract 
 Alzheimer’s disease is one of the most prevalent terminal conditions in the world. 
Though the exact mechanism remains unknown, a prevailing theory is the amyloid cascade 
hypothesis, where the aggregation of amyloid-β causes membrane disruption and cell death. This 
is purported to occur via the two-step mechanism, with initial pore formation followed by gross 
membrane fragmentation. The nature of amyloid-β binding to the membrane was investigated 
through the modulation of membrane composition via cholesterol concentration, and the offering 
of another platform for amyloid-β binding. It was shown that cholesterol prevented gross 
fragmentation of the membrane without ganglioside and that the peptide preferred binding to the 
membrane than to the inhibitory platform provided via the introduction of a self-assembly 
protein sequence, though the effects of ganglioside remains to be seen. 
 
6.2 Introduction 
 As discussed above, Alzheimer’s disease (AD) is a devastating neurodegenerative 
disease.
1-3
 Though the exact mechanism of the disease is unknown, a prevailing theory of AD 
onset is the amyloid cascade hypothesis, in which the formation of fibrils and oligomers of the 
amyloid-β (Aβ) peptide is the source of apoptosis and neural degeneration in brains, leading the 
memory loss and cognitive impairment.
86-127
 The exact mechanism of this interaction is 
unknown, but is believed to involve the influx of calcium and potential membrane disruption. 
This ion channel hypothesis has been widely supported via atomic force and electron 
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microscopy, as well as conductance experiments, though it does not characterize the membrane 
fragmentation seen.
116-119 
 Recently, Sciacca, et al, proposed a two-step mechanism by which Aβ can cause 
membrane disruption and cell death.
128
 In this mechanism, initial interaction of small Aβ 
monomers and oligomers interact with the membrane to form pores, through which calcium 
influx can occur. As the peptide oligomerizes further, a fragmentation pathway occurs, causing 
gross membrane disruption. Thus, this mechanism encompasses both the ion channel hypothesis 
and the flaw within that analysis, as discussed above. It was also demonstrated in this work that 
the presence of ganglioside was essential for this process to happen, due to the orientation effects 
of gangliosides in the lipid membrane inducing Aβ insertion.128-145 
 However, it was still unresolved as to the effects of other components of the membrane, 
namely cholesterol. The effect of cholesterol in Aβ aggregation and membrane disruption is still 
controversial, though recent studies seem to support the idea that membrane cholesterol has a 
protective effect against pore formation and membrane disruption.
150-190
 Furthermore, as 
cholesterol is a major component of lipid rafts, it would be present near the ganglioside site in 
the membrane, potentially countering the effect of the sugar. 
146-149 
Likewise, the binding affinity of Aβ to ganglioside is unknown. Self-assembling peptides, 
such as TK9, have shown some inhibitory effects toward Aβ aggregation through insertion 
within the oligomers formed.
191-195 
Thus, the inherent binding of TK9 to peptide is more 
preferential than Aβ binding to itself. Therefore, TK9 can be used as a means by which to 
monitor the binding strength of Aβ to the membrane, as binding to the membrane would elicit 
changes in membrane structure, as shown in the two-step mechanism, whereas inhibition would 
not.
128, 194-195 
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Knowledge of the membrane-peptide interaction would afford insight into the binding 
mechanism of Aβ and the pathophysiology of AD. Defining the specific roles of cholesterol in 
membrane binding, as well as fully understanding the kinetics and binding strength of Aβ to the 
membrane would help elucidate key factors in the two-step mechanism, and shedding more light 
on the cause of AD. It was thus proposed to study the aggregation rates of Aβ in the presence of 
cholesterol- and ganglioside-containing membranes, in the presence of TK9, via the standard 
thioflavin-T experiment, as well as analyzing the membrane integrity of these membranes 
through a measurement of the amount of dye that leaks through the membrane. It was 
hypothesized that TK9 would prevent Aβ aggregation and dye leakage, with the effect increasing 
at higher concentrations, while cholesterol would not have any effect on the aggregation overall, 
or the dye leakage in the presence of ganglioside. 
 
6.3 Experimental 
6.3.1 General Considerations 
 All conversions and manipulations were done to the open air. Peptide samples were 
purchased from Genscript. Extrusion equipment, total lipid brain extract, 1-palmitoyl-2- oleoyl-
sn-glycero-3-phosphocholine (POPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-Lserine 
sodium salt (POPS), cholesterol, and ganglioside extract were purchased from Avanti. The TK9 
sample was provided by Dr. Anirban Bhunia. Ammonium thiocyanate, ferric chloride 
hexahydrate, Sephadex, Triton-X, and thioflavin-T were purchased from Sigma-Aldrich. The 6-
carboxyfluorescein was purchased from Fluka. Lyophilization and absorbance measurements 
were done on the instruments provided by Biophysics at the University of Michigan. 
Fluorescence measurements were done on a Biotek Synergy 2 plate reader with 96 well Corning 
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non-binding surface plates.  Solvents were either purchased from Sigma-Aldrich or provided by 
the University of Michigan solvent line.  
 
6.3.2 Amyloid-β Preparation 
 A 0.1 mg aliquot of Aβ was dissolved in 190 μL of millipure water and 10 μL of 1% 
ammonium hydroxide. Next, the concentration was standardized through measurement of the 
absorbance of the peptide at 280 nm, given an extinction coefficient of 1490 1/(M*cm). The 
sample was then stored at 4 °C until use.  
 
6.3.3 TK9 Preparation 
 TK9 was dissolved in millipure water in 2.5 mM aliquots, which were diluted in 
millipure water to a concentration of 500 μM, and stored at 4 °C until use. 
 
6.3.4 Lipid Preparation 
 To perform assays, large unilamellar vesicles were prepared. Chloroform samples of 
lipids were taken to form the following ratios: 7:3 POPC/POPS and 7:3:3 
POPC/POPS/cholesterol, along with a sample of total lipid brain extract (TLBE). These samples 
were dried under nitrogen gas and lyophilized overnight to remove any residual solvent. The 
resultant film was rehydrated with a buffer solution (10 mM phosphate buffer, pH 7.4, 100 mM 
NaCl for thioflavin-T experiments, with the addition of 10 μM of carboxyfluorescein for dye-
leakage experiments), to a concentration of 4 mg/mL for thioflavin-T experiments, and 10 
mg/mL for dye-leakage. The solution was then passed through a 100 nm polycarbonate 
membrane on an extruder to obtain vesicles with an average size of 100 nm. 
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6.3.5 Thioflavin-T Experiments 
 The 4 mg/mL lipid solution of choice was diluted to 0.2 mg/mL in the same buffer 
solution as before, along with thioflavin-T at a final concentration of 20 μM. To this solution was 
added amyloid-β such that the concentration was 10 μM. If desired, TK9 was added in 
concentrations of 10 μM, 50 μM, and 100 μM. Each condition was plated in triplicate, with 
peptide-free samples being used as controls. Aggregation was measured via fluorescence, with an 
excitation wavelength of 440 nm and an emission wavelength of 480 nm. Data was collected 
over 48 hours at 30 °C, with measurement every 3 minutes and 30 seconds of sample agitation 
before each measurement. 
 
6.3.6 Dye-leakage experiments 
 After preparation of the dye-filled vesicles, external dye molecules were removed via 
gravity column chromatography through the use of a Sephadex G50 gel exclusion column, with 
the collection of the first visibly colored band. The concentration of the lipid was then assessed 
via the Stewart assay. A 10 μL sample of lipid was diluted in 1 mL of chloroform and 1 mL of the 
Stewart buffer, containing ammonium thiocyanate (400 mM) and ferric chloride hexahydrate 
(170 mM).  After vigorous shaking, the chloroform layer was allowed to settle and was collected 
for absorbance measurements at 461 nm. Comparison to a previously made calibration curve was 
used to determine the final concentration of lipid.  
 After, the lipid was diluted to 0.2 mg/mL, and to this solution was added amyloid-β such 
that the concentration was 10 μM. If desired, TK9 was added in concentrations of 10 μM, 50 μM, 
and 100 μM. Each condition was plated in triplicate, with peptide-free samples being used as 
controls. Dye leakage was measured via fluorescence, with an excitation wavelength of 494 nm 
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and an emission wavelength of 520 nm. Data was collected over 48 hours at 30 °C, with 
measurement every 3 minutes and 30 seconds of sample agitation before each measurement. 
After collection, a 10% Triton-X solution in water was used to lyse the vesicles, and a separate 
measurement was taken as the maximum value for normalization purposes. All dye leakage data 
was collected on the same plate as the aggregation data. 
 
6.4 Results and Discussion 
6.4.1 Effects of Cholesterol on Amyloid-β Membrane Interactions 
 Initial samples were made with the following concentrations of lipid: 7:3 POPC/ POPS, 
and 7:3:3 POPC/POPS/cholesterol. The POPC and POPS lipids were chosen due to their 
applicability in eukaryotic investigations. The concentration of cholesterol chosen was 30% of 
the total membrane, representative of the average concentration of cholesterol in human neuronal 
cells. Both thioflavin-T (ThT) and dye leakage studies were done. 
 At first, the ganglioside free samples were measured to determine the effect of cholesterol 
on Aβ aggregation and dye leakage. As seen in Figure 6.1, the ThT data was unaffected by the 
introduction of cholesterol into the model membrane. This is to be expected, as cholesterol in the 
membrane has had no previously displayed effect on Aβ aggregation.168-169 Though there were 
slight changes in the ThT spectrum for each condition, the overall spectrum still showed 
sigmoidal aggregation. Thus, these variations are not important, and the depression seen with the 
introduction of membrane is expected. A discussion on the calculation of the various spectra can 
be found in the supplementary information for all samples. 
 Next, a dye leakage experiment was done on the samples. This data appears in Figure 6.2. 
Based on the graph in the figure, it can be stated that the cholesterol actually acts as a protector 
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against membrane disruption. Figure 2 displays the cholesterol and ganglioside free membrane 
against only the cholesterol-free membrane. Based on the aggregation rate of Aβ, the increase in 
dye leakage seen in the phospholipid-only membrane was due to the effects of fibrilization. This 
effect is greater than that of the cholesterol and phospholipid membranes, though both are quite 
small compared to that seen in previous studies with total lipid brain extract (TLBE).
128
  
 To fully understand the conclusions from this data, further studies need to be undertaken. 
These include studying the effects of gangliosides on membrane interactions, as this has been 
previously demonstrated to increase the amount of leakage seen.
128
 Furthermore, Fura-2 studies 
to determine the appearance of pores in the membrane as a function of TK9 concentration, as 
well as 
1
H-
15
N HSQC NMR and 
31
P NMR, to fully understand the physical nature of the 
membrane and oligomers over time. These studies are currently ongoing. 
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Figure 6.1. Kinetics of amyloid formation measured by 
ThT fluorescent emission. The graph shows 10 μM 
peptide in buffer in the absence of membranes (blue 
line) and in the presence of 0.2 mg/mL POPC/POPS 7:3 
LUVs (red line), and 0.2 mg/mL 
POPC/POPS/Cholesterol 7:3:3 LUVs (red line). 
Experiments were performed at room temperature in 
10 mM phosphate buffer, 100 mM NaCl, pH 7.4. 
Results are the average of three measurements. Data 
was normalized to the maximum value for each 
sample. Data was obtained at an excitation of 440 nm 
and an emission of 480 nm.  
Figure 6.2. Membrane disruption induced by amyloid-β 
as measured by the 6-carboxyfluorescein dye leakage 
assay. The graph illustrates the release of 6-
carboxyfluorescein induced by 10 μM peptide from 0.2 
mg/mL POPC/POPS LUVs 7:3 (blue line) and 0.2 mg/mL 
POPC/POPS/cholesterol LUVs 7:3:3(red line). Dye leakage 
occurs only after a lag period and is detected at a 
negligible level in these samples due to the lack of 
ganglioside. Experiments were performed at room 
temperature in 10 mM phosphate buffer, 100 mM NaCl, 
pH 7.4. Results are the average of three measurements. 
Data was normalized to the total dye in solution as 
determined by obtaining a spectrum after membrane 
lysing with Triton-X. Data was obtained at an excitation 
of 494 nm and an emission of 480 nm. 
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6.4.2 Effects of TK9 on Amyloid-β Membrane Interactions 
 After conclusion of the membrane studies, the effect of TK9 was investigated. Initially, 
the effect of TK9 on Aβ in solution was probed. TK9 has been demonstrated to be inhibitory in 
relation to the amyloid precursor protein,
196
 but its effect on Aβ in solution is unknown in the 
literature. Therefore, initial samples of 10 μM Aβ were placed in solution for a ThT assay, along 
with varying concentrations of TK9. This data is presented in Figure 6.3. As shown in the graph, 
as the amount of TK9 increased, the resultant fluorescence value decreased. This fluorescence 
intensity is directly correlated to the amount of Aβ fibril present in the solution; thus, this 
lowered signal intensity is indicative of inhibitory properties of the TK9 peptide. Furthermore, 
the lag phase of Aβ aggregation increased with the increase in TK9 concentration, again a 
function of the inhibitory properties of the peptide. TK9, though self-assembling, did not afford 
any native ThT fluorescence; therefore, it was ignored as a contributor to ThT data. 
 Given this inhibitory nature, the data suggested that Aβ preferentially binds to TK9 rather 
than itself, causing the lack of aggregation seen. With this in mind, studies of the effect of TK9 in 
the presence of membrane were carried out. As TK9 is known to have self-assembly 
characteristics, forming β-sheets, it was thought that it may interact with membranes, causing 
disruption in dye leakage studies. Therefore, control studies were done with TK9 alone as well as 
Aβ. The ThT data is in Figures 6.4, and the 6-carboxyfluorescein data are Figures 6.5 and 6.6. 
 Based on the data presented, TK9 did not inhibit the aggregation of Aβ in the presence of 
membrane to the extent that it did in solution. As seen in Figure 6.3, the lag phase greatly 
increased as a function of TK9 concentration, along with a corresponding decrease in 
fluorescence intensity. Though this effect is seen in the presence of lipid, it is not as dramatic. 
Furthermore, binding with the lipid was not inhibited by the presence of TK9. As shown in 
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Figure 6.6, the dye leakage curves were essentially unchanged when TK9 was introduced. 
Though TK9 has its own basal leakage value (Figure 6.7), it is not large enough to cause the 
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Figure 6.3. Kinetics of amyloid formation measured by 
ThT fluorescent emission. The graph shows 10 μM 
peptide in buffer in solution (dark blue line) and in the 
presence of 10 μM TK9 (red line), 50 μM TK9 (purple 
line), and 100 μM TK9 (light blue lien). Experiments 
were performed at room temperature in 10 mM 
phosphate buffer, 100 mM NaCl, pH 7.4. Results are 
the average of three measurements. Data was 
normalized to the maximum value for each sample. 
Data was obtained at an excitation of 440 nm and an 
emission of 480 nm.  
Amyloid-β with TLBE membrane 
Amyloid-β with 1:1 ratio of TK9 and TLBE membrane 
Amyloid-β with 1:5ratio of TK9 and TLBE membrane 
Amyloid-β with 1:10 ratio of TK9 and TLBE membrane 
Figure 6.4. Kinetics of amyloid formation measured by 
ThT fluorescent emission. The graph shows 10 μM 
peptide in buffer in the presence of 0.2 mg/mL TLBE 
(purple line), 0.2 mg/mL TLBE and 10 μM TK9 (red 
line), 0.2 mg/mL TLBE and 50 μM TK9 (brown line), 
and 0.2 mg/mL TLBE and 100 μM TK9 (pink line).  
Experiments were performed at room temperature in 
10 mM phosphate buffer, 100 mM NaCl, pH 7.4. 
Results are the average of three measurements. Data 
was normalized to the maximum value for each 
sample. Data was obtained at an excitation of 440 nm 
and an emission of 480 nm.  
Figure 6.5. Membrane disruption induced by TK9 measured 
by the 6-carboxyfluorescein dye leakage assay. The graph 
illustrates the release of 6-carboxyfluorescein induced by 10 
μM TK9 (blue line), 50 μM TK9 (red line), and 100 μM TK9 
(green line) in 0.2 mg/mL of TLBE. Dye leakage occurs only 
after a lag period and is detected at a negligible level in 
these samples due to the lack of ganglioside. Experiments 
were performed at room temperature in 10 mM phosphate 
buffer, 100 mM NaCl, pH 7.4. Results are the average of 
three measurements. Data was normalized to the total dye 
in solution as determined by obtaining a spectrum after 
membrane lysing with Triton-X. Data was obtained at an 
excitation of 494 nm and an emission of 480 nm. 
0
0.2
0.4
0.6
0.8
1
0 500 1000 1500 2000 2500Fr
ac
ti
o
n
 d
ye
 le
ak
e
d
 (
n
o
 u
n
it
s)
 
Time (min) 
0
0.05
0.1
0 500 1000 1500 2000 2500F
ra
ct
io
n
 d
ye
 le
ak
e
d
 (
n
o
 u
n
it
s)
 
Time (min) 
100 μM of TK9 and TLBE membrane  
50 μM of TK9 and TLBE membrane 
10 μM of TK9 and TLBE membrane 
Amyloid-β and TLBE membrane 
Amyloid-β with 1:1 ratio of TK9 and TLBE membrane 
Amyloid-β with 1:5 ratio of TK9 and TLBE membrane 
TK9 with TLBE membrane 
Figure 6.6. Membrane disruption induced by TK9 measured by 
the 6-carboxyfluorescein dye leakage assay. The graph 
illustrates the release of 6-carboxyfluorescein induced by 10 
μM TK9 (green line), and 10 μM peptide with 10 μM TK9 
(purple line), 50 μM TK9 (light blue line), and no TK9 (red line), 
all in 0.2 mg/mL of TLBE. Dye leakage occurs only after a lag 
period and is detected at a negligible level in these samples 
due to the lack of ganglioside. Experiments were performed at 
room temperature in 10 mM phosphate buffer, 100 mM NaCl, 
pH 7.4. Results are the average of three measurements. Data 
was normalized to the total dye in solution as determined by 
obtaining a spectrum after membrane lysing with Triton-X. 
Data was obtained at an excitation of 494 nm and an emission 
of 480 nm. 
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leakages seen in Figure 6.5 to imply inhibition of Aβ membrane binding. Thus, Aβ must interact 
with the membrane at the same rate with and without TK9, though aggregation is inhibited. 
Many factors could explain this confusing data. The lipid used for this investigation was 
bovine total brain extract lipid (TLBE), which contains cholesterol and ganglioside and models 
humans well.
204
 As discussed above, ganglioside is a known promoter of Aβ aggregation and 
membrane disruption, as measured by ThT and dye leakage.
129-131
 Therefore, it is likely that Aβ 
has a binding preference to the membrane ganglioside rather than the TK9 peptide. Though 
aggregation itself is inhibited, or at least slowed, this could be because of the effect on free 
peptide, rather than bound. In fact, it could be that the fluorescence shown from Figure 6.4 
indicates that fibrilization still occurs on the membrane surface, but solution values are inhibited. 
Thus, the membrane and the peptide have a favorable interaction than the peptide as TK9, as 
inhibition is decreased. This could be a thermodynamic effect, in that the binding strength of the 
Aβ-ganglioside interaction is simply much stronger than the TK9-Aβ interaction. On the other 
hand, it could be a kinetic interaction, in that the Aβ-ganglioside interaction simply happens on a 
faster time scale than the effects of TK9, such that the Aβ peptide is already inserted within the 
membrane before TK9 can even affect aggregation. 
 To fully understand this data, further studies need to be undertaken. These include Fura-2 
studies to determine the appearance of pores in the membrane as a function of TK9 
concentration, as well as 
1
H-
15
N HSQC NMR and 
31
P NMR, to fully understand the physical 
nature of the membrane and oligomers over time. It is to be thought that the cholesterol would 
show protection against pore formation in Fura-2, while these would still be present with all 
concentrations of TK9. NMR would confirm the binding to membrane in presence of cholesterol 
and TK9. These studies are currently ongoing, and will be completed as soon as possible. 
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6.5 Conclusion 
In this study, the effect of membrane composition on the aggregation rate of amyloid-β, 
as well as its effects on membrane integrity was investigated, with the goal of gaining insight 
into the mechanism of amyloid-β oligomerization in the context of Alzheimer’s disease. It was 
shown that cholesterol inhibits membrane disruption if alone in a lipid membrane, though this 
remains unproven in the presence of aggregation promoters such as gangliosides. Further studies 
were done with the peptide TK9, known to inhibit the amyloid precursor protein, to determine its 
effect on amyloid-β both with and without the presence of a membrane. Though this sequence 
prevented amyloid-β aggregation without the presence of a membrane, introduction of lipids 
removed all inhibitory effects of TK9. This was most likely due to the kinetic or thermodynamic 
preference of amyloid-β for the gangliosides present in the membrane. However, there remains 
many question marks about the interaction of amyloid-β with these membranes, as Fura-2 
studies, to analyze the formation of pores in the membrane upon introduction of peptide, as well 
as one- and two-dimensional nuclear magnetic resonance procedures, to study the aggregation 
rate and gain a physical picture of the interaction, are ongoing. In conclusion, it can be stated that 
the mechanism of amyloid-β aggregation in the presence of various membrane compositions has 
been probed, underscoring important conclusions of the two-step mechanism, and lending 
support to that formulation. Eventual consolidation of that mechanism would allow clinical 
applications in the analysis of the pathophysiology of Alzheimer’s disease and the eventual 
development of pharmaceuticals to combat it.  
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Chapter 7: 
Concluding Remarks and Future Directions 
 
The attention paid to Alzheimer’s disease and amyloid-β, as the main aggressor in the 
amyloid cascade hypothesis, has never been higher. A full understanding of the physiological and 
biochemical methods of this disease has the potential to improve the quality of life of millions of 
future Alzheimer’s patients. With the aging of the baby boomer generation, Alzheimer’s disease 
is going to become more socially and economically cumbersome. Already the most expensive 
disease in the developed world, causing endless stress for caregivers, the imminent increase in 
cases threatens to upend the current health care system. Therefore, there is an even greater need 
for the development of better theories to explain how this disease actually functions. 
Furthermore, the implications of the amyloid cascade hypothesis and amyloid-β aggregation 
extend well beyond the confines of Alzheimer’s disease. The amyloid hypothesis is implicated in 
diseases as varied as Parkinson’s disease, Huntington’s disease, and even type II diabetes, 
increasing the scope of the impact of potential amyloid-β mechanisms. 
However, as displayed in this analysis, there still remains much work before the 
mechanism is fully determined for this disease. Though changing the moieties of membrane 
composition, as done above, have given some insight into how amyloid-β interacts with the 
membrane, and its preference for gangliosides over all else, the exact nature of this preferential 
binding still is not understood. Furthermore, many more components of the membrane, such as 
sphingomyelin and other glycophospholipids, remain untested. Even a full characterization of the 
two-step mechanism in the context of the above mechanism, through the use of Fura-2 assays 
and nuclear magnetic resonance studies remains to be seen, though experiments are ongoing. 
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Likewise, the difference between in vivo and in vitro data is striking. No data presented 
above can be taken as a true representation of the human body, as factors such as genetics, local 
environmental stress, bodily injury, diet and others may impact the progression of this disease. 
The studies done above are isolated from effects that may be as important as those analyzed. 
 Amyloid research, however, is benefitting from an increase in attention. Two-dimensional 
infrared spectroscopy and newly developed nuclear magnetic resonance pulse sequences are 
being applied to amyloid data, giving insight into previously unknown aspects of aggregation. 
Though theoretical obstacles remain before the full implementation of these techniques, the 
potential improvements in data suggested by initial results could revolutionize the field. 
These improvements in amyloid analysis and mechanistic understanding, however, do not 
lose sight of the overall goal: to treat Alzheimer’s disease, among others. All amyloid studies are 
done with one eye toward the pharmaceutical applications of this technique, as the elucidation of 
the mechanism of amyloid-β aggregation affords therapeutic targets. The improvements to the 
understanding of the mechanism discussed above represent steps toward reaching that potential. 
Being able to isolate gangliosides as the driving force in amyloid-β and membrane interactions 
highlights aspects of the potential mechanism of action that can be a target for the eventual 
synthesis of therapeutics, while simultaneously disavowing self-assembling peptides as a 
potential therapeutic agent. Once the mechanism is determined, clinical applications will follow. 
 This is an exciting time to be involved in amyloid-β research. With the new technologies 
discussed above, as well as potential explanations for membrane interaction and disruption 
hypothesized, the five-year outlook is extremely bright. Though many questions remained, the 
progress recently made in leaps and bounds suggests that those questions will not remain 
unanswered for long. 
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Appendix B.2: 
Supplementary Information 
 
Mathematical formulation of Thioflavin-T data (Figures 6.1, 6.3, 6.5, and 6.6) 
 
Samples were taken for each condition, with and without amyloid-β, in triplicate. The baseline 
value was taken to be that without amyloid-β, and the three values were averaged at each time 
point. These were then subtracted from each individual sample with amyloid-β value, at the 
corresponding time point. The amyloid-β data was then normalized to the highest fluorescence 
value for each sample, and each condition was averaged to give relative fluorescence values. 
These were then plotted as above. 
 
Mathematical formulation of 6-Carboxyfluorescein data (Figures 6.2, 6.4, 6.7, and 6.8) 
 
Samples were taken for each condition, with and without amyloid-β, in triplicate. Each sample 
was measured in fluorescence units, over the total time of the experiment. These were then 
normalized to the value obtained after vesicle lysing using a Triton-X solution, done for each 
sample. Then the samples without amyloid-β were averaged and subtracted from each sample of 
the amyloid-β conditions. These conditions were then averaged and plotted as above, to give 
fraction of dye leaked.  
 
Details of data acquired available upon request.  
 
cxvi 
FINAL REMARKS 
BIOPHYSICS REVISITED 
 
As displayed in the above investigation, biophysical techniques are useful in investigating 
the nature of Alzheimer’s disease and cancer. Furthermore, it is easily seen that the techniques 
used are in fact as chemical as they are biophysical, being at the interface of the two sciences. 
Through the use of spectroscopic techniques such as nuclear magnetic resonance and 
fluorescence, improvements to current methodologies and a better understanding of the 
mechanism of disease progression have been reached. Though metabolomics has a ways to go 
before truly becoming a science able to act in a diagnostic fashion, the simplification and 
standardization of spectra delineated above allows it to afford more accurate data, an important 
step toward clinical applications. Likewise, though the two-step mechanism and the amyloid 
hypothesis have not been, by any means, definitively proven, the studies done above give insight 
into the nature of amyloid-membrane binding, and its potential implications for the onset of 
Alzheimer’s disease. Future directions for this research abound, and do not need to be discussed 
here. It is evident that the contribution above represents only a small step toward the full 
understanding of these terminal diseases, and leaves much to be learned in its wake. These 
diseases may never be solved, but that is not important. What is important is that they have been 
fought, they are fought, and they will be fought, as long as the scientific spirit lives on. 
 
